KOL | Harry Roger BüllerDepartment of Medicine, Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands | From KU Leuven Department of Cardiovascular ... |
Kol CV for Harry Roger Büller
| Year | |
|---|---|
| 2022 | Department of Medicine, Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands |
| 2021 | From KU Leuven Department of Cardiovascular Sciences, Vascular Medicine and Hemostasis, Leuven, Belgium (P.V.); Anthos Therapeutics, Cambridge, MA (B.A.Y., J.S., D.B.); International Trial Expertise Advisory and Services (A.S.) and the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (H.R.B.) - both in Amsterdam; Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City (G.E.R.); and the Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada (J.I.W.). Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands (H.R.B.). |
| 2020 | From the Faculty of Medical Sciences, State University of Groningen, Groningen, the Netherlands (M.O.); Department of Vascular Medicine, Amsterdam University Medical Centre, Amsterdam, the Netherlands (H.R.B., N.V.Es.); Department of Radiology, Haaglanden Medical Centre, The Hague, the Netherlands (D.K.); Department of Radiology, Nederlands Kanker Instituut, Amsterdam, the Netherlands (S.F.O.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, U.S.A. (T.M.); Department of Intensive Care Medicine, Erasmus Medical Centre, Rotterdam, the Netherlands (D.G.); 7. National Institute of Public Health, Ministry of Health, Bilthoven, the Netherlands (J.V.D.); Department of Vascular Medicine, Maastricht University, Maastricht, the Netherlands (H.T.C.); Edinburgh Imaging, Queens Medical Research Institute, University of Edinburgh, Edinburgh, U.K.(E.J.R.V.B.) Department of Vascular Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands |
| 2019 | Department of Vascular Medicine, Academic Medical Center, Universiteit van Amsterdam, Amsterdam, The Netherlands. Dept of Vascular Medicine, Amsterdam Cardiovascular Science, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands |
| 2018 | Department of Vascular Medicine, Academic Medical Centre Amsterdam, University of Amsterdam, Amsterdam, Netherlands |
| 2017 | Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, AZ, Amsterdam, The Netherlands. From Academic Medical Center and Slotervaartziekenhuis, Amsterdam, the Netherlands; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Université de Bretagne Occidentale, Brest, France; Hospital of Padua, Padua, Italy; Clinica Universidad de Navarra, Pamplona, Spain; Virgen del Rocio Hospital, Seville, Spain; Karolinska Institutet, Stockholm, Sweden; Warsaw Medical University, Warsaw, Poland; Centre Hospitalo-Universitaire Estaing, Clermont-Ferrand, France; University of Utah, Salt Lake City, Utah; University Hospital Leuven, Leuven, Belgium; and University G. D'Annunzio, Chieti-Pescara, Italy. |
| 2016 | Center for Experimental and Molecular Medicine, Amsterdam Medical Center, Amsterdam, The Netherlands |
| 2015 | Academic Medical Center University of Amsterdam Department of Vascular Medicine Amsterdam the Netherlands |
| 2014 | From the College of Public Health, University of Oklahoma Health Sciences Center (G.E.R., M.M., A.W.); Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand (P.A.); División Hemostasia, Academia Nacional de Medicina, Buenos Aires, Argentina (A.N.B.); Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (H.B.); SA Pathology–Department of Hematology, Flinders Medical Center, Adelaide, South Australia, Australia (A.G.); Thrombosis and Thrombophilia Centre, Guy’s & St Thomas’ NHS Foundation Trust, London, United Kingdom (B.J.H.); Boston University School of Medicine, MA (E.M.H.); Thrombosis Research Institute, London, United Kingdom (A.K.); Center for Thrombosis and Hemostasis, Johannes Gutenberg University, Mainz, Germany (S.V.K.); Department of Laboratory Medicine, University of Yamanashi, Tamaho, Yamanashi, Japan (Y.O.); and McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada (J.I.W.). Department of General Practice, Academic Medical Centre, University of Amsterdam, Amsterdam and |
| 2013 | Department of Vascular Medicine, F4-140, Academic Medical Centre, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands Academic Medical Center, Amsterdam (H.R.B.) |
| 2012 | Academic Medical Center, Department of Vascular Medicine, Amsterdam (H.R.B.) Vascular Medicine, AMC, Amsterdam, the Netherlands |
| 2011 | Internal Medicine, Academic Medical Center, Amsterdam, Netherlands, From the Academic Medical Center and Slotervaart Hospital, Amsterdam |
Harry Roger Büller: Påvirke statistikk
Kjør rapport
| Concept | World rank |
|---|---|
| studies 3 months | #1 |
| thrombosis vitamin | #1 |
| popliteal veins sensitivity | #1 |
| vka share | #1 |
| lmwh acute treatment | #1 |
| daily dalteparin treatment | #1 |
| heparins cancer patients | #1 |
| quantitative dimer | #1 |
| current practise | #1 |
| leg ultrasonography patients | #1 |
| cdrscore combination | #1 |
| replacement vka | #1 |
| quantitative ddimer tests | #1 |
| subcutaneous nadroparin placebo | #1 |
| relatives mutation | #1 |
| topic thrombophlebitis | #1 |
| elevated ctni patients | #1 |
| wound haematoma | #1 |
| obese controls difference | #1 |
| patients protein deficiencies | #1 |
| normal dimer | #1 |
| activecontrol placebo | #1 |
| combination ddimer testing | #1 |
| symptomatic legs dvt | #1 |
| outpatients symptomatic dvt | #1 |
| ambulatory computers | #1 |
| 8h flight | #1 |
| leg veins patients | #1 |
| patency smokers | #1 |
| superficial thrombophlebitis incidence | #1 |
| ili score | #1 |
| vkas efficacy | #1 |
| bleeding clinically | #1 |
| abnormal vaginal bleeding | #1 |
| elevated biomarkers hospital | #1 |
| bleeding einstein | #1 |
| idrabiotaparinux idraparinux | #1 |
| cancer cdr | #1 |
| protecht shr | #1 |
| dose daily edoxaban | #1 |
| apixaban extended treatment | #1 |
| easier monitoring | #1 |
| enoxaparin primary efficacy | #1 |
| fetal loss miscarriage | #1 |
| noncarriers annual incidence | #1 |
| dimer result | #1 |
| pulmonary embolism idraparinux | #1 |
| wells rules | #1 |
| test venography | #1 |
| pregnancyrelated complications relatives | #1 |
| rivaroxaban dvt treatment | #1 |
| antidote vitamin | #1 |
| acute treatment lmwh | #1 |
| equinox study | #1 |
| patients retropubic prostatectomy | #1 |
| unexplained dvt | #1 |
| 208791 | #1 |
| somittrial | #1 |
| suspected cdr | #1 |
| respondents lmwh | #1 |
| excluded pulmonary | #1 |
| clinically suspected dvt | #1 |
| warfarin cstatistic | #1 |
| 0·620·74 | #1 |
| heparins vitamin antagonists | #1 |
| screening carriers | #1 |
| ddimer test | #1 |
| intravenous unfractionated | #1 |
| carriers relative risks | #1 |
| pulmonary embolism tests | #1 |
| risk homozygous women | #1 |
| followup overt cancer | #1 |
| lowmolecularweight heparin category | #1 |
| progression svt | #1 |
| fviii concentration | #1 |
| sustained antithrombotic effects | #1 |
| edoxaban risk factors | #1 |
| elevated fviii patients | #1 |
| recommendations dvt | #1 |
| ankle brachial prevalence | #1 |
| p0424 | #1 |
| category perelated death | #1 |
| warfarin cancer patients | #1 |
| 6 months avidin | #1 |
| rtap lmwh | #1 |
| uesvt | #1 |
| pulmonary embolism studies | #1 |
| baseline characteristics duration | #1 |
| patients uedvt uesvt | #1 |
| cancer edoxaban | #1 |
| rfviia 3 | #1 |
| 25mg apixaban | #1 |
| anticoagulation period | #1 |
| treated vka | #1 |
| fviii venous thromboembolism | #1 |
| safety outcome | #1 |
| vitamin antagonists treatment | #1 |
| 547253 | #1 |
| ft4 level patients | #1 |
| normal levels fviii | #1 |
| acenocoumarol efficacy | #1 |
| cancer patients uedvt | #1 |
| relatives tafi levels | #1 |
| ccus 4 | #1 |
| doacs cirrhosis patients | #1 |
| treat thrombosis | #1 |
| tb402 enoxaparin | #1 |
| ventilation scan chest | #1 |
| tb402 prevention | #1 |
| levonorgestrel desogestrelcontaining | #1 |
| tests pulmonary embolism | #1 |
| rnapc2 patients | #1 |
| double heterozygous carriers | #1 |
| cancer clinical presentation | #1 |
| ifngamma pselectin | #1 |
| apc resistance factor | #1 |
| smoking graft patency | #1 |
| pulmonary angiography study | #1 |
| lmwh departments | #1 |
| lmwhmediated | #1 |
| amplify trial | #1 |
| anticoagulant fondaparinux | #1 |
| submassive elevated ctni | #1 |
| edoxaban dalteparin | #1 |
| respondents 60 | #1 |
| age recurrent vte | #1 |
| treatment idraparinux | #1 |
| evaluable patients apixaban | #1 |
| 95 3633 patients | #1 |
| vte procoagulant activity | #1 |
| diagnostic management patients | #1 |
| non‐invasive diagnostic work‐up | #1 |
| time recombinant | #1 |
| cdr normal | #1 |
| vitamin anticoagulants | #1 |
| long haul flights | #1 |
| neoplasms heparin | #1 |
| fondaparinux rfviia injection | #1 |
| simplified rule proportion | #1 |
| xainhibitors | #1 |
| gentamicin patients netilmicin | #1 |
| survival fondaparinux | #1 |
| subcutaneous length life | #1 |
| ldfr symptomatic legs | #1 |
| rnapc2 inhibition | #1 |
| patients tests prevalence | #1 |
| graft patency patency | #1 |
| —brachial | #1 |
| elderly outpatients combination | #1 |
| efficacy outcome | #1 |
| sspe proximal | #1 |
| ipe expert radiologists | #1 |
| cancer patients cvcs | #1 |
| lmwh replacement | #1 |
| prediction models recurrence | #1 |
| 2630 pilots | #1 |
| anticoagulants double | #1 |
| matisse trials | #1 |
| beta thromboglobulin org | #1 |
| venous thrombosis vwf | #1 |
| enoxaparin vkas treatment | #1 |
| pulmonary embolism | #1 |
| cancer 145 patients | #1 |
| 3 idraparinux | #1 |
| upper extremity uedvt | #1 |
| enoxaparin initial treatment | #1 |
| single dose tb402 | #1 |
| symptomatic pts | #1 |
| plateletactivating antibodies risk | #1 |
| qscan | #1 |
| edoxabantreated | #1 |
| messages justification | #1 |
| bmi fondaparinux | #1 |
| aptt org 10172 | #1 |
| combination nonhigh cdr | #1 |
| lowmolecularweight heparin 95 | #1 |
| 2 diagnostic management | #1 |
| mutation arg506 | #1 |
| absolute thrombotic risk | #1 |
| crp test patients | #1 |
| clinical probability risk | #1 |
| clinical presentation category | #1 |
| doacs initial heparin | #1 |
| fviii homocysteine | #1 |
| dvt anticoagulants | #1 |
| travellers thrombosis | #1 |
| cip diagnostic management | #1 |
| randomized studies efficacy | #1 |
| pulmonary embolism carriers | #1 |
| 393 patients warfarin | #1 |
| tinaquant assay comparison | #1 |
| ldf diagnosis | #1 |
| heparinoid | #1 |
| perelated death classification | #1 |
| pioped study study | #1 |
| alternative diagnoses patients | #1 |
| suspected symptomatic | #1 |
| dvt 3 | #1 |
| incidence ctni | #1 |
| apixaban randomized patients | #1 |
| thromboembolism relatives | #1 |
| standard therapy months | #1 |
| 00515 | #1 |
| suspected perfusion scan | #1 |
| baseline pvo | #1 |
| early time recurrence | #1 |
| placebo rnapc2 | #1 |
| guidelines abi | #1 |
| safety idraparinux | #1 |
| venous thrombosis hyperglycemia | #1 |
| women factor leiden | #1 |
| perelated death category | #1 |
| symptomatic venous | #1 |
| normal venogram | #1 |
| proportion 75 years | #1 |
| 50 rivaroxaban | #1 |
| vka netherlands | #1 |
| false normal | #1 |
| scores occult cancer | #1 |
| guideline adherence justification | #1 |
| ultrasonography dvt | #1 |
| animal female heparin | #1 |
| limited screening 95 | #1 |
| death vte studies | #1 |
| analysis hokusai | #1 |
| botticelli dvt dose‐ranging | #1 |
| hokusaivte study | #1 |
| 12 kg1 enoxaparin | #1 |
| combined training gps | #1 |
| heparin acenocoumarol | #1 |
| cdr ddimer test | #1 |
| cstatistic model discrimination | #1 |
| study centre duration | #1 |
| referral basis | #1 |
| thrombosis vte | #1 |
| 7268 patients | #1 |
| safety 60 dose | #1 |
| travel‐related venous thrombosis | #1 |
| vte arterial | #1 |
| hellp syndrome mutations | #1 |
| pulmonary embolism cdr | #1 |
| gastrointestinal cancer edoxaban | #1 |
| embolism suspected | #1 |
| strategies abdominal pelvic | #1 |
| procoagulant factors levels | #1 |
| patients tb402 | #1 |
| enoxaparin heparin treatment | #1 |
| heparin initial | #1 |
| embolism sensitivity | #1 |
| hokusai‐vte cancer study | #1 |
| initial heparin patients | #1 |
| cus strategies | #1 |
| heparins data | #1 |
| vte airline pilots | #1 |
| abelacimab | #1 |
| double reports | #1 |
| patients advanced prostate | #1 |
| venous thrombus growth | #1 |
| predefined outcomes | #1 |
| heparin survival | #1 |
| cancer patients patients | #1 |
| proportion pulmonary embolism | #1 |
| initial treatment patients | #1 |
| coagulation factors markers | #1 |
| venous thrombosis mutations | #1 |
| prothrombin 20210a mutation | #1 |
| dalteparin 6 months | #1 |
| death category | #1 |
| molecular weight fondaparinux | #1 |
| vitamin antagonist patients | #1 |
| rnapc2 groups placebo | #1 |
| fetal loss stillbirth | #1 |
| wells clinical | #1 |
| strategies diagnostic management | #1 |
| ventilation lung scanning | #1 |
| pvoq | #1 |
| edoxaban east asian | #1 |
| major bleeds vka | #1 |
| normal ddimer result | #1 |
| desogestrelcontaining coagulation factors | #1 |
| idraparinux 6 months | #1 |
| vte fatal | #1 |
| p0001 saline | #1 |
| isolated deficiencies proteins | #1 |
| recurrent thrombosis pts | #1 |
| fxiaso enoxaparin | #1 |
| comparison vidas assay | #1 |
| ufh grade 1a | #1 |
| edoxaban cancer patients | #1 |
| milliliter enoxaparin | #1 |
| thrombophilia patients doacs | #1 |
| pvo ctscan | #1 |
| 36 papers | #1 |
| standard treatment idraparinux | #1 |
| venography feasibility | #1 |
| deficiency proteins | #1 |
| ventricular dysfunction edoxaban | #1 |
| synthetic selective factor | #1 |
| idraparinux months | #1 |
| standardintensity vkas doacs | #1 |
| patients wells rule | #1 |
| perfusion scan | #1 |
| hemorrhage heparin | #1 |
| early discharge strategies | #1 |
| cdrs patients | #1 |
| fetal loss carriers | #1 |
| fondaparinux unfractionated | #1 |
| controlled trials thrombophilia | #1 |
| rhir lmwh | #1 |
| lmwh users incidence | #1 |
| ddimer test patients | #1 |
| avws prevalence | #1 |
| cart lower levels | #1 |
| relevant major | #1 |
| puerperium diagnostic suspicion | #1 |
| clinical probability exclusion | #1 |
| 97 compression ultrasonography | #1 |
| pulmonary angiography ultrasonography | #1 |
| idraparinux patients | #1 |
| abdominal pelvic strategies | #1 |
| vte risk day | #1 |
| simple diagnostic strategy | #1 |
| org heparin | #1 |
| rule exclusion | #1 |
| carriers thrombophilic defects | #1 |
| bleeding risk treatment | #1 |
| unexplained dvt patients | #1 |
| realtime bmode ultrasonography | #1 |
| falsenormal | #1 |
| tests prevalence abi | #1 |
| laalleles | #1 |
| phase doacs | #1 |
| thrombophlebitis tomography | #1 |
| calf dvt ultrasound | #1 |
| prescriptionbased | #1 |
| 3633 patients edoxabantreated | #1 |
| initial heparin edoxaban | #1 |
| postthrombotic symptoms patients | #1 |
| polyethylenglycolhirudin | #1 |
| adjusted dose ufh | #1 |
| placebo 25mg apixaban | #1 |
| patients clinical probability | #1 |
| 50 years combination | #1 |
| dose response apixaban | #1 |
| loss subsequent pregnancy | #1 |
| dvt impedance plethysmography | #1 |
| low levels ft4 | #1 |
| acenocoumarol initial treatment | #1 |
| intracranial clinical presentation | #1 |
| patients inherited thrombophilia | #1 |
| orthopedic thromboprophylaxis | #1 |
| clinical decision rule | #1 |
| dimer clinical | #1 |
| feasibility venography | #1 |
| aptt org | #1 |
| original wells | #1 |
| normohomocysteinemic relatives hyperhomocysteinaemia | #1 |
| patients advanced malignancy | #1 |
| netherlands lmwh | #1 |
| patients treatment duration | #1 |
| bleeding risk lmwh | #1 |
| dvt 69 | #1 |
| rabinov | #1 |
| ddimer result | #1 |
| endotoxemia tests | #1 |
| pvo qscan | #1 |
| normal ddimer concentration | #1 |
| patients artificial graft | #1 |
| patients antithrombotic prescriptions | #1 |
| wellscdr | #1 |
| wells simplified | #1 |
| probability normal | #1 |
| vte occurred | #1 |
| prospective management study | #1 |
| nonhigh cdr | #1 |
| anticoagulants chemotherapy | #1 |
| dvt symptomatic | #1 |
| association travel | #1 |
| 9 incidence | #1 |
| survival lmwh | #1 |
| nadroparin aspirin | #1 |
| extensive screening cancer | #1 |
| incidental symptomatic vte | #1 |
| 2479 relatives | #1 |
| prophylaxis crt | #1 |
| apc resistance tests | #1 |
| individualized duration | #1 |
| previous surveys netherlands | #1 |
| bleeding rates quality | #1 |
| laalleles platelets | #1 |
| oral apixaban treatment | #1 |
| inherited thrombophilia patients | #1 |
| pharmacological methods prophylaxis | #1 |
| distal clots | #1 |
| combination cdr | #1 |
| adjunct thrombolysis | #1 |
| advanced malignancy | #1 |
| risk percentage points | #1 |
| thrice daily gentamicin | #1 |
| factor viii relatives | #1 |
| 750 μg l1 | #1 |
| rnapc2 groups | #1 |
| silent dvt | #1 |
| fviii normal levels | #1 |
| elderly patients dvt | #1 |
| failure rate efficiency | #1 |
| recurrent thromboembolism enoxaparin | #1 |
| dalteparin major bleeding | #1 |
| rfviia idraparinux | #1 |
| fxainhibitors | #1 |
| heparin initial treatment | #1 |
| 15 lmwh | #1 |
| standardintensity vkas | #1 |
| 95ci tb402 | #1 |
| abnormal ipg | #1 |
| international thrombosis experts | #1 |
| strategy abdominal pelvic | #1 |
| chest perfusion scan | #1 |
| 500 org | #1 |
| ultrasound strategies patients | #1 |
| pyridines recurrence | #1 |
| lmprovement | #1 |
| factor viii homocysteine | #1 |
| cdr dimer | #1 |
| gogh dvt trial | #1 |
| efficiency subgroups | #1 |
| anticoagulants probability | #1 |
| vte risk coc | #1 |
| lowmolecularweight heparin treatment | #1 |
| studies doac treatment | #1 |
| svt lmwh | #1 |
| women elevated levels | #1 |
| relatives elevated levels | #1 |
| einstein dvt patients | #1 |
| lmwh edoxaban | #1 |
| members symptomatic carriers | #1 |
| ultrasonography leg veins | #1 |
| hokusaivte trial | #1 |
| relative risks carriers | #1 |
| obese hemophilic patients | #1 |
| total vte patients | #1 |
| cancer patients cdr | #1 |
| efficacy vte | #1 |
| prothrombin individuals | #1 |
| protein levels mortality | #1 |
| reduceddose noacs | #1 |
| 560 pharmacies | #1 |
| tb402 12 kg1 | #1 |
| undvt | #1 |
| revascularisation procedures patients | #1 |
| cdrscore | #1 |
| rfviia fondaparinux | #1 |
| presentation 1 week | #1 |
| ddimer test combination | #1 |
| recurrent vte immobilization | #1 |
| cancer patients ufh | #1 |
| types major bleeding | #1 |
| coagulationinhibiting | #1 |
| uesvt patients | #1 |
| poc test patients | #1 |
| idraparinux recurrent thromboembolism | #1 |
| role exclusion | #1 |
| excluding pulmonary | #1 |
| lmwh plasma levels | #1 |
| models development studies | #1 |
| impedance thrombophlebitis | #1 |
| diagnostic strategy primary | #1 |
| practiceassistants | #1 |
| ctscan qscan | #1 |
| lmwh venous thrombosis | #1 |
| outcome recurrent | #1 |
| travel venous thromboembolism | #1 |
| initial treatment dvt | #1 |
| atherosclerosis hemophilia patients | #1 |
| dalteparin vte treatment | #1 |
| presenting location vte | #1 |
| longhaul flight | #1 |
| factual hemorrhage heparin | #1 |
| ivte clinical practice | #1 |
| 5395 patients | #1 |
| specificity pulmonary embolism | #1 |
| vte difference | #1 |
| segmental subsegmental | #1 |
| rabinovpaulin | #1 |
| fviii vte | #1 |
| monoclonal antibodies apc | #1 |
| patients idraparinux | #1 |
| departments orthopedic surgery | #1 |
| 3633 patients edoxaban | #1 |
| proximal extent ipe | #1 |
| xageneration | #1 |
| hyperhomocysteinemia relatives | #1 |
| nadroparin patients | #1 |
| chest perfusion scintigraphy | #1 |
| local radiologist | #1 |
| s1p1activation | #1 |
| study ecq | #1 |
| 0·2 3633 patients | #1 |
| vitamin antagonists time | #1 |
| patients laalleles | #1 |
| echocardiography normotensive patients | #1 |
| ultrasonography diagnostic | #1 |
| prophylaxis idraparinux | #1 |
| doses 75 microg | #1 |
| compression ultrasonography | #1 |
| recurrent vte doacs | #1 |
| subsequent symptomatic cancer | #1 |
| clinical probability patients | #1 |
| individuals air travel | #1 |
| elevated fviii | #1 |
| recurrence major bleeding | #1 |
| intrinsic coagulation vivo | #1 |
| level loss patency | #1 |
| frequency venous thromboembolism | #1 |
| clinically suspected cancer | #1 |
| influenza case patients | #1 |
| edoxaban warfarin groups | #1 |
| idraparinux vitamin antagonist | #1 |
| idraparinux vte | #1 |
| death venous thromboembolism | #1 |
| outcome clinically | #1 |
| heparin org 10172 | #1 |
| inr range ttr | #1 |
| apixaban conventional therapy | #1 |
| treatment cumulative incidence | #1 |
| presenting location women | #1 |
| obstetric complications relatives | #1 |
| questionnaires thrombosis | #1 |
| nondiagnostic lung scan | #1 |
| matisse dvt | #1 |
| uesvt median | #1 |
| uesvt uedvt | #1 |
| ctscanreading | #1 |
| tsh antitpo | #1 |
| protein mortality | #1 |
| simplified geneva score | #1 |
| vkas lmwh | #1 |
| beneficial lmwh | #1 |
| age multiple comorbidities | #1 |
| intensity vkas doacs | #1 |
| intravenous injections lmwh | #1 |
| idraparinux 25 | #1 |
| current comprehensions | #1 |
| residual thrombotic mass | #1 |
| cdr physicians | #1 |
| matisse clinical trials | #1 |
| pulmonary angiography strategies | #1 |
| idraparinux placebo | #1 |
| patients mismatched scan | #1 |
| timeperiod | #1 |
| calfvein thrombi | #1 |
| standard therapy rivaroxaban | #1 |
| pulmonary embolism fondaparinux | #1 |
| progression vte | #1 |
| crptest | #1 |
| vivo coagulation factor | #1 |
| evaluable patients 95 | #1 |
| heparins cancer spread | #1 |
| uedvt recurrent vte | #1 |
| deepvein thrombosis incidence | #1 |
| extended anticoagulation doacs | #1 |
| fviii women | #1 |
| symptomatic recurrent vte | #1 |
| diagnosis deepvein thrombosis | #1 |
| intestinal microbiota coagulation | #1 |
| coagulation clinical | #1 |
| 5‐snp scores | #1 |
| pulmonary embolism role | #1 |
| recurrent vte statin | #1 |
| netherlands vka | #1 |
| d‐dimer test | #1 |
| withheld | #1 |
| uedvt terms | #1 |
| controlledstudy | #1 |
| united states rnapc2 | #1 |
| proximal location ipe | #1 |
| 5 years lmwh | #1 |
| patients malignancy | #1 |
| wells rule primary | #1 |
| 69 conclusions | #1 |
| prolactin venous thrombosis | #1 |
| cstatistic major bleeding | #1 |
| rivaroxaban replacement | #1 |
| protein resistance control | #1 |
| quantitative ddimer test | #1 |
| rule cdr | #1 |
| 378 patients edoxaban | #1 |
| khorana | #1 |
| efficacy heparin therapy | #1 |
| venous thrombosis pregnancy | #1 |
| netherlands 5 years | #1 |
| axa activity 5 | #1 |
| thrombo‐embolic events | #1 |
| rate recurrent | #1 |
| doubleheterozygotes | #1 |
| reduceddose noacs stroke | #1 |
| aged venous | #1 |
| fibrinolysis levels | #1 |
| severity clinical presentation | #1 |
| quantitative ddimer testing | #1 |
| constans score | #1 |
| preference doacs | #1 |
| uesvt mortality | #1 |
| patients normal tests | #1 |
| diagnostic strategies patients | #1 |
| systematic search cteph | #1 |
| recurrent dvt dvt | #1 |
| fviii hyperhomocysteinemia | #1 |
| 023 relatives | #1 |
| incidence venous | #1 |
| efficacy conventional treatment | #1 |
| presentation category | #1 |
| decisions duration | #1 |
| failure cip | #1 |
| platelets iqr | #1 |
| diagnostic strategies strategies | #1 |
| severe presentation patients | #1 |
| reocclusion antithrombotic drug | #1 |
| standalone ddimer testing | #1 |
| riskstroponin | #1 |
| inr studies | #1 |
| predefined outcomes vte | #1 |
| 0·2 edoxabantreated | #1 |
| reported incidence vte | #1 |
| relatives normal fviii | #1 |
| vte location | #1 |
| ddimer test result | #1 |
| levels procoagulant factors | #1 |
| patients acute recurrent | #1 |
| category fxainhibitors | #1 |
| einsteinextension | #1 |
| patients ivte | #1 |
| cvc crt | #1 |
| ecq ankle brachial | #1 |
| doac recipients | #1 |
| duration heparin treatment | #1 |
| patients unexplained dvt | #1 |
| compression ultrasonography patients | #1 |
| failure diagnostic management | #1 |
| enoxaparin tb402 | #1 |
| venous thromboembolism episode | #1 |
| plasma concentration fviii | #1 |
| thrombophilia late loss | #1 |
| vte addition | #1 |
| 123362 | #1 |
| mortality postthrombotic symptoms | #1 |
| extended anticoagulation apixaban | #1 |
| patients compression ultrasonography | #1 |
| compression ultrasonography presentation | #1 |
| selective beta‐blocker treatment | #1 |
| ultrasound compression ultrasound | #1 |
| smoking patency | #1 |
| mutation relatives | #1 |
| coagulation fibrinolytic proteins | #1 |
| vte day | #1 |
| ldf cus | #1 |
| malignancy achieved inr | #1 |
| treatment venous | #1 |
| patients deep | #1 |
| therapeutic doses lmwh | #1 |
| included patients study | #1 |
| org aptt | #1 |
| idraparinux standard therapy | #1 |
| rivaroxaban lmwh vka | #1 |
| patients reduceddose noacs | #1 |
| uedvt clinical | #1 |
| crt cvc | #1 |
| venous thromboembolism idraparinux | #1 |
| antithrombotic prescriptions adherence | #1 |
| uesvt recurrent vte | #1 |
| embolism wells | #1 |
| dvt 56 | #1 |
| heparin vitamin antagonist | #1 |
| venous thromboembolism edoxaban | #1 |
| noacs prevention | #1 |
| 95 elevated ctni | #1 |
| increasing levels ft4 | #1 |
| vte trial | #1 |
| rivaroxaban acute dvt | #1 |
| cancer patients cancer | #1 |
| association protein levels | #1 |
| oral edoxaban dose | #1 |
| avidin idrabiotaparinux | #1 |
| einsteindvt | #1 |
| extended treatment edoxaban | #1 |
| treatment experimental thrombosis | #1 |
| 20210a mutation | #1 |
| rnapc2 united states | #1 |
| 65±9years | #1 |
| annual incidence patients | #1 |
| hokusai‐vte trial | #1 |
| recurrence bleeding risk | #1 |
| patients initial heparin | #1 |
| lmwh delivery | #1 |
| ufh grade | #1 |
| patients examiner | #1 |
| tomography angiography vte | #1 |
| prevention topic guidelines | #1 |
| pulmonary embolism life | #1 |
| presence venous thrombosis | #1 |
| weight heparinoid | #1 |
| fxainhibitors vka recipients | #1 |
| scenarioanalysis | #1 |
| oral administration bsf | #1 |
| carriers pulmonary embolism | #1 |
| mdct expert radiologist | #1 |
| pulmonary embolism metaanalysis | #1 |
| deep vein thrombosis | #1 |
| ml1 ctpa | #1 |
| vte study | #1 |
| acenocoumarol therapy acenocoumarol | #1 |
| dvt costs | #1 |
| doacs factor | #1 |
| scan pulmonary embolism | #1 |
| chromogenic endotoxin | #1 |
| acute recurrent patients | #1 |
| hokusai vte cancer | #1 |
| qscan 3 weeks | #1 |
| normal lung scan | #1 |
| pulmonary embolism basis | #1 |
| 7268 patients suspected | #1 |
| thiazoles venous | #1 |
| avidin vte | #1 |
| elevated fviii age | #1 |
| year prophylaxis | #1 |
| tests venography | #1 |
| departments pharmacological prophylaxis | #1 |
| variable d‐dimer thresholds | #1 |
| oral rivaroxaban treatment | #1 |
| principal safety | #1 |
| lmwhs 95 | #1 |
| patients enoxaparin vkas | #1 |
| clinically suspected uedvt | #1 |
| risk pulmonary embolism | #1 |
| probability lung scan | #1 |
| wellsrule | #1 |
| older patients cdr | #1 |
| rule dimer | #1 |
| 250 patients cancer | #1 |
| embolism radionuclide | #1 |
| venography tests | #1 |
| relatives normal levels | #1 |
| rivaroxaban standard therapy | #1 |
| elevated cardiac troponins | #1 |
| dose rnapc2 | #1 |
| preferred oral anticoagulant | #1 |
| wellscdrscore | #1 |
| relatives antithrombin | #1 |
| acquired atiii deficiency | #1 |
| 53 amputations | #1 |
| vka treatment treatment | #1 |
| absolute annual incidences | #1 |
| major bleeding cancer | #1 |
| combination cdrs | #1 |
| ddimer levels cdr | #1 |
| dimer test | #1 |
| thromboembolism 3 | #1 |
| relevant bleeding | #1 |
| presenting vte location | #1 |
| idraparinux | #1 |
| successful attenuation | #1 |
| clinical uedvt | #1 |
| casedescription | #1 |
| cdr ddimer levels | #1 |
| avidin placebo | #1 |
| vka recipients | #1 |
| orthopedic surgery netherlands | #1 |
| simplified wells rule | #1 |
| combination cdrscore | #1 |
| selective ddimer thresholds | #1 |
| lmwh rtap | #1 |
| amplify trial apixaban | #1 |
| administration lmwh | #1 |
| timerequirement | #1 |
| probability ventilation | #1 |
| doacs anatomical extent | #1 |
| carriers recurrence | #1 |
| lmwh immobilization | #1 |
| enoxaparin warfarin antiplatelet | #1 |
| anticoagulant treatment vte | #1 |
| single‐detector row | #1 |
| hokusaivte trial patients | #1 |
| venous thrombosis recurrence | #1 |
| wells cdr | #1 |
| submassive incidence | #1 |
| control anticardiolipin antibodies | #1 |
| consensus strategy strategy | #1 |
| heparins inhibition | #1 |
| nadroparin therapeutic dose | #1 |
| local radiologist experts | #1 |
| suspected deep | #1 |
| d‐dimer level | #1 |
| positive vte | #1 |
| sgs pretest probability | #1 |
| aged nadroparin | #1 |
| prevalence coagulation | #1 |
| patients khorana | #1 |
| ivte | #1 |
| anticoagulant treatment patients | #1 |
| infections gentamicin | #1 |
| category death | #1 |
| embolism randomized | #1 |
| oral anticoagulants phase | #1 |
| iii plg | #1 |
| compression ultrasound dvt | #1 |
| compression ultrasonography detection | #1 |
| subsequent diagnosis malignancy | #1 |
| 95 intracranial | #1 |
| women edoxaban | #1 |
| conventional therapy enoxaparin | #1 |
| acenocoumarol heparin | #1 |
| tb402 50 | #1 |
| method factor | #1 |
| clinically relevant disease | #1 |
| 5mg apixaban | #1 |
| subcutaneous idraparinux | #1 |
| probability cdr | #1 |
| 3 rfviia | #1 |
| idraparinux versus | #1 |
| symptomatic recurrent | #1 |
| wells rule exclusion | #1 |
| normotensive patients studies | #1 |
| studies ttr | #1 |
| elevated levels fviii | #1 |
| management study | #1 |
| achieved inr patients | #1 |
| heparin vitamin | #1 |
| thromboembolism treated | #1 |
| scores riete score | #1 |
| safety clinical utility | #1 |
| threemonth incidence | #1 |
| exclusion pulmonary | #1 |
| probabilityscan | #1 |
| strategies ultrasonography | #1 |
| presentation major | #1 |
| asymptomatic extension | #1 |
| probability categories | #1 |
| 12 months edoxaban | #1 |
| months standard therapy | #1 |
| flebography | #1 |
| extra hospital visits | #1 |
| age∗10μg | #1 |
| sensitivity 100 percent | #1 |
| enoxaparin vkas | #1 |
| reduceddose noacs warfarin | #1 |
| 5 avidin infusion | #1 |
| efficiency diagnostic strategies | #2 |
| test cancer | #2 |
| bleeding edoxaban | #2 |
| compression doppler | #2 |
| vte 1000 personyears | #2 |
| vitamin antagonist rivaroxaban | #2 |
| impedance plethysmography diagnosis | #2 |
| patients hemorr2hages | #2 |
| sr34006 | #2 |
| concomitant thrombophilic | #2 |
| biomarkers casecontrol studies | #2 |
| failure rate strategy | #2 |
| treated edoxaban | #2 |
| recurrent vte risk | #2 |
| central localization | #2 |
| hokusai vte | #2 |
| gauge plethysmography | #2 |
| secondary efficiency | #2 |
| serum tnf activity | #2 |
| vte 12 | #2 |
| quality warfarin treatment | #2 |
| scan normal | #2 |
| oral direct inhibitors | #2 |
| inflammation neutrophils thrombosis | #2 |
| relevant patient subgroups | #2 |
| patients oral factor | #2 |
| treatment ttr | #2 |
| thyroid hormone coagulation | #2 |
| score dimer | #2 |
| khorana protecht | #2 |
| age‐adjusted d‐dimer testing | #2 |
| screening fvl | #2 |
| levels coagulation factors | #2 |
| 95 0·2 | #2 |
| raskob | #2 |
| mild risk factor | #2 |
| normohomocysteinemic relatives | #2 |
| diagnostic lung | #2 |
| pravastatin therapy children | #2 |
| protein rnapc2 | #2 |
| fibrinolysis pentoxifylline | #2 |
| heparin treatment influenza | #2 |
| pharmacological strategies | #2 |
| blood coagulation inhibition | #2 |
| heparin administered | #2 |
| thrombophilic disorders | #2 |
| relation coagulation factors | #2 |
| low‐molecular‐weight heparin | #2 |
| uptake noacs | #2 |
| coumarin sensitivity | #2 |
| prothrombin pulmonary embolism | #2 |
| undiagnosed malignancy | #2 |
| uedvt cancer patients | #2 |
| 17 apixaban | #2 |
| cancer addition | #2 |
| influenza coagulation | #2 |
| major bleeding edoxaban | #2 |
| thromboinflammation cardiovascular disease | #2 |
| hellp syndrome prevalence | #2 |
| symptomatic outpatients | #2 |
| recurrent deep | #2 |
| thromboembolism thrombophilia | #2 |
| model cancer patients | #2 |
| exclude pulmonary | #2 |
| suspected pulmonary embolism | #2 |
| ufh 6 months | #2 |
| rivaroxaban 30 bid | #2 |
| risk anticoagulation therapy | #2 |
| analysis venous | #2 |
| embolism deep | #2 |
| adapted ddimer thresholds | #2 |
| 95 cancer patients | #2 |
| alife study | #2 |
| venous thrombophlebitis | #2 |
| patients prior vte | #2 |
| treated anticoagulants | #2 |
| principal safety outcome | #2 |
| hyperglycemia diagnosis | #2 |
| annual incidences | #2 |
| pulmonary embolism efficacy | #2 |
| blood coagulation rnapc2 | #2 |
| heparin nadroparin | #2 |
| mutation 35 | #2 |
| apixaban lmwh vka | #2 |
| prolactin relation | #2 |
| pulmonary embolism purpose | #2 |
| outcome symptomatic | #2 |
| tinaquant vidas | #2 |
| amuse strategy | #2 |
| risk khorana | #2 |
| vte elevated fviii | #2 |
| patients abi measurement | #2 |
| mdct reference standard | #2 |
| decision rule | #2 |
| lower clinical utility | #2 |
| wells cdr cdr | #2 |
| hmb primary outcome | #2 |
| influenza prothrombotic state | #2 |
| absolute incidence | #2 |
| major bleeding recurrent | #2 |
| comparator individuals 95 | #2 |
| hemorr2hages atria scores | #2 |
| heparin compounds | #2 |
| surgical casts | #2 |
| common alternative diagnoses | #2 |
| clinically suspected | #2 |
| rnapc2 | #2 |
| bleeding complications treatment | #2 |
| rnapc2 doses | #2 |
| 95 comparator individuals | #2 |
| acquired antithrombin | #2 |
| crnm bleeds | #2 |
| brain metastases doacs | #2 |
| n1423 | #2 |
| recurrence thromboembolism | #2 |
| suspected pulmonary | #2 |
| secondary strategies | #2 |
| nonpermanent heart failure | #2 |
| duration anticoagulant | #2 |
| suspected upper | #2 |
| vitamin antagonists quality | #2 |
| safety pravastatin therapy | #2 |
| extended constans score | #2 |
| dimer thresholds | #2 |
| graft occlusion patients | #2 |
| fvl carriers carriers | #2 |
| nct00633893 | #2 |
| major clinically | #2 |
| received edoxaban | #2 |
| sspe patients patients | #2 |
| plasma concentrations endotoxin | #2 |
| coagulation fibrinolytic | #2 |
| regression pravastatin | #2 |
| intermediate phenotype vte | #2 |
| ultrasonography patients | #2 |
| endogenous activated protein | #2 |
| statins recurrent vte | #2 |
| cdr wells cdr | #2 |
| fviii increased risk | #2 |
| recombinant nematode | #2 |
| limits cancer | #2 |
| rivaroxaban thiazoles | #2 |
| pentasaccharide fondaparinux | #2 |
| ddimer determination | #2 |
| vte orthopedic surgery | #2 |
| impedance plethysmography patients | #2 |
| uedvt performance | #2 |
| n832 | #2 |
| hospitalbased strategies | #2 |
| events severe | #2 |
| ventilation scanning | #2 |
| efficiency strategy | #2 |
| patients peripheral graft | #2 |
| ageadjusted ddimer testing | #2 |
| standardised time intervals | #2 |
| negative ageadjusted ddimer | #2 |
| thrombosis normal | #2 |
| 95 dvt | #2 |
| hokusai vtecancer study | #2 |
| intrinsic cascade | #2 |
| coagulation factors prolactin | #2 |
| duration anticoagulant treatment | #2 |
| primary hospitalbased strategies | #2 |
| ufh survival | #2 |
| angioplasty clopidogrel | #2 |
| 20210a mutations | #2 |
| arterial thrombotic disease | #2 |
| uedvt efficiency | #2 |
| levothyroxine exposure | #2 |
| major bleeding cindexes | #2 |
| healthcare settings findings | #2 |
| f5 r506q | #2 |
| medscape | #2 |
| normal ddimer test | #2 |
| venographically | #2 |
| administration rviia | #2 |
| clinical prediction model | #2 |
| vidas assay | #2 |
| enoxaparin warfarin | #2 |
| venous | #2 |
| embolism primary | #2 |
| simplired test | #2 |
| 8292 patients | #2 |
| fibrinolytic proteins | #2 |
| incidental venous | #2 |
| death vte | #2 |
| 6 months scores | #2 |
| measurement ankle brachial | #2 |
| computed venous | #2 |
| travel venous | #2 |
| sustained antithrombotic | #2 |
| patients low probability | #2 |
| hasbled score hemorr2hages | #2 |
| life treatment duration | #2 |
| performance constans rule | #2 |
| cancer recurrent vte | #2 |
| factor iia | #2 |
| bleeding rate patients | #2 |
| gcpg | #2 |
| computerized impedance | #2 |
| pregnancy venous thrombosis | #2 |
| fibrinolysis influenza | #2 |
| efficiency original score | #2 |
| employees longhaul flight | #2 |
| interleukin‐10 response | #2 |
| heparin effective | #2 |
| thrombophilic defects risk | #2 |
| amadeus study | #2 |
| mutations propeptide | #2 |
| women therapeutic doses | #2 |
| idraparinux vitamin | #2 |
| anticoagulated patients permanent | #2 |
| nematode anticoagulant | #2 |
| primary efficacy outcome | #2 |
| incidental vte | #2 |
| presentation dvt | #2 |
| cdr variables cdr | #2 |
| patients khorana score | #2 |
| subcutaneous length | #2 |
| rfviia injection rfviia | #2 |
| composite scores area | #2 |
| ate cancer patients | #2 |
| mutations cleavage sites | #2 |
| beta‐receptor blockade | #2 |
| vte svt | #2 |
| embolism safely | #2 |
| exposure flights | #2 |
| crd42017056309 | #2 |
| simplified wells | #2 |
| warfarintreated | #2 |
| wells cdr patients | #2 |
| endotoxininduced activation coagulation | #2 |
| clinical probability estimate | #2 |
| plasmin activity inhibition | #2 |
| bleeding occurred | #2 |
| antagonists vka | #2 |
| 8 wk risk | #2 |
| major bleeding intermediate | #2 |
| plasma d‐dimer concentration | #2 |
| treatment deep | #2 |
| recombinant hirudin cgp | #2 |
| rule proportion | #2 |
| clinical pretest probability | #2 |
| 3306 patients | #2 |
| cha2ds2vasc nri | #2 |
| incidence recurrent | #2 |
| months 25 | #2 |
| global public awareness | #2 |
| resource utilisation treatment | #2 |
| exclusion pulmonary embolism | #2 |
| venous thromboembolism enoxaparin | #2 |
| single administration tb402 | #2 |
| enoxaparin difference | #2 |
| lowmolecularweight heparin women | #2 |
| pulmonary embolism asthma | #2 |
| apixaban enoxaparin warfarin | #2 |
| subsegmental emboli | #2 |
| vein compressibility | #2 |
| primary healthcare secondary | #2 |
| current clinical challenges | #2 |
| lmwh efficacy | #2 |
| lmwh users | #2 |
| pregnancy coc | #2 |
| risk deep | #2 |
| rule combined | #2 |
| ddimer assay | #2 |
| c1173t dimorphism | #2 |
| deficiencies proteins | #2 |
| euro138 | #2 |
| referred patients secondary | #2 |
| years 36 | #2 |
| healthy donor fmt | #3 |
| cancer active cancer | #3 |
| capillary blood sample | #3 |
| therapy venous | #3 |
| cdr combination | #3 |
| clinical models patients | #3 |
| simplified wells specificity | #3 |
| vein thrombosis | #3 |
| subcutaneous fondaparinux | #3 |
| hokusai‐vte | #3 |
| prevalence hemostatic abnormalities | #3 |
| “gestalt | #3 |
| deep vein | #3 |
| cancer patients ipe | #3 |
| prevalence avws | #3 |
| 3month incidence | #3 |
| alternative diagnoses | #3 |
| patients ft4 level | #3 |
| influence heparins | #3 |
| gestalt probability | #3 |
| desogestrelcontaining | #3 |
| ventilation scan | #3 |
| monoclonal replacement | #3 |
| nct00643201 | #3 |
| dvt hip | #3 |
| hasbled | #3 |
| iii deficiency | #3 |
| low probability models | #3 |
| failurerate | #3 |
| older children vte | #3 |
| 6575 years | #3 |
| introduction mdct | #3 |
| patients venous | #3 |
| ipe cancer patients | #3 |
| primary rule | #3 |
| discontinuation ufh | #3 |
| patients wells | #3 |
| 3633 patients | #3 |
| factor viiic | #3 |
| mechanisms heparin | #3 |
| predictable pharmacokinetics | #3 |
| standard therapy treatment | #3 |
| treatment vte recurrence | #3 |
| venous thrombosis travel | #3 |
| coagulation air travel | #3 |
| idiopathic venous | #3 |
| strategies efficiency | #3 |
| death clinical studies | #3 |
| protein thrombophilia | #3 |
| subcutaneous lmwh | #3 |
| topic heparin heparin | #3 |
| rnapc2 fviia | #3 |
| dvt systematic differences | #3 |
| einstein patients | #3 |
| prolactin controls | #3 |
| cohort study employees | #3 |
| 02011 | #3 |
| pulmonary embolism primary | #3 |
| vte major burden | #3 |
| definition perelated death | #3 |
| products follow | #3 |
| female humans inhibitors | #3 |
| diagnosis pulmonary embolism | #3 |
| pulmonary embolism gestalt | #3 |
| single diagnostic | #3 |
| plethysmography impedance | #3 |
| thromboembolism background | #3 |
| safely | #3 |
| cancer patients ate | #3 |
| presenting location | #3 |
| recurrent thromboembolic | #3 |
| thombosis | #3 |
| safely exclude | #3 |
| diagnosis pulmonary | #3 |
| efficacy heparin | #3 |
| treatment vitamin antagonists | #3 |
| crt cancer patients | #3 |
| placebo n4 | #3 |
| negative predictive proportion | #3 |
| pulmonary embolism models | #3 |
| 100 years year | #3 |
| female hemorrhage humans | #3 |
| venous thrombosis positive | #3 |
| enoxaparin follow | #3 |
| antithrombin iii concentrate | #3 |
| wells rule dvt | #3 |
| vte denmark | #3 |
| hf severity risk | #3 |
| incidence total vte | #3 |
| adult patients vte | #3 |
| patients incidental vte | #3 |
| inhibition blood coagulation | #3 |
| heparin heparin | #3 |
| warfarin subgroup | #3 |
| administration rnapc2 | #3 |
| cardiac troponine | #3 |
| lmwh pph | #3 |
| bleeding 3 | #3 |
| einstein dvt | #3 |
| oral hormonal cross | #3 |
| svt vte | #3 |
| dvt primary | #3 |
| 95 wells rule | #3 |
| pad smokers | #3 |
| wells rule gestalt | #3 |
| venous thromboembolism apixaban | #3 |
| treatment vka | #3 |
| extensive screening | #3 |
| vte 3 | #3 |
| revised geneva efficiency | #3 |
| studies cus strategies | #3 |
| vte venous thrombosis | #3 |
| endogenous apc | #3 |
| multiple comorbidities polypharmacy | #3 |
| patients ultrasonography | #3 |
| lmwh | #3 |
| ctnt risk stratification | #3 |
| favour lmwh | #3 |
| patients 6 months | #3 |
| knee factor | #3 |
| normal ctnt presentation | #3 |
| fxiaso | #3 |
| intravenous loading dose | #3 |
| diagnosis deep | #3 |
| baseline values placebo | #3 |
| outpatient treatment dvt | #3 |
| safely excluded | #3 |
| treatment lowmolecularweight heparin | #3 |
| treatment low | #3 |
| incidental pulmonary embolism | #3 |
| tinaquant assay | #3 |
| selectine | #3 |
| venous thromboembolism thrombophilia | #3 |
| thiophenes venous | #3 |
| tfindependent | #3 |
| 12month study period | #3 |
| ddimer assays | #3 |
| compensated dic | #3 |
| dvt major | #3 |
| normal result | #3 |
| ft4 risk | #3 |
| mutation venous | #3 |
| atria hemorr2hages | #3 |
| venous thromboembolism | #3 |
| chemotherapy prophylaxis | #3 |
| combination wells score | #3 |
| bleeding major | #3 |
| proximalvein thrombosis | #3 |
| impedance predictive | #3 |
| tb‐402 | #3 |
| coagulation influence | #3 |
| idrabiotaparinux warfarin | #3 |
| venous arterial | #3 |
| safety acenocoumarol | #3 |
| sensitivity compression | #3 |
| composite stroke | #3 |
| patients proximalvein thrombosis | #3 |
| vte low | #3 |
| dose reduction edoxaban | #3 |
| dvt einstein | #3 |
| lowmolecularweight humans length | #3 |
| approaches primary | #3 |
| activecontrol | #3 |
| patients gastrointestinal cancer | #3 |
| age annual incidence | #3 |
| patients venography | #3 |
| idrabiotaparinux | #3 |
| ddimer threshold | #3 |
| probability dimer | #3 |
| time venous thrombosis | #3 |
| primary wells rule | #3 |
| pulmonary embolism‐related death | #3 |
| travel venous thrombosis | #3 |
| outpatients dvt | #3 |
| cancer randomised trials | #3 |
| lowmolecularweight heparin placebo | #3 |
| einstein studies | #3 |
| embolism‐related | #3 |
| ultrasonography strategies | #3 |
| detection dvt | #3 |
| platelet agents | #3 |
| incidence enoxaparin | #3 |
| thromboembolism low | #3 |
| stable acute | #3 |
| factors prothrombin | #3 |
| heparins cancer | #3 |
| thrombophilic defect | #3 |
| vte performance | #3 |
| users incidence | #3 |
| apc protective | #3 |
| thrombophlebitis treatment | #3 |
| studies hemorrhage | #3 |
| heparin edoxaban | #3 |
| patients 6575 years | #3 |
| nadroparin placebo | #3 |
| venous thrombosis cancer | #3 |
| dalteparin difference | #3 |
| 20210ga | #3 |
| axa activity | #3 |
| dip placebo | #3 |
| 3month vte incidence | #3 |
| gestalt 95 | #3 |
| pph lmwh | #3 |
| recombinant hirudin rhir | #3 |
| outcome venous | #3 |
| recurrence thrombophlebitis | #3 |
| dimer blood | #3 |
| patients edoxaban | #4 |
| women apc resistance | #4 |
| leiden carriers | #4 |
| rivaroxaban 20 | #4 |
| measurement abi | #4 |
| diagnostic management | #4 |
| hemorr2hages | #4 |
| netherlands pulmonary | #4 |
| coagulation endotoxin | #4 |
| chinese korean ethnicity | #4 |
| disease burden vte | #4 |
| women normal levels | #4 |
| postthrombotic symptoms | #4 |
| idiopathic venous thrombosis | #4 |
| abdomen relationship | #4 |
| chemotherapy vte prophylaxis | #4 |
| thromboembolism arterial | #4 |
| refuted | #4 |
| venography patients | #4 |
| vte global burden | #4 |
| thrombophilic families | #4 |
| enoxaparin female humans | #4 |
| 335 patients | #4 |
| pregnancies carriers | #4 |
| global disease burden | #4 |
| protecht | #4 |
| primary pulmonary embolism | #4 |
| 10172 | #4 |
| 6 months prophylaxis | #4 |
| vitamin antagonist treatment | #4 |
| gramnegative bacteria humans | #4 |
| symptomatic deep | #4 |
| amadeus trial | #4 |
| diagnostic management strategies | #4 |
| patient education treatment | #4 |
| episode venous | #4 |
| travel thrombosis | #4 |
| embolism tomography | #4 |
| vitamin antagonists | #4 |
| vte netherlands | #4 |
| thromboembolism vitamin | #4 |
| cleavage sites apc | #4 |
| patients primary healthcare | #4 |
| probability prospective | #4 |
| risk occult cancer | #4 |
| primary failure rate | #4 |
| ddimer assay patients | #4 |
| thrombophilia 95 | #4 |
| criteria dose reduction | #4 |
| patient category | #4 |
| embolism roc | #4 |
| ageadjusted cutoff patients | #4 |
| serial impedance plethysmography | #4 |
| 3587 | #4 |
| vte highincome countries | #4 |
| clinically relevant bleeding | #4 |
| lmwhs standard heparin | #4 |
| treatment unfractionated heparin | #4 |
| fibrin generation test | #4 |
| bleeding anticoagulants | #4 |
| vte total | #4 |
| patients submassive | #4 |
| recurrent vte months | #4 |
| lmwh cancer patients | #4 |
| vka treatment | #4 |
| 0651 | #4 |
| dutch orthopedic | #4 |
| warfarin 3 months | #4 |
| venous thrombosis levels | #4 |
| patients crcl 60 | #4 |
| mbe patients | #4 |
| thrombosis air | #4 |
| diagnosis uedvt | #4 |
| arterial thrombotic | #4 |
| edoxaban patients | #4 |
| extended treatment | #4 |
| 150 microg levonorgestrel | #4 |
| preexisting heparin | #4 |
| patients alternative diagnosis | #4 |
| advanced cancer 95 | #4 |
| proximal patients | #4 |
| death survey | #4 |
| patients dimer | #4 |
| rfviia injection | #4 |
| clot resolution | #4 |
| life duration | #4 |
| chads2 p0001 | #4 |
| serial impedance | #4 |
| coagulation factors risk | #4 |
| dimer assays | #4 |
| population rivaroxaban | #4 |
| rviia thrombin generation | #4 |
| vte global | #4 |
| estrogen therapy patients | #4 |
| received warfarin | #4 |
| dose noacs | #4 |
| contraindications treatment | #4 |
| diagnostic prediction models | #4 |
| negative point | #4 |
| embolism dimer | #4 |
| noacs cancer patients | #4 |
| thromboembolism study | #4 |
| sankyo | #4 |
| 35±4 | #4 |
| total vte | #4 |
| thrombosis deep | #4 |
| impedance plethysmography | #4 |
| thromboembolism treatment | #4 |
| patients fondaparinux | #4 |
| global burden vte | #4 |
| patients clinically | #4 |
| lmwh female heparin | #4 |
| cancer vwf | #4 |
| hemostatic profile | #4 |
| thromboembolism occurred | #4 |
| levels ft4 | #4 |
| procoagulant factors | #4 |
| clot lysis patients | #4 |
| hyperhomocysteinemic relatives | #4 |
| ultrasonography venous | #4 |
| chemotherapy shr | #4 |
| thromboembolism factor | #4 |
| lowmolecularweight heparin | #4 |
| “reversal | #4 |
| nct00571649 | #4 |
| chromogenic compounds | #4 |
| risk vkas | #4 |
| thrombosis symptomatic | #4 |
| thromboembolism systematic | #4 |
| vte treatment patients | #4 |
| prophylaxis lmwh | #4 |
| vitamin antagonists patients | #4 |
| embolism background | #4 |
| venous thromboembolism patients | #4 |
| doac studies | #4 |
| safety pravastatin | #4 |
| control anticoagulation | #4 |
| noacs netherlands | #4 |
| thrombosis uedvt | #4 |
| patients venous thromboembolism | #4 |
| lowmolecular weight heparins | #4 |
| 150 microg desogestrel | #4 |
| thrombosis ischemic stroke | #4 |
| apixaban efficacy | #4 |
| tinaquant | #4 |
| enoxaparin day | #4 |
| patients nonpermanent | #4 |
| point dimer | #4 |
| questionnaires venous | #4 |
| rule pulmonary | #4 |
| series venograms | #4 |
| activation fibrinolytic | #4 |
| disease vte | #4 |
| predilution postdilution | #4 |
| oral rivaroxaban | #4 |
| daily netilmicin | #4 |
| preschool contraceptives | #5 |
| diagnostic strategies | #5 |
| secondary dvt | #5 |
| thromboembolism studies | #5 |
| outpatients hospital | #5 |
| clinical presentation clinical | #5 |
| fviia rnapc2 | #5 |
| women warfarin | #5 |
| pulmonary embolism patients | #5 |
| pad smoking | #5 |
| patients subtherapeutic | #5 |
| rivaroxaban enoxaparin vka | #5 |
| thrombosis primary | #5 |
| fviii families | #5 |
| clinical probability | #5 |
| dimer combination | #5 |
| hirudin treatment | #5 |
| adjusted dimer | #5 |
| coc pregnancy | #5 |
| elevated plasma level | #5 |
| embolism reproducibility | #5 |
| fh patients cvd | #5 |
| inhibition plasminogen activation | #5 |
| compression ultrasound | #5 |
| ventricular dysfunction echocardiography | #5 |
| heparin compared | #5 |
| incidence prognostic significance | #5 |
| pregnancy pph | #5 |
| recurrent dvt patients | #5 |
| low molecularweight humans | #5 |
| cgp 39393 | #5 |
| endogenous activated | #5 |
| endotoxin chimpanzees | #5 |
| cdr patients | #5 |
| thrombosis leg | #5 |
| isolated calfvein thrombosis | #5 |
| upper extremity thrombosis | #5 |
| suspected uedvt | #5 |
| bleeding cancer | #5 |
| vka patients | #5 |
| thrombophlebitis ultrasonography | #5 |
| asymptomatic carriers mutation | #5 |
| iii plasminogen | #5 |
| thromboembolism | #5 |
| dvt prevalence | #5 |
| patients recurrent dvt | #5 |
| antithrombotic drug treatment | #5 |
| severe pph women | #5 |
| ft4 level | #5 |
| coronary angioplasty angioplasty | #5 |
| thromboembolism thrombosis | #5 |
| day rivaroxaban | #5 |
| clinical probability assessment | #5 |
| venous thromboembolism studies | #5 |
| phlebography plethysmography | #5 |
| normal ctpa | #5 |
| medea study | #5 |
| outcome major | #5 |
| patients pulmonary embolism | #5 |
| patients wells score | #5 |
| sensitivity negative predictive | #5 |
| factor leiden 95 | #5 |
| burden vte | #5 |
| risk prediction scores | #5 |
| deepvein thrombosis | #5 |
| 8491 | #5 |
| previous venous thromboembolism | #5 |
| endotoxin testing | #5 |
| vte factor | #5 |
| exclusion venous thromboembolism | #5 |
| diagnosis questionnaire | #5 |
| vte patients cancer | #5 |
| specificity thrombophlebitis | #5 |
| low‐molecular‐weight | #5 |
| netilmicin patients | #5 |
| patients parenteral anticoagulants | #5 |
| transfusion blood loss | #5 |
| vte 6 | #5 |
| gestalt | #5 |
| secondary venous thrombosis | #5 |
| lmwh recommended | #5 |
| treatment fondaparinux | #5 |
| patients superficial thrombophlebitis | #5 |
| 2 rules | #5 |
| panwards | #5 |
| hokusai | #5 |
| repeated ultrasonography | #5 |
| predilution | #5 |
| thromboembolism idraparinux | #5 |
| southern latin america | #5 |
| treatment acute dvt | #5 |
| lmwh incidence | #5 |
| 8292 | #5 |
| thrombosis upper | #5 |
| cancer strategy | #5 |
| consensus strategy | #5 |
| efficiency patients | #5 |
| molecularweight heparin | #5 |
| daiichi sankyo | #5 |
| patients anticoagulation clinic | #6 |
| patients diagnostic | #6 |
| 393 patients | #6 |
| c1173 | #6 |
| ultrasonography normal | #6 |
| selective beta | #6 |
| risk increasing levels | #6 |
| synthetic pentasaccharides | #6 |
| 39393 | #6 |
| dimer cut | #6 |
| embolism ventricular | #6 |
| svt extension | #6 |
| daily gentamicin | #6 |
| combined utility | #6 |
| initial heparin treatment | #6 |
| treatment ufh | #6 |
| symptoms intermittent claudication | #6 |
| warfarin venous thromboembolism | #6 |
| effects levonorgestrel | #6 |
| ft4 patients | #6 |
| vte anticoagulant treatment | #6 |
| patients lowmolecularweight heparin | #6 |
| pulmonary embolism presence | #6 |
| recurrent pulmonary | #6 |
| standardized morbidity ratio | #6 |
| antagonists treatment | #6 |
| patients uedvt | #6 |
| arterial cardiovascular | #6 |
| lmwh users users | #6 |
| elisapositive | #6 |
| patients factor mutation | #6 |
| amplify | #6 |
| cancer primary patients | #6 |
| dalteparin dose | #6 |
| wells rule | #6 |
| 10±4 | #6 |
| subcutaneous low | #6 |
| risk khorana score | #6 |
| anticoagulants hemorrhage | #6 |
| embolism pulmonary | #6 |
| oral anticoagulants dabigatran | #6 |
| conventional therapy treatment | #6 |
| leiden | #6 |
| endotoxininduced activation | #6 |
| fixeddose regimen | #6 |
| lmwh cancer | #6 |
| blood coagulation mechanism | #6 |
| edoxaban efficacy | #6 |
| grade 1a ufh | #6 |
| anticoagulants female | #6 |
| diagnostic workup | #6 |
| oral edoxaban | #6 |
| anticoagulant treatment | #6 |
| rate major bleeding | #6 |
| incidence recurrence | #6 |
| thromboembolism bleeding | #6 |
| subjects vte | #6 |
| women hyperhomocysteinemia | #6 |
| simplired dimer | #6 |
| low absolute risk | #6 |
| isolated deficiencies | #6 |
| prevalence vte | #6 |
| duration rivaroxaban | #6 |
| treatment pulmonary embolism | #6 |
| subcutaneous nadroparin | #6 |
| probability pulmonary | #6 |
| proportion cancer patients | #6 |
| apixaban treatment dose | #6 |
| enoxaparin incidence | #6 |
| 049 95 | #6 |
| vte controls | #6 |
| funding bayer | #6 |
| clinically relevant subgroups | #6 |
| perioperative blood loss | #6 |
| patients pulmonary angiography | #6 |
| patients iohexol | #6 |
| 12month cumulative incidence | #6 |
| neoplasms pulmonary embolism | #6 |
| treatment intermittent claudication | #6 |
| thrombophilic defects | #6 |
| vte cancer | #6 |
| patients suspected | #6 |
| levonorgestrel desogestrel | #6 |
| patients tests | #6 |
| patients proximal | #6 |
| thrombosis guidelines | #6 |
| vka | #6 |
| compression stockings patients | #6 |
| outcome occurred | #6 |
| myocardial infarction ctni | #6 |
| severe antithrombin | #6 |
| severe dic | #6 |
| fviia inhibition | #6 |
| assay fibrin | #6 |
| efficiency proportion | #6 |
| stressinduced hyperglycaemia | #6 |
| pembqol questionnaire | #6 |
| repeatedly normal | #6 |
| venograms | #6 |
| symptomatic legs | #6 |
| dabigatran etexilate dabigatran | #6 |
| d‐dimer testing | #6 |
| dvt trial | #6 |
| factor leiden carriers | #6 |
| effects ufh | #6 |
| treatment svt | #6 |
| endotoxin assays | #6 |
| heparin org | #7 |
| rates edoxaban | #7 |
| thrombophilia pregnancy loss | #7 |
| tb402 | #7 |
| relation levels | #7 |
| carriers defects | #7 |
| pulmonary embolism sensitivity | #7 |
| statin treatment risk | #7 |
| thrombophlebitis adolescent | #7 |
| venous thrombosis treatment | #7 |
| unselected women | #7 |
| thromboembolism vte | #7 |
| diagnosis venous thrombosis | #7 |
| blood coagulation humans | #7 |
| relation prolactin levels | #7 |
| thromboembolism adult | #7 |
| doppler skin | #7 |
| inhibitor apixaban | #7 |
| primary dvt | #7 |
| noncompressibility | #7 |
| lung scan | #7 |
| etexilate oral | #7 |
| coagulation humans | #7 |
| carriers venous thromboembolism | #7 |
| phenprocoumon polymorphism | #7 |
| plasma levels ifngamma | #7 |
| stockings control | #7 |
| diagnostic suspicion | #7 |
| rivaroxaban 10 | #7 |
| aspirin combined | #7 |
| day initial treatment | #7 |
| administration bsf | #7 |
| mpc1609 | #7 |
| placebo rivaroxaban | #7 |
| spiral sensitivity | #7 |
| neoplasms pulmonary | #7 |
| levels factor viii | #7 |
| negative ddimer test | #7 |
| prothrombin risk | #7 |
| major bleeding | #7 |
| primary efficacy | #7 |
| 680 | #7 |
| specific antidotes | #7 |
| recurrent dvt | #7 |
| anticoagulant parameters | #7 |
| dvt ipg | #7 |
| vte cancer diagnosis | #7 |
| nondiagnostic lung scans | #7 |
| patients standard heparin | #7 |
| negative predictive npv | #7 |
| thromboembolism total | #7 |
| major bleeding rate | #7 |
| antithrombin protein | #7 |
| perelated death | #7 |
| silent pulmonary embolism | #7 |
| ottawa score | #7 |
| leg ultrasonography | #7 |
| deepvein thrombosis patients | #7 |
| protein protein deficiencies | #7 |
| factor female humans | #7 |
| embolism prospective | #7 |
| general practitioners guideline | #7 |
| 220 dabigatran | #7 |
| arterial cardiovascular disease | #7 |
| combination ipg | #7 |
| vitamin antagonists vka | #7 |
| major bleeding vkas | #7 |
| incidence recurrent vte | #7 |
| mutations factor viii | #7 |
| 597939 | #7 |
| presence cteph | #7 |
| proportion older patients | #7 |
| treatment doac | #7 |
| ufh treatment | #7 |
| vka therapy | #7 |
| tnf injection | #7 |
| oral glucocorticoids risk | #8 |
| current approach | #8 |
| 150 enoxaparin | #8 |
| contrast venography | #8 |
| proximal deepvein thrombosis | #8 |
| optimal intensity | #8 |
| treatment venous thrombosis | #8 |
| nondiagnostic scan | #8 |
| oral apixaban | #8 |
| dimer tests | #8 |
| comorbidity polypharmacy | #8 |
| prospective management | #8 |
| inherited thrombophilic | #8 |
| anticoagulants antineoplastic | #8 |
| overt cancer | #8 |
| ageadjusted ddimer cutoff | #8 |
| lmwh grade 1a | #8 |
| patients extended anticoagulation | #8 |
| funding daiichi | #8 |
| occult cancer patients | #8 |
| v617f jak2 | #8 |
| leiden prothrombin | #8 |
| administration low | #8 |
| 1599 patients | #8 |
| inr values patients | #8 |
| ufh initial treatment | #8 |
| patients excluded | #8 |
| xii deficient | #8 |
| enoxaparin vka | #8 |
| aged phlebography | #8 |
| thrombosis adolescent | #8 |
| warfarin hazard ratio | #8 |
| low clinical probability | #8 |
| homocysteine markers | #8 |
| inr determination | #8 |
| point ultrasonography | #8 |
| symptomatic deepvein thrombosis | #8 |
| chemotherapy low risk | #8 |
| deficiency antithrombin | #8 |
| levonorgestrelcontaining | #8 |
| vka lmwh | #8 |
| heparin vitamin antagonists | #8 |
| euro55 | #8 |
| dimer concentration | #8 |
| wells scores | #8 |
| agnelli | #8 |
| venous thrombosis hyperhomocysteinaemia | #8 |
| severe preeclampsia patients | #8 |
| anticoagulation unprovoked vte | #8 |
| tests pulmonary | #8 |
| 0·2 | #8 |
| apixaban enoxaparin | #8 |
| products humans | #8 |
| unprovoked vte patients | #8 |
| probability lung | #8 |
| risk employees | #8 |
| analysis apixaban | #8 |
| cancer pulmonary embolism | #8 |
| normal computed | #8 |
| arg506 factor | #8 |
| vascular endothelial barrier | #8 |
| oac adherence | #8 |
| vte score | #8 |
| vitamin antagonists vkas | #8 |
| proximal deep | #8 |
| duration treatment | #8 |
| discontinuation anticoagulant treatment | #8 |
| compression surveys | #8 |
| structured algorithm | #8 |
| risks dvt | #8 |
| years cumulative incidence | #8 |
| international organisations | #8 |
| testing rule | #8 |
| increased fibrinolytic | #8 |
| nafronyl | #8 |
| physicians stockings | #8 |
| initial heparin | #8 |
| recurrent vte bleeding | #8 |
| p0001 hasbled score | #8 |
| persistent risk factors | #8 |
| bnp ctnt | #8 |
| patients symptomatic vte | #8 |
| recurrent vte mb | #8 |
| carriers fvl | #8 |
| objectively confirmed | #8 |
| acute symptomatic vte | #8 |
| pvoct | #8 |
| prevention vte | #8 |
| consecutive outpatients | #8 |
| fxi aso | #8 |
| thrombosis prophylaxis | #8 |
| 97 95 | #8 |
| concomitant cancer | #9 |
| edoxaban major bleeding | #9 |
| iii concentrate | #9 |
| incidental pulmonary | #9 |
| fxa inhibitor | #9 |
| postdilution | #9 |
| placebo plasma levels | #9 |
| characteristics severity | #9 |
| months efficacy | #9 |
| acute medical illnesses | #9 |
| cancer cell extravasation | #9 |
| therapeutic dose patients | #9 |
| discontinuing anticoagulation | #9 |
| vte relatives | #9 |
| independent committee | #9 |
| thrombosis venous thromboembolism | #9 |
| serotonin platelet | #9 |
| nonpermanent | #9 |
| longterm treatment vte | #9 |
| prothrombin 20210a | #9 |
| lipoproteina women | #9 |
| bled bleeding | #9 |
| patients fxa inhibitors | #9 |
| weight heparin | #9 |
| cancer episode | #9 |
| heparin therapy patients | #9 |
| oral antithrombins | #9 |
| treatment prophylaxis | #9 |
| normal ddimer | #9 |
| combination stroke | #9 |
| atiii concentrates | #9 |
| male oligosaccharides | #9 |
| vte rcts | #9 |
| ultrasonogram | #9 |
| büller | #9 |
| factors thrombophlebitis | #9 |
| carriers factor leiden | #9 |
| abnormal vaginal | #9 |
| oral contraceptive pregnancy | #9 |
| thrombosis compared | #9 |
| thromboembolism cancer | #9 |
| enoxaparin factor | #9 |
| comorbidities polypharmacy | #9 |
| treatment edoxaban | #9 |
| strategies dimer | #9 |
| lmwh mortality | #9 |
| fondaparinux cancer patients | #9 |
| patients active cancer | #9 |
| major bleeding treatment | #9 |
| crcl 60 | #9 |
| anticoagulant pathways | #9 |
| tafi levels | #9 |
| compression stockings prevention | #9 |
| daiichisankyo | #9 |
| embolism venous | #9 |
| method enoxaparin | #9 |
| generation pill | #9 |
| incidence postthrombotic syndrome | #9 |
| apixaban oral factor | #9 |
| thrombosis thromboinflammation | #9 |
| diagnostic prediction model | #9 |
| cofact | #9 |
| cancer factor | #9 |
| diagnosis mdct | #9 |
| homocysteine women | #9 |
| hemorr2hages atria | #9 |
| venous thrombosis | #10 |
| oral thrombin inhibitor | #10 |
| nadroparine | #10 |
| lmwh studies | #10 |
| vte efficacy | #10 |
| subcutaneous metaanalysis | #10 |
| 4470 | #10 |
| inherited thrombophilic factors | #10 |
| magellan study | #10 |
| treatment uedvt | #10 |
| major bleeding crnmb | #10 |
| year years | #10 |
| 100 years discontinuation | #10 |
| normohomocysteinemic | #10 |
| cvd fh patients | #10 |
| treatment vitamin | #10 |
| inr cases | #10 |
| fondaparinux risk | #10 |
| oral administration dabigatran | #10 |
| heparin nomogram | #10 |
| intimamedia thickness imt | #10 |
| thr incidence | #10 |
| venous thromboembolic event | #10 |
| embolism clinical | #10 |
| ddimer concentration | #10 |
| rates recurrent vte | #10 |
| patients endotoxemia | #10 |
| pregnancy carriers | #10 |
| induced coagulation | #10 |
| factor prevention | #10 |
| simplified geneva | #10 |
| deficiencies antithrombin | #10 |
| severity clinical | #10 |
| thrombosis background | #10 |
| vnv | #10 |
| bled scores | #10 |
| factor levels patients | #10 |
| wells | #10 |
| ageadjusted cutoff | #10 |
| incidence 1000 personyears | #10 |
| protein dic | #10 |
| schedule heparin | #10 |
| hypocoagulable state | #10 |
| patients venous thrombosis | #10 |
| magellan trial | #10 |
| cancer patients vte | #10 |
| 1215 patients | #10 |
| incidence major bleeding | #10 |
| anticoagulants | #10 |
| cus diagnosis | #10 |
| embolism patients | #10 |
| crp test | #10 |
| 598 patients | #10 |
| animal heparin | #10 |
| rabbits administration | #10 |
| treatment aprotinin | #10 |
| asymptomatic pulmonary embolism | #10 |
| dvt lower extremity | #10 |
| rfviia blood loss | #10 |
| fii mutation | #10 |
| thrombophlebitis adult | #10 |
| probability pulmonary embolism | #10 |
| retrospective study efficacy | #10 |
| single loss | #10 |
| snp scores | #10 |
| aged antithrombin | #10 |
| extremity deep | #10 |
| leg veins | #10 |
| injection avidin | #10 |
| gramnegative septicemia | #10 |
| cancer patients lmwh | #10 |
| lmwh pregnancies | #11 |
| intensity anticoagulation | #11 |
| vte vwf | #11 |
| 30 microg ethinylestradiol | #11 |
| crnmb 95 | #11 |
| dabigatran enoxaparin | #11 |
| patients cancer vte | #11 |
| pcc dabigatran | #11 |
| thromboembolism major | #11 |
| pregnancyrelated complications | #11 |
| endotoxin pentoxifylline | #11 |
| cancer patients evidence | #11 |
| ldfr | #11 |
| edoxaban | #11 |
| incidence major | #11 |
| 750 μg | #11 |
| lmwh pregnancy | #11 |
| ufh studies | #11 |
| patients probability | #11 |
| levels prolactin | #11 |
| medical conferences | #11 |
| recombinant human tnf | #11 |
| pyridines thiazoles | #11 |
| gps training | #11 |
| carriers factor | #11 |
| haemophilia vwd | #11 |
| embolism prevalence | #11 |
| combination dimer | #11 |
| dvt | #11 |
| pulmonary embolism incidence | #11 |
| previous venous | #11 |
| fondaparinux hemorrhage | #11 |
| patients anticoagulant treatment | #11 |
| screening cancer | #11 |
| clinical pretest | #11 |
| oral dabigatran | #11 |
| org 10172 | #11 |
| inhibitors hemorrhage | #11 |
| knee clinical trials | #11 |
| air travel | #11 |
| weight humans | #11 |
| hospital lmwh | #11 |
| mutations prevalence | #11 |
| d‐dimer levels | #11 |
| patients cvcs | #11 |
| endotoxin assay | #11 |
| cancer patients dvt | #11 |
| reference testing | #11 |
| 880 patients | #11 |
| heparinoid org | #11 |
| sulfates dermatan | #11 |
| gentamicin treatment patients | #11 |
| variation inr | #11 |
| adult anticoagulants | #11 |
| embolism recurrence | #11 |
| factor venous | #11 |
| pulmonary angiography venography | #11 |
| hemodynamically stable | #12 |
| 9702 | #12 |
| nephro | #12 |
| thrombophilic | #12 |
| warfarin treated | #12 |
| crd42013003526 | #12 |
| event recurrence | #12 |
| outpatient management patients | #12 |
| months primary | #12 |
| warfarin recurrent vte | #12 |
| fondaparinux unfractionated heparin | #12 |
| recurrent vte | #12 |
| doseadjustment | #12 |
| deficient women | #12 |
| recurrent vte anticoagulation | #12 |
| ageadjusted ddimer | #12 |
| patients lmwhs | #12 |
| thrombosis dvt | #12 |
| livebirth rate | #12 |
| vka noacs | #12 |
| paulin | #12 |
| patients incidental | #12 |
| risk venous | #12 |
| dvt treatment | #12 |
| anticoagulation unprovoked | #12 |
| 9295 | #12 |
| venous thromboembolism incidence | #12 |
| peghirudin | #12 |
| geneva score | #12 |
| factor leiden prothrombin | #12 |
| 72 children | #12 |
| bnp cardiac troponin | #12 |
| perelated | #12 |
| prevention venous thrombosis | #12 |
| outcomes venous thromboembolism | #12 |
| noacs vka | #12 |
| women factor | #12 |
| observation risk | #12 |
| concomitant disorders | #12 |
| female heparin humans | #12 |
| anticoagulant factor | #12 |
| humanized arthroplasty | #12 |
| annual incidence vte | #12 |
| subsegmental pulmonary emboli | #12 |
| patients lupus anticoagulant | #12 |
| control metaanalysis | #12 |
| safety efficiency | #12 |
| vte recurrence risk | #12 |
| hirulog1 | #12 |
| proximal veins | #12 |
| bayer schering pharma | #12 |
| pioped study | #12 |
| proximal vein | #12 |
| treatment crt | #12 |
| thrombin generation fibrinolysis | #12 |
| topic venous | #12 |
| stopping anticoagulation | #12 |
| warfarin therapy inr | #12 |
| dvt lower | #13 |
| marder score | #13 |
| factor leiden mutation | #13 |
| strain gauge plethysmography | #13 |
| uedvt | #13 |
| category studies | #13 |
| bleeding events edoxaban | #13 |
| obesity haemophilia patients | #13 |
| vte 64 | #13 |
| vte groups | #13 |
| prevention venous thromboembolism | #13 |
| major hip | #13 |
| continuous intravenous heparin | #13 |
| randomized cross | #13 |
| factor viii apc | #13 |
| plethysmography | #13 |
| arterial thromboembolism ate | #13 |
| superficial thrombophlebitis | #13 |
| clinical decision rules | #13 |
| time prothrombin | #13 |
| recombinant hirudin rhirudin | #13 |
| levels factor | #13 |
| selective testing | #13 |
| plethysmograms | #13 |
| groups inr | #13 |
| dimer threshold | #13 |
| pselectin patients | #13 |
| heparin low | #13 |
| treatment venous thromboembolism | #13 |
| vte major | #13 |
| indication anticoagulation | #13 |
| arixtra | #13 |
| safety doacs | #13 |
| patients thrombophilia | #13 |
| hematologic pregnancy trimester | #13 |
| nct00986154 | #13 |
| dabigatran vte | #13 |
| antithrombin iii activity | #13 |
| thrombosis acute | #13 |
| thrombosis young | #13 |
| ufh dalteparin | #13 |
| dabigatran 220 | #13 |
| safety oral | #13 |
| inhibition tnf | #13 |
| 86 percent | #13 |
| daily subcutaneous | #13 |
| 95 carriers | #13 |
| patients anticoagulant | #13 |
| conventional anticoagulants | #13 |
| vte recurrence 95 | #13 |
| spiral computed tomography | #13 |
| bayer healthcare | #13 |
| vte female humans | #13 |
| inferiority efficacy | #13 |
| dimer testing | #13 |
| association venous thrombosis | #13 |
| occult cancer | #13 |
| rivaroxaban thiophenes | #13 |
| deepvein thrombosis dvt | #13 |
| concomitant antiplatelet therapy | #13 |
| vte | #13 |
| conventionaltherapy | #14 |
| treated lmwh | #14 |
| costs dvt | #14 |
| crnm | #14 |
| loss women | #14 |
| acute deep | #14 |
| fvl carriers | #14 |
| cadherins endothelium | #14 |
| effects hyperthyroidism | #14 |
| atiii deficiency | #14 |
| safety edoxaban | #14 |
| anticoagulant rivaroxaban | #14 |
| aged plethysmography | #14 |
| incidence severe pph | #14 |
| recurrent venous | #14 |
| limited screening | #14 |
| standard heparin | #14 |
| recurrent venous thromboembolism | #14 |
| symptomatic pulmonary | #14 |
| riete score | #14 |
| vte months | #14 |
| factor viii levels | #14 |
| obstetric complications women | #14 |
| edoxaban warfarin | #14 |
| vte statin | #14 |
| plasminogen apoa | #14 |
| cancer patients anticoagulation | #14 |
| ultrasound strategies | #14 |
| aged anticoagulants | #14 |
| experimental endotoxaemia | #14 |
| edoxaban oral factor | #14 |
| bolus intravenous injection | #14 |
| placebo rfviia | #14 |
| aspirin women | #14 |
| female fibrin | #14 |
| dvt lower extremities | #14 |
| patients outpatients | #14 |
| doseranging study | #14 |
| thrombosis | #14 |
| lmwh vka | #14 |
| pregnancy venous | #14 |
| gastrointestinal bleeding patients | #14 |
| revised geneva | #14 |
| awareness pad | #14 |
| 17 placebo | #14 |
| unprovoked vte vte | #14 |
| patients vka therapy | #14 |
| higher ddimer levels | #14 |
| low molecular | #14 |
| patients dvt | #14 |
| thrombophilia patients | #14 |
| treatment duration patients | #14 |
| patients acute vte | #14 |
| 12 kg1 | #14 |
| thromboembolism age | #14 |
| thyroid hormone excess | #15 |
| activation contact | #15 |
| symptomatic events | #15 |
| lomoparan | #15 |
| studies pulmonary | #15 |
| abdominal pelvic | #15 |
| vitaminkantagonists | #15 |
| clinically relevant endpoints | #15 |
| arg562 | #15 |
| control subjects prevalence | #15 |
| prior venous thromboembolism | #15 |
| thrombus growth | #15 |
| diagnosis venous | #15 |
| factor leiden | #15 |
| doacs aspirin | #15 |
| edoxaban treatment | #15 |
| coc vte | #15 |
| established vte | #15 |
| cteph incidence | #15 |
| generation oral | #15 |
| inr range | #15 |
| subcutaneous regimen | #15 |
| anticoagulants patients | #15 |
| patients vitamin antagonists | #15 |
| recombinant factor viia | #15 |
| khorana score | #15 |
| patients ctpa | #15 |
| cardiovascular diseases thrombosis | #15 |
| oral direct factor | #15 |
| subcutaneous enoxaparin | #15 |
| inr patient | #15 |
| lmwh ufh | #15 |
| 500 pg | #15 |
| pregnancy outcome pregnancy | #15 |
| experimental thrombosis | #15 |
| fondaparinux efficacy | #15 |
| enoxaparin vte | #15 |
| treatment 12 months | #15 |
| thrombinography | #15 |
| antagonist vka | #15 |
| thrombosis diagnosis | #15 |
| probability assessment | #15 |
| arg506 | #15 |
| prophylaxis venous thromboembolism | #15 |
| hyperthyroidism atrial fibrillation | #15 |
| coagulation | #15 |
| primary safety outcome | #15 |
| thromboembolism time | #16 |
| vterelated death | #16 |
| venous thrombosis warfarin | #16 |
| major bleeding anticoagulation | #16 |
| combination clinical | #16 |
| postthrombotic syndrome children | #16 |
| netilmicin gentamicin | #16 |
| thrombosis low | #16 |
| bleeding aged | #16 |
| thrombosis haemostasis | #16 |
| impaired fibrinolysis | #16 |
| vte khorana score | #16 |
| 6 months placebo | #16 |
| ddimer levels patients | #16 |
| arterial vascular events | #16 |
| women unexplained | #16 |
| subsequent pregnancy loss | #16 |
| avws patients | #16 |
| factor inhibitor | #16 |
| risk clinically | #16 |
| thrombosis adult | #16 |
| thrombosis association | #16 |
| dvt lmwh | #16 |
| 100 95 | #16 |
| major bleeding events | #16 |
| recurrent symptomatic | #16 |
| analysis rivaroxaban | #16 |
| positivity threshold | #16 |
| cancer cancer patients | #16 |
| abdomino | #16 |
| patients acenocoumarol | #16 |
| test clinical | #16 |
| deep venous thrombosis | #16 |
| occult cancer detection | #16 |
| factors major | #16 |
| viia activity | #16 |
| cancer screening patients | #16 |
| warfarin acenocoumarol | #16 |
| thromboembolism patients | #17 |
| compared enoxaparin | #17 |
| excessive blood loss | #17 |
| diagnosis svt | #17 |
| dimer assay | #17 |
| mutation women | #17 |
| gentamicin netilmicin | #17 |
| incidence pts | #17 |
| vte edoxaban | #17 |
| women mutation | #17 |
| 2688 | #17 |
| permanent patients | #17 |
| lower specificity | #17 |
| anticoagulants clinical | #17 |
| management crt | #17 |
| 516 patients | #17 |
| lmwhs patients | #17 |
| ctscans | #17 |
| fibrinolysis treatment | #17 |
| factors venous | #17 |
| prohemostatic | #17 |
| endotoxemia bacteremia | #17 |
| scan classification | #17 |
| 12 months patients | #17 |
| hematoma heparin | #17 |
| thrombosis clinical | #17 |
| fragment f1 | #17 |
| anticoagulants drug | #17 |
| patients impedance | #17 |
| recurrent vte events | #17 |
| anticoagulant therapy patients | #17 |
| patients overt hypothyroidism | #17 |
| dvt prevention | #17 |
| rivaroxaban oral factor | #17 |
| factor monoclonal | #17 |
| pharmo record linkage | #17 |
| female humans vte | #17 |
| vkorc1 gene | #17 |
| topic hemorrhage humans | #17 |
| diagnostic strategy | #18 |
| simplired | #18 |
| cancer vte | #18 |
| stable anticoagulation | #18 |
| venous thromboembolism rivaroxaban | #18 |
| antithrombotic treatment patients | #18 |
| vka vte | #18 |
| weight adjusted | #18 |
| annual incidence | #18 |
| 4 clinical | #18 |
| warfarin hazard | #18 |
| poc test | #18 |
| edoxaban vte | #18 |
| thromboembolism venous | #18 |
| intravenous heparin therapy | #18 |
| flight hours | #18 |
| combined form | #18 |
| sanofi aventis | #18 |
| lmwh doacs | #18 |
| relevant nonmajor | #18 |
| prothrombin g20210a | #18 |
| 023 | #18 |
| thrombosis pulmonary | #18 |
| patients strategy | #18 |
| outcome events | #18 |
| thrombosis total | #18 |
| proximal vein thrombosis | #18 |
| commercial airline pilots | #18 |
| treatment vkas | #18 |
| women pregnancy loss | #18 |
| favor lmwh | #18 |
| aptt heparin | #18 |
| apc thrombin generation | #18 |
| hivinfected patients cart | #18 |
| vka edoxaban | #18 |
| ufh lmwh | #19 |
| vwf vte | #19 |
| retropubic prostatectomy | #19 |
| increased risk relatives | #19 |
| patients elevated biomarkers | #19 |
| recurrence vte | #19 |
| endogenous fibrinolysis | #19 |
| increased fibrinolytic activity | #19 |
| patients derivation | #19 |
| ipdma | #19 |
| low platelets | #19 |
| 35 women | #19 |
| thromboembolism administration | #19 |
| patients sspe | #19 |
| 56 95 | #19 |
| local angiogenesis | #19 |
| acute recurrent | #19 |
| venous thromboembolism relatives | #19 |
| patients major bleeding | #19 |
| extended oral | #19 |
| patients prevalence | #19 |
| edoxaban dose | #19 |
| vitamin antagonist | #19 |
| fibrinolytic response | #19 |
| recurrent venous thrombosis | #19 |
| treatment heparin | #19 |
| coagulation studies | #19 |
| venography sensitivity | #19 |
| active search | #19 |
| objective testing | #19 |
| systemic activation coagulation | #19 |
| dvt rivaroxaban | #19 |
| studies factor | #19 |
| doubleblinding | #19 |
| lmwh patients | #19 |
| versions version | #19 |
| ddimer tests | #19 |
| fondaparinux enoxaparin | #19 |
| subcutaneous dalteparin | #19 |
| adjusted dose | #19 |
| prognostic echocardiography | #19 |
| abnormal ultrasound | #19 |
| oral dabigatran enoxaparin | #19 |
| antibodynegative | #19 |
| symptomatic dvt | #19 |
| therapy rivaroxaban | #20 |
| thrombosis ultrasonography | #20 |
| incidences death | #20 |
| shr 95 | #20 |
| risk thrombophilia | #20 |
| single criterion | #20 |
| standardtherapy hazard ratio | #20 |
| control situation | #20 |
| compared ufh | #20 |
| nadroparin | #20 |
| diagnostic workup patients | #20 |
| prothrombin mutation | #20 |
| proteins thrombin | #20 |
| malignancy time | #20 |
| life venous thrombosis | #20 |
| calf veins | #20 |
| excluded patients | #20 |
| distance treatment | #20 |
| subsegmental | #20 |
| new agent | #20 |
| cancer severity | #20 |
| pregnancyrelated vte | #20 |
| impedance plethysmography ipg | #20 |
| blindly | #20 |
| antagonists vkas | #20 |
| abi measurement | #20 |
| intravenous injections | #20 |
| carriers prothrombin | #20 |
| absolute risk | #20 |
| guidance ssc | #20 |
| treatment vte | #20 |
| ctnt bnp | #20 |
| symptomatic venous thrombosis | #20 |
| thrombophilia vte | #20 |
| portola | #20 |
| antitpo | #20 |
| dabigatran 150 | #20 |
| residual venous | #20 |
| warfarin edoxaban | #20 |
| patients ddimer testing | #20 |
| synthetic cross | #20 |
| anticoagulation clinic | #20 |
| recurrence bleeding | #20 |
| abi risk factors | #20 |
| versions questionnaire | #20 |
| established atherosclerosis | #20 |
| injections subcutaneous | #20 |
| statin vte | #20 |
| treatment apixaban | #21 |
| prothrombin 20210 | #21 |
| ddimer concentrations | #21 |
| disease ischemic | #21 |
| internists cardiologists | #21 |
| d‐dimer | #21 |
| thrombosis anticoagulants | #21 |
| risk cohort study | #21 |
| vte patients | #21 |
| fibrinolysis inflammation | #21 |
| deep venous | #21 |
| concomitant anti | #21 |
| venogram | #21 |
| patients 3 months | #21 |
| outcome incidence | #21 |
| occult malignancy | #21 |
| discriminatory performance | #21 |
| major bleeding patients | #21 |
| hemostatic abnormalities | #21 |
| doacs lmwhs | #21 |
| thromb | #21 |
| carriers noncarriers | #21 |
| treatment acenocoumarol | #21 |
| hemodynamically stable patients | #21 |
| current standard treatment | #21 |
| distance quality | #21 |
| host defense response | #22 |
| cttr | #22 |
| safety treatment | #22 |
| treatment dvt | #22 |
| acute vte | #22 |
| dimer age | #22 |
| public awareness | #22 |
| anticoagulants humans | #22 |
| anticoagulants heparin | #22 |
| thrombophilia screening | #22 |
| dose subcutaneous | #22 |
| daily enoxaparin | #22 |
| patients severe hf | #22 |
| doppler venous thrombosis | #22 |
| lpa plasminogen | #22 |
| recurrent thromboembolism | #22 |
| patients recurrent symptoms | #22 |
| patients immobilization | #22 |
| vascular endotoxins | #22 |
| ttr inr | #22 |
| alternative anticoagulation | #22 |
| riskbenefit ratio | #22 |
| time inr | #22 |
| venous thromboembolic | #22 |
| bleeding treatment | #22 |
| hormonal cross | #22 |
| cmax ctrough | #22 |
| patientyears | #22 |
| dichotomously | #22 |
| development dic | #23 |
| time platelet | #23 |
| life pulmonary embolism | #23 |
| prevalence venous thromboembolism | #23 |
| percentage increase | #23 |
| patients coagulation disorders | #23 |
| standardduration | #23 |
| bidirectional relation | #23 |
| venous arterial thrombosis | #23 |
| gentamicin patients | #23 |
| cancer patients risk | #23 |
| thromboembolism anticoagulants | #23 |
| rivaroxaban dosing | #23 |
| odis | #23 |
| elevated ctni | #23 |
| hasbled score | #23 |
| vte studies | #23 |
| ambulatory cancer patients | #23 |
| kakkar | #23 |
| normal angiogram | #23 |
| n1157 | #23 |
| 5392 | #23 |
| enoxaparin 40 | #23 |
| direct factor inhibitors | #23 |
| fondaparinux | #23 |
| 011 | #23 |
| lower extremity amputation | #23 |
| clotbound thrombin | #23 |
| 2 investigators | #23 |
| recurrence venous | #23 |
| bleeding complication | #24 |
| lowmolecularweight humans | #24 |
| fondaparinux placebo | #24 |
| prevalence deficiencies | #24 |
| recurrent thromboembolism patients | #24 |
| ufh patients | #24 |
| parameters fibrinolysis | #24 |
| subtherapeutic | #24 |
| overt hyperthyroidism | #24 |
| recurrent pulmonary embolism | #24 |
| levels fviii | #24 |
| therapy heparin | #24 |
| desogestrel levonorgestrel | #24 |
| years episode | #24 |
| month incidence | #24 |
| rates venous thromboembolism | #24 |
| thrombosis carriers | #24 |
| specific antidote | #24 |
| food drugs | #24 |
| presence dvt | #24 |
| followup incidence | #24 |
| patients abnormal perfusion | #24 |
| 049 | #24 |
| ddimer testing | #24 |
| independent external validation | #24 |
| safety fondaparinux | #24 |
| a21gly | #24 |
| patients severe bleeding | #24 |
| predefined criteria | #24 |
| patients acute treatment | #24 |
| viiic | #24 |
| suggestions improvement | #25 |
| amadeus | #25 |
| lmwh treatment | #25 |
| cha2ds2vasc chads2 | #25 |
| xii activity | #25 |
| middeldorp | #25 |
| expert radiologists | #25 |
| patients gastrointestinal bleeding | #25 |
| specificity efficiency | #25 |
| willebrand factor adamts13 | #25 |
| studies lmwh | #25 |
| influence smoking | #25 |
| anatomical extent | #25 |
| treatment symptomatic | #25 |
| perfusion lung scan | #25 |
| thromboembolism acute | #25 |
| f1 2 levels | #25 |
| factors anticoagulants | #25 |
| sepsis intravascular coagulation | #25 |
| fatima | #25 |
| vte clinical | #25 |
| fibrinogen degradation | #25 |
| edoxaban vka | #26 |
| edoxaban versus | #26 |
| viia complex | #26 |
| dalteparin ufh | #26 |
| thromboprophylaxis hospitalized patients | #26 |
| patients symptomatic dvt | #26 |
| specificity negative predictive | #26 |
| 9715 | #26 |
| events year | #26 |
| homozygous carriers | #26 |
| patients cdr | #26 |
| treatment lmwh | #26 |
| parameters risk | #26 |
| doacs vitamin antagonists | #26 |
| failure rate | #26 |
| major bleeding bleeding | #26 |
| miscarriage stillbirth | #26 |
| venous thromboemboli | #26 |
| ecq | #26 |
| rethoracotomy | #26 |
| hormonal manipulation | #26 |
| patients essential thrombocythaemia | #26 |
| asymptomatic carriers | #26 |
| unprovoked vte | #26 |
| rate recurrent vte | #26 |
| noncarriers 95 | #27 |
| combined training | #27 |
| thrombosis venous | #27 |
| extremity venous | #27 |
| patients elevated levels | #27 |
| patients major hemorrhage | #27 |
| unprovoked venous | #27 |
| 0·63 | #27 |
| vte thr | #27 |
| npv patients | #27 |
| enoxaparin female | #27 |
| female heterozygote | #27 |
| thrombocytopenia antibodies | #27 |
| training gps | #27 |
| patients 50 | #27 |
| treating physician | #27 |
| lmwh prophylaxis | #27 |
| lowmolecularweight heparin patients | #27 |
| airline pilots | #27 |
| thrombophlebitis | #27 |
| low molecularweight heparin | #27 |
| anticoagulants factor | #27 |
| months studies | #27 |
| venous thromboembolism carriers | #27 |
| current guidance | #27 |
| anticoagulants blood | #27 |
| day 35 | #27 |
| cancer spread | #27 |
| perfusion lung | #27 |
| nonmajor | #27 |
| vte doacs | #27 |
| patients unprovoked | #28 |
| 4650 | #28 |
| cancer venous thromboembolism | #28 |
| factors recurrent | #28 |
| embolism retrospective | #28 |
| pembqol | #28 |
| monitoring therapy | #28 |
| 2½ | #28 |
| unexplained | #28 |
| vte 6 months | #28 |
| presentation followup | #28 |
| hirudin therapy | #28 |
| rfviia placebo | #28 |
| receiving rivaroxaban | #28 |
| anticoagulation women | #28 |
| pph severe pph | #28 |
| apc plasma | #28 |
| vitamin aged | #28 |
| coagulation tissue factor | #28 |
| anticoagulants compared | #28 |
| objective tests | #28 |
| acutely medical patients | #28 |
| tests diagnostic | #28 |
| therapeutic doses | #28 |
| specific reversal agent | #28 |
| authors incidence | #29 |
| heparin versus | #29 |
| thrombosis 95 | #29 |
| dutch famine | #29 |
| recurrence svt | #29 |
| patients avws | #29 |
| thrombo | #29 |
| g20210a mutation | #29 |
| aged morpholines | #29 |
| pulmonary embolism death | #29 |
| septicemia | #29 |
| sex‐specific differences | #29 |
| prediction scores | #29 |
| pulmonary angiography | #29 |
| diagnosis dvt | #29 |
| major bleeding rivaroxaban | #29 |
| 1000 individuals | #29 |
| oral glucocorticoids | #29 |
| thrombosis treatment | #29 |
| aspirin placebo | #29 |
| acenocoumarol patients | #29 |
| spread cancer | #29 |
| dabigatran pcc | #29 |
| plateletactivating antibodies | #29 |
| bleeding increased | #29 |
| years year | #29 |
| direct oral anticoagulants | #29 |
| blind trials | #29 |
| resistance activated protein | #29 |
| 8240 | #29 |
| dvt pulmonary embolism | #29 |
| aminoglycoside therapy | #29 |
| patients standard therapy | #29 |
| pbac score | #29 |
| current management strategies | #29 |
| cindexes | #29 |
| pulmonary embolism recurrence | #29 |
| 1000 personyears incidence | #30 |
| vte coc | #30 |
| patients vte | #30 |
| costs diagnosis | #30 |
| thromboembolism warfarin | #30 |
| administration pentoxifylline | #30 |
| rule patients | #30 |
| prevention venous | #30 |
| embolism risk | #30 |
| direct oral factor | #30 |
| support techniques | #30 |
| 95 risk | #30 |
| doac vka | #30 |
| markers coagulation activation | #30 |
| cancer venous | #30 |
| new anticoagulants | #30 |
| residual thrombosis | #30 |
| subcutaneous heparin | #30 |
| ufh vte | #30 |
| xii factor | #30 |
| f1 2 | #30 |
| women recurrent miscarriage | #31 |
| 8755 | #31 |
| extended prophylaxis | #31 |
| placebo observation | #31 |
| imaging sensitivity specificity | #31 |
| experimental endotoxemia | #31 |
| patients deepvein thrombosis | #31 |
| pharmacological prophylaxis | #31 |
| events 95 | #31 |
| standardtherapy | #31 |
| prevalence probability | #31 |
| inhibitor edoxaban | #31 |
| incidence pph | #31 |
| thromboembolism adolescent | #31 |
| antithrombotic therapies | #31 |
| thromboprophylaxis risk | #31 |
| incidence cteph | #31 |
| term risk | #31 |
| rfviia novoseven | #31 |
| apixaban placebo | #31 |
| iii activity | #31 |
| analysis reviewers | #31 |
| recurrent patients | #31 |
| recurrent episode | #31 |
| activation blood coagulation | #31 |
| ufh fondaparinux | #31 |
| dvt pulmonary | #31 |
| dimer cutoff | #31 |
| ventilation scintigraphy | #31 |
| rhir | #31 |
| 2 antiplasmin | #31 |
| bled | #31 |
| vte ufh | #31 |
| recurrent vte patients | #31 |
| 0206 | #31 |
| warfarin vte | #32 |
| negative dimer | #32 |
| factor female | #32 |
| low clinical | #32 |
| netherlands predictive | #32 |
| factors thrombolytic | #32 |
| khorana score patients | #32 |
| parenteral anticoagulants | #32 |
| year 95 | #32 |
| normal genotype | #32 |
| international society thrombosis | #32 |
| varicosis | #32 |
| parenteral anticoagulation | #32 |
| generation patients | #32 |
| leiden mutation | #32 |
| resistance activated | #32 |
| negative septicemia | #32 |
| treatment anticoagulants | #32 |
| age adjusted | #32 |
| suspected patients | #32 |
| ufh | #32 |
| factor viii patients | #33 |
| mega study | #33 |
| pulmonary angiogram | #33 |
| low probability | #33 |
| prophylaxis vte | #33 |
| heparin lmwh | #33 |
| chapter patients | #33 |
| active implementation | #33 |
| thromboembolism young | #33 |
| subcutaneous male | #33 |
| activation factors | #33 |
| additional tests | #33 |
| apixaban treatment | #33 |
| nephrotoxicity gentamicin | #33 |
| rhirudin | #33 |
| cancer patients diagnosis | #33 |
| unitage | #33 |
| warfarin risks | #33 |
| anticoagulant protein | #33 |
| data meta | #33 |
| pregnancy loss women | #34 |
| 10 95 | #34 |
| subsegmental pulmonary embolism | #34 |
| control trials | #34 |
| bilateral venography | #34 |
| lmwh unfractionated heparin | #34 |
| warfarin adult | #34 |
| deficiency protein | #34 |
| thrombosis lower | #34 |
| 3 months treatment | #34 |
| vte compared | #34 |
| 590 | #34 |
| phytonadione | #34 |
| anticoagulant | #34 |
| reocclusion patients | #34 |
| compare efficacy | #34 |
| 9241 | #34 |
| grade 1a | #34 |
| apcsr | #34 |
| vte thrombophilia | #34 |
| plasmin alpha | #34 |
| hemorrhage heparin humans | #34 |
| patients efficiency | #35 |
| anticoagulants benzimidazoles | #35 |
| risk members | #35 |
| embolism | #35 |
| 36 95 | #35 |
| rviia | #35 |
| radiologists diagnosis | #35 |
| pph blood loss | #35 |
| lung scanning | #35 |
| activation coagulation | #35 |
| neoplasms venous | #35 |
| prevention model | #35 |
| enoxaparin prevention | #35 |
| statin association | #35 |
| surgery hip | #35 |
| weekly subcutaneous | #35 |
| factors travel | #36 |
| catheterrelated infection | #36 |
| fibrinogen depletion | #36 |
| riskbenefit | #36 |
| novoseven | #36 |
| thrombophilia venous | #36 |
| regular monitoring | #36 |
| 4139 | #36 |
| inherited risk factors | #36 |
| iii antithrombin | #36 |
| treatment acute vte | #36 |
| 287 patients | #36 |
| studies echocardiography | #36 |
| acute symptomatic | #36 |
| viii levels | #36 |
| levels coagulation | #36 |
| dose reduction patients | #36 |
| peripheral endovascular | #36 |
| 1698 | #36 |
| venous thromboembolism dabigatran | #36 |
| hellp patients | #36 |
| fibrinolytic activation | #36 |
| venous thromboembolic disease | #36 |
| outcome composite | #37 |
| vte increased | #37 |
| tat complexes | #37 |
| thrombosis humans | #37 |
| recombinant hirudin | #37 |
| ototoxicity nephrotoxicity | #37 |
| perelated mortality | #37 |
| genotype 95 | #37 |
| warfarin 95 | #37 |
| lwmh | #37 |
| cumulative incidence vte | #37 |
| screening occult | #37 |
| bagsvaerd | #37 |
| ctpa patients | #37 |
| magellan | #37 |
| pad studies | #37 |
| anticoagulants prevention | #37 |
| suspected venous | #37 |
| rivaroxaban thromboprophylaxis | #37 |
| factors thrombophilia | #37 |
| venography | #37 |
| excluding | #37 |
| risk venous thrombosis | #37 |
| anticoagulant action | #37 |
| prophylactic heparin | #37 |
| risk factors pts | #37 |
| 10 total | #38 |
| doac lmwh | #38 |
| coagulation protein | #38 |
| rivaroxaban placebo | #38 |
| patients ddimer levels | #38 |
| nonmajor bleeding | #38 |
| catheterrelated thrombosis | #38 |
| restenosis reocclusion | #38 |
| anticoagulants female humans | #38 |
| age recurrence | #38 |
| 3306 | #38 |
| vte bleeding | #38 |
| recurrence day | #38 |
| congenital deficiencies | #38 |
| sensitivity biomarkers | #38 |
| fetal loss women | #38 |
| submassive pulmonary | #38 |
| 2835 | #38 |
| vte cancer patients | #38 |
| embolus | #39 |
| continued treatment | #39 |
| incidence patients | #39 |
| subcutaneous intention | #39 |
| time compression | #39 |
| submassive | #39 |
| compression stocking | #39 |
| superficial vein thrombosis | #39 |
| children familial hypercholesterolemia | #39 |
| doacs | #39 |
| heparins lmwhs | #39 |
| specificity patients | #39 |
| 277 patients | #39 |
| enoxaparin placebo | #39 |
| fibrin fibrinogen | #39 |
| septic syndrome | #39 |
| diagnostic prediction | #39 |
| low molecular weight | #39 |
| incidence cancer | #39 |
| systemic inflammatory responses | #39 |
| tfmp | #40 |
| clotting activation | #40 |
| arterial vascular | #40 |
| dalteparin treatment | #40 |
| activatable fibrinolysis | #40 |
| day 6 months | #40 |
| fviiic | #40 |
| thrombinantithrombin complexes | #40 |
| anticoagulant therapy | #40 |
| episode venous thromboembolism | #40 |
| pemb | #40 |
| common femoral vein | #40 |
| standardized definition | #40 |
| therapeutic dosages | #40 |
| bleeding | #40 |
| grade 1a patients | #40 |
| anticoagulation therapy patients | #40 |
| international clinical | #40 |
| endotoxininduced | #40 |
| patients normal | #40 |
| ambulatory cancer | #40 |
| risk recurrent vte | #41 |
| 95 genotype | #41 |
| submassive pulmonary embolism | #41 |
| lowmolecularweight heparins | #41 |
| lung scintigraphy | #41 |
| cancer lmwh | #41 |
| 7268 | #41 |
| endotoxin induced | #41 |
| heparin therapy | #41 |
| anticoagulated patients | #41 |
| pentasaccharides | #41 |
| dabigatran etexilate | #41 |
| placebo 6 months | #41 |
| triage tests | #41 |
| calf vein thrombosis | #41 |
| patients vasopressors | #42 |
| 8101 | #42 |
| neoplasms thrombosis | #42 |
| prophylaxis venous | #42 |
| standardization committee | #42 |
| cell extravasation | #42 |
| stroke thrombosis | #42 |
| type graft | #42 |
| patients silent | #42 |
| netilmicin | #42 |
| thrombosis administration | #42 |
| major contributor | #42 |
| anticoagulation risk | #42 |
| patients prospective | #42 |
| 543 patients | #43 |
| probability patients | #43 |
| fetal loss | #43 |
| initial treatment | #43 |
| monthly incidence | #43 |
| draft document | #43 |
| warfarin anticoagulants | #43 |
| vkas patients | #43 |
| heparin risk | #43 |
| ischemic events | #43 |
| post‐thrombotic syndrome | #43 |
| venous thromboembolism vte | #43 |
| rtap | #43 |
| patients vte risk | #43 |
| venous thrombosis thrombophilia | #43 |
| cancer adjusted | #43 |
| uedvt patients | #44 |
| expert physicians | #44 |
| factors thromboembolism | #44 |
| 20 30 | #44 |
| efficiency models | #44 |
| experimental venous thrombosis | #44 |
| 10–14 | #44 |
| recurrent vte 95 | #44 |
| role coagulation | #44 |
| mild hyperhomocysteinaemia | #44 |
| 95 pulmonary embolism | #44 |
| indications patients | #44 |
| rate venous | #44 |
| patients tinzaparin | #44 |
| edoxaban therapy | #44 |
| nonvka oral anticoagulants | #44 |
| enoxaparin risk | #44 |
| protein sepsis | #44 |
| restoration euthyroidism | #44 |
| dvt patients | #45 |
| coagulation activation | #45 |
| coumarin therapy | #45 |
| wells score | #45 |
| dose adjusted | #45 |
| 95 warfarin | #45 |
| patients bnp | #45 |
| oral direct | #45 |
| treated warfarin | #45 |
| venous thrombotic | #45 |
| years algorithm | #45 |
| dose lmwh | #45 |
| fondaparinux patients | #45 |
| revascularisation procedures | #45 |
| standard therapy | #46 |
| daily rivaroxaban | #46 |
| percent confidence | #46 |
| stroke risk assessment | #46 |
| treatment model | #46 |
| major bleeding placebo | #46 |
| ssc isth | #46 |
| day levels | #46 |
| pioped | #46 |
| hospital outpatients | #46 |
| management venous | #46 |
| prothrombin fragment f1 | #46 |
| ruling | #46 |
| extended duration | #46 |
| patients unprovoked vte | #46 |
| healthcare settings | #46 |
| abtpo | #46 |
| bleeding rivaroxaban | #46 |
| episode vte | #47 |
| central venous lines | #47 |
| male methimazole | #47 |
| outcome vitamin | #47 |
| mutation pregnancy | #47 |
| roccurve | #47 |
| ambulatory anticoagulants | #47 |
| plasma ddimer levels | #47 |
| new oral anticoagulant | #47 |
| boehringer ingelheim | #47 |
| mechanical prophylaxis | #47 |
| iiia receptors | #47 |
| bristol myers squibb | #47 |
| intermediate risk risk | #48 |
| rivaroxaban compared | #48 |
| risk recurrent | #48 |
| subcommittee | #48 |
| factors rivaroxaban | #48 |
| fondaparinux heparin | #48 |
| thromboprophylactic | #48 |
| recurrence venous thromboembolism | #48 |
| small studies | #48 |
| travel risk | #48 |
| elevated plasma levels | #48 |
| patients acute dvt | #48 |
| patients pulmonary | #48 |
| thrombotic burden | #48 |
| diagnosis physicians | #48 |
| daiichi | #48 |
| vte diagnosis | #49 |
| factor viii deficiency | #49 |
| calf vein | #49 |
| rivaroxaban prevention | #49 |
| levels protein | #49 |
| women aspirin | #49 |
| lowmolecularweight heparin lmwh | #49 |
| enoxaparin | #49 |
| incidence venous thromboembolism | #50 |
| acute respiratory insufficiency | #50 |
| buller | #50 |
| dvt diagnosis | #50 |
| intensity treatment | #50 |
| prospective diagnostic | #50 |
| treatment threshold | #50 |
| outpatient therapy | #50 |
| cardiac surgery mortality | #50 |
| thromboembolism aged | #50 |
| nonselective betablockers | #50 |
| atria patients | #50 |
| etexilate | #50 |
| transient risk factor | #50 |
| vitamink antagonists | #50 |
| discrimination model | #51 |
| strategies treatment | #51 |
| factor vte | #51 |
| previous survey | #51 |
| patients 11 | #51 |
| tomography pulmonary | #51 |
| effects coagulation | #51 |
| global disease | #51 |
| acenocoumarol | #51 |
| 95 apixaban | #51 |
| normal perfusion | #51 |
| protein deficiencies | #51 |
| inhibitors heparin | #52 |
| pdvt | #52 |
| free thyroxine ft4 | #52 |
| vte major bleeding | #52 |
| patients comorbid conditions | #52 |
| lung scans | #52 |
| 1·12 | #52 |
| hematologic malignancies patients | #52 |
| svt patients | #52 |
| doacs vka | #52 |
| 3 month | #52 |
| risk venous thromboembolism | #52 |
| lmwh fondaparinux | #52 |
| apixaban vte | #52 |
| unnecessarily | #52 |
| absolute risks | #53 |
| thromboembolism prevention | #53 |
| 479 patients | #53 |
| versus enoxaparin | #53 |
| hemostatic balance | #53 |
| cross study | #53 |
| reported incidence | #53 |
| postthrombotic syndrome | #53 |
| preference patients | #53 |
| 1522 | #53 |
| suspected venous thromboembolism | #53 |
| thrombophilic factors | #53 |
| 40 daily | #53 |
| patients initially | #53 |
| warfarintreated patients | #53 |
| endocrine disorders | #54 |
| 2537 | #54 |
| prethrombotic | #54 |
| antithrombotic drug | #54 |
| patients incidence | #54 |
| bled score | #54 |
| male pulmonary embolism | #54 |
| 034 | #54 |
| chads2 cha2ds2vasc | #54 |
| thromboembolism death | #54 |
| 378 patients | #54 |
| major bleeds | #54 |
| patients obese | #54 |
| pai1 levels patients | #54 |
| acquired risk factors | #54 |
| familial thrombophilia | #54 |
| vte mortality | #54 |
| proximal extent | #55 |
| treatment thresholds | #55 |
| biological pan | #55 |
| legs patients | #55 |
| dosereduction | #55 |
| long term risk | #55 |
| nondeficient | #55 |
| methods randomized | #55 |
| rivaroxaban | #55 |
| anticoagulants arthroplasty replacement | #55 |
| compared lmwh | #55 |
| unfractionated heparin | #55 |
| insurances | #55 |
| unfractionated heparin ufh | #55 |
| enoxaparin patients | #56 |
| weight heparins | #56 |
| enoxaparin rivaroxaban | #56 |
| risk major bleeding | #56 |
| inr values | #56 |
| reduced capacity | #56 |
| physicians guidelines | #56 |
| vitamin warfarin | #56 |
| preeclampsia hellp syndrome | #56 |
| vasopressors | #56 |
| time event | #56 |
| vte death | #56 |
| seventh accp conference | #56 |
| level mortality | #56 |
| deficiency prevalence | #56 |
| major bleeding apixaban | #56 |
| venous outflow obstruction | #56 |
| tromboembólica | #56 |
| 20210a | #56 |
| calf dvt | #57 |
| risk factors vte | #57 |
| antithrombin iii heparin | #57 |
| clinical models | #57 |
| ctscan | #57 |
| levels survival | #57 |
| inhibitors female humans | #57 |
| subsegmental pulmonary | #57 |
| thrombin activatable | #58 |
| ruled | #58 |
| unfractionated heparin patients | #58 |
| spiral computed | #58 |
| pharmo | #58 |
| doacs patients | #58 |
| lowmolecular weight heparin | #58 |
| inhibitors female | #58 |
| fibrinolysis humans | #58 |
| malignancy mortality | #58 |
| acute venous thromboembolism | #59 |
| aventis | #59 |
| risk factors sensitivity | #59 |
| factor generation | #59 |
| risk periods | #59 |
| incidence symptomatic | #59 |
| bias trial | #59 |
| direct oral | #59 |
| safety warfarin | #59 |
| mutation prothrombin | #59 |
| heterozygous factor | #59 |
| risk vte | #59 |
| thrombosis aged | #59 |
| warfarin treatment | #59 |
| clot lysis time | #59 |
| pulmonary embolism 95 | #60 |
| acute pulmonary embolism | #60 |
| target inr | #60 |
| atrial fibrillation metaanalysis | #60 |
| awareness risk factors | #60 |
| 079 95 | #60 |
| prevalence pulmonary | #60 |
| fixeddose | #60 |
| women difference | #60 |
| constans | #60 |
| pediatric venous thromboembolism | #60 |
| anticoagulants treatment | #60 |
| hemorrhage humans | #60 |
| rosendaal | #61 |
| association protein | #61 |
| hypocoagulable | #61 |
| free thyroxine | #61 |
| month surgery | #61 |
| dvt 95 | #61 |
| amuse | #61 |
| benzimidazoles dabigatran | #61 |
| tests prevalence | #61 |
| perfusion ventilation | #61 |
| 3633 | #61 |
| long‐term treatment | #61 |
| cdr score | #61 |
| post thrombotic | #62 |
| activated partial | #62 |
| procoagulant state | #62 |
| ttr patients | #62 |
| general practitioners patients | #62 |
| combined contraceptives oral | #62 |
| protein fibrinogen | #62 |
| patients administration | #62 |
| human endotoxemia | #62 |
| 250 patients | #62 |
| 273 patients | #62 |
| informatizado | #62 |
| revised geneva score | #63 |
| quantitative test | #63 |
| factor leiden risk | #63 |
| management anticoagulation | #63 |
| common odds ratio | #63 |
| venous thromboembolisms | #63 |
| cvrs | #63 |
| 33 women | #63 |
| rivaroxaban lmwh | #63 |
| smoking smoking cessation | #63 |
| treatment network | #63 |
| symptoms dvt | #63 |
| vte thromboprophylaxis | #63 |
| physicians predictive | #63 |
| women mutations | #63 |
| injection endotoxin | #63 |
| acute pulmonary | #64 |
| bleeding events patients | #64 |
| decision rules | #64 |
| oral thrombin | #64 |
| patients aortic valve | #64 |
| postthrombotic | #64 |
| cancer noncancer patients | #64 |
| dvts | #64 |
| thrombophilic risk | #64 |
| superficial vein | #64 |
| blinded trial | #64 |
| factor inhibitors | #64 |
| vkas treatment | #64 |
| heparin fondaparinux | #64 |
| selfadjustment | #64 |
| prior vte | #64 |
| fvl vte | #65 |
| accuracy diagnostic tests | #65 |
| prevalence abnormalities | #65 |
| ultrasonograms | #65 |
| treatment pad | #65 |
| stroke thromboembolism | #65 |
| prothrombin g20210a mutation | #65 |
| axa | #66 |
| elfa | #66 |
| rapid triage | #66 |
| statin therapy risk | #66 |
| dvt sensitivity | #66 |
| death classification | #66 |
| female heparin | #66 |
| 0 points | #66 |
| newer anticoagulants | #66 |
| risk factor thrombosis | #66 |
| 95 bleeding | #66 |
| standard therapy patients | #67 |
| 1127 | #67 |
| rate major | #67 |
| atrial fibrillation stroke | #67 |
| patients tertiles | #67 |
| apixaban | #67 |
| patients factor | #67 |
| 3594 | #68 |
| academic medical centre | #68 |
| ranging study | #68 |
| 1894 | #68 |
| patients benefits | #68 |
| 20210g | #68 |
| fibrinolytic | #68 |
| coagulation fibrinolysis | #68 |
| patients bnp levels | #68 |
| perioperative blood | #68 |
| 05 95 | #68 |
| postphlebitic | #69 |
| ionis | #69 |
| recurrent thrombosis patients | #69 |
| heparin ufh | #69 |
| certoparin | #69 |
| enfermedad tromboembólica | #69 |
| suspected | #69 |
| justify | #69 |
| plasma interleukin | #69 |
| thrombosis blood | #69 |
| thrombosis recurrence | #70 |
| patients protein | #70 |
| fixed dose | #70 |
| rivaroxaban treatment | #70 |
| ischemic events patients | #70 |
| elevated cardiac | #70 |
| aged predictive | #70 |
| α2ap | #70 |
| vwfrco | #70 |
| cutoff levels | #70 |
| withhold | #70 |
| gramnegative sepsis | #70 |
| test patients | #70 |
| major bleeding complications | #70 |
| mantelhaenszel | #70 |
| 8190 | #70 |
| thromboprophylaxis | #71 |
| tests prospective | #71 |
| levels vwf | #71 |
| plasminogen plg | #71 |
| unfractionated | #71 |
| topic costs | #71 |
| asymptomatic atherosclerosis | #71 |
| diagnostic sensitivity specificity | #71 |
| vte vka | #71 |
| clopidogrel placebo | #71 |
| patients lmwh | #72 |
| elevated factor | #72 |
| overt hypothyroidism | #72 |
| activation prothrombin | #72 |
| trifurcation | #72 |
| complications hematologic | #72 |
| hf studies | #72 |
| versus vitamin | #72 |
| antithrombin iii iii | #72 |
| new anticoagulant | #72 |
| pooled rate | #72 |
| viia factor | #72 |
| ddimer values | #72 |
| noacs | #73 |
| tomography spiral | #73 |
| 12 months 95 | #73 |
| soluble fibrin | #73 |
| analysis diagnostic | #73 |
| ddimer measurement | #73 |
| prolongations | #73 |
| reversal agent | #73 |
| ingelheim | #73 |
| 2550 | #74 |
| suspected dvt | #74 |
| dvt study | #74 |
| soluble thrombomodulin | #74 |
| 1732 | #74 |
| proteins patients | #74 |
| experimental metastasis | #74 |
| 2124 | #74 |
| female hemorrhage | #74 |
| 5395 | #74 |
| study selection | #74 |
| longterm risk | #74 |
| carriers | #74 |
| prethrombotic state | #74 |
| selective factor | #75 |
| postoperative dvt | #75 |
| 2904 | #75 |
| thrombolytic therapy patients | #75 |
| carotid femoral arteries | #75 |
| 8492 | #75 |
| incidence bleeding events | #75 |
| retrospective follow | #75 |
| 1334 | #75 |
| angiography ctpa | #76 |
| risk thrombosis | #76 |
| combined contraceptives | #76 |
| oral combined contraceptives | #76 |
| extended anticoagulation | #76 |
| early time | #76 |
| tests primary | #76 |
| duration thromboprophylaxis | #76 |
| factor xii deficiency | #76 |
| individual patient | #77 |
| patients secondary | #77 |
| p023 | #77 |
| boehringer | #77 |
| social aspects | #77 |
| thrombosis pregnancy | #77 |
| ipg | #78 |
| women thrombophilia | #78 |
| elevated dimer | #78 |
| unprovoked | #78 |
| female fibrinolysis | #78 |
| arterial wall thickness | #78 |
| 20 daily | #78 |
| arterial thromboembolism | #78 |
| vte fvl | #79 |
| humans pulmonary | #79 |
| suspected acute | #79 |
| limulus test | #79 |
| efficacy agents | #79 |
| 2486 | #79 |
| time therapeutic | #79 |
| vkas | #79 |
| topic heparin | #79 |
| factor adult | #79 |
| sspe patients | #80 |
| thromboembolism incidence | #80 |
| daily bid | #80 |
| validation models | #80 |
| 95 05 | #80 |
| subhazard ratio | #80 |
| vte rate | #80 |
| patient data | #80 |
| suspected cancer | #80 |
| bleeding mortality | #80 |
| alife | #80 |
| heterozygous deficiency | #80 |
| test evaluation | #81 |
| lmwh vte | #81 |
| walking distance | #81 |
| systemic inflammatory | #81 |
| topic risk | #81 |
| prothrombin complex concentrate | #81 |
| vascular events | #81 |
| outpatient basis | #81 |
| knee arthroplasty patients | #81 |
| weitz | #81 |
| posthoc analysis | #82 |
| prospective validation | #82 |
| heparin prevention | #82 |
| clinical sign | #82 |
| thrombosis thrombophilia | #82 |
| 50 micrograms | #82 |
| timeperiods | #82 |
| mammography patients | #82 |
| 3month followup | #82 |
| thrombosis incidence | #82 |
| common practice | #82 |
| symptomatic carriers | #82 |
| thrombolytic drugs | #82 |
| placebo women | #82 |
| crnmb | #82 |
| patients thrombi | #83 |
| 2213 | #83 |
| bleeding women | #83 |
| bistro | #83 |
| elective coronary | #83 |
| 287 | #83 |
| dimer patients | #83 |
| inhibitor dabigatran | #83 |
| heparin treatment | #84 |
| diagnostic outcome | #84 |
| inhibitor rivaroxaban | #84 |
| normotensive patients | #84 |
| healthcare setting | #84 |
| prophylactic dose | #84 |
| duration therapy | #84 |
| screening humans | #84 |
| inherited thrombophilia | #84 |
| thrombosis svt | #85 |
| anticoagulants antiphospholipid | #85 |
| venous thrombosis patients | #85 |
| normal levels | #85 |
| endotoxins | #85 |
| peripheral vascular diseases | #85 |
| antithrombin iii protein | #85 |
| asymptomatic dvt | #85 |
| elevated ddimer levels | #86 |
| rhapc | #86 |
| dabigatran vka | #86 |
| venovenous hemofiltration | #86 |
| 75 microg | #86 |
| 10⁶ | #86 |
| major bleeding warfarin | #86 |
| 4576 | #86 |
| clinical impact | #87 |
| vidas | #87 |
| patients 28 | #87 |
| obstetric patients | #87 |
| acute venous | #87 |
| ≤50 | #87 |
| avws | #87 |
| contact activation | #87 |
| post‐hoc analysis | #87 |
| 95 100 | #87 |
| internist | #88 |
| aged multicenter | #88 |
| activation factor | #88 |
| lmwhs | #88 |
| treatment statins | #88 |
| 3319 | #88 |
| treatment incidence | #88 |
| 4 points | #88 |
| cdr | #88 |
| venographic | #88 |
| washout period | #88 |
| adequate treatment | #89 |
| unexplained recurrent | #89 |
| rates major bleeding | #89 |
| vte venous thromboembolism | #89 |
| anticoagulants dabigatran | #89 |
| tests test | #89 |
| ventilation lung | #89 |
| safety noacs | #89 |
| stroke bleeding | #89 |
| beta blockers | #89 |
| severe hf | #89 |
| smoking incidence | #89 |
| reversal strategies | #89 |
| cytokine release | #89 |
| matisse | #89 |
| costs patient | #89 |
| ddimer | #89 |
| venous thrombosis risk | #90 |
| popliteal vein | #90 |
| fibrinolytic factors | #90 |
| thrombophilic risk factors | #90 |
| new patients | #90 |
| outweighs | #90 |
| 2293 | #90 |
| vka dabigatran | #90 |
| pediatric venous | #90 |
| primary thromboprophylaxis | #90 |
| 60 95 | #91 |
| anticoagulants doacs | #91 |
| agents hemorrhage | #91 |
| perfusion ratio | #91 |
| pyridines pyridones | #91 |
| thromboembolism pregnancy | #91 |
| inconvenience | #91 |
| thrombosis women | #91 |
| cdrs | #91 |
| 20210 | #91 |
| single intravenous | #92 |
| prophylaxis incidence | #92 |
| thrombotic disease | #92 |
| combined clinical | #92 |
| anticoagulation reversal | #93 |
| direct thrombin inhibitors | #93 |
| 95 years | #93 |
| scenario analyses | #93 |
| incidence knee | #93 |
| compression patients | #93 |
| rivaroxaban edoxaban | #93 |
| hf severity | #94 |
| vte surgery | #94 |
| atherogenic lipid | #94 |
| 1027 | #94 |
| heparins | #94 |
| patients symptomatic | #94 |
| test result | #94 |
| 125 patients | #94 |
| children vte | #94 |
| direct oral anticoagulant | #95 |
| 2 levels | #95 |
| viia rfviia | #95 |
| european consensus statement | #95 |
| efficacy rivaroxaban | #96 |
| ddimer level | #96 |
| 6 12 months | #96 |
| xii deficiency | #96 |
| risk symptomatic | #96 |
| randomised crossover study | #96 |
| symptomatic vte | #96 |
| fondaparinux treatment | #96 |
| haemophilia patients | #97 |
| difference rates | #97 |
| tpa release | #97 |
| symptomatic pulmonary embolism | #97 |
| pyrazoles pyridones | #97 |
| doacs risk | #97 |
| studies evaluated | #97 |
| abnormal perfusion | #97 |
| invasive testing | #97 |
| fibrin generation | #97 |
| hypercoagulable | #98 |
| 2875 | #98 |
| pregnancy postpartum period | #98 |
| simplify | #98 |
| essential thrombocythaemia | #98 |
| major bleed | #98 |
| activated protein apc | #98 |
| supervised exercise therapy | #98 |
| 16slice | #98 |
| risk arterial | #99 |
| unselected | #99 |
| hirudin | #99 |
| 2·0 | #99 |
| lmwh warfarin | #99 |
| probast | #99 |
| acute dvt | #99 |
| perfusion scintigraphy | #99 |
| fatty foods | #100 |
| doubleblind trial | #100 |
| warfarin patients | #100 |
| gbd 2010 | #100 |
| 3 trials | #100 |
| patient groups | #100 |
| increasing levels | #100 |
| prevention recurrent | #100 |
| 1116 | #100 |
| previews | #100 |
| aptts | #101 |
| factor viia | #101 |
| factor vii factor | #101 |
| morpholines | #101 |
| alternative diagnosis | #102 |
| venous thromboembolism women | #102 |
| pts patients | #102 |
| enoxaparin fondaparinux | #102 |
| 265 patients | #102 |
| 40 microg | #102 |
| low pretest probability | #102 |
| 338 | #103 |
| adjudicated | #103 |
| pregnancy puerperium | #103 |
| cteph patients | #103 |
| therapeutic consequences | #103 |
| arthroscopic anterior | #103 |
| doppler method | #103 |
| endogenous thrombin | #103 |
| partial restoration | #104 |
| term treatment | #104 |
| assay variation | #104 |
| absolute increase | #104 |
| apparent increase | #104 |
| recurrence women | #104 |
| fibrin degradation products | #104 |
| heparin pregnancy | #104 |
| oral factor | #104 |
| separate analyses | #104 |
| antithrombin iii | #104 |
| diagnostic imaging humans | #104 |
| conventional therapy patients | #105 |
| 7 children | #105 |
| 1089 | #105 |
| embryo loss | #105 |
| 314 | #106 |
| thrombophilia | #106 |
| elevated levels | #106 |
| hospitalized patients hf | #106 |
| chest ray | #106 |
| blind double | #106 |
| study total | #106 |
| fibrinolytic systems | #106 |
| thromboprophylaxis patients | #106 |
| 2479 | #106 |
| thrombosis age | #106 |
| essentials | #106 |
| vte risk | #107 |
| simplified version | #107 |
| thromboembolic | #107 |
| ddimer levels | #107 |
| topic recurrence | #107 |
| definition classification | #107 |
| survival cancer patients | #107 |
| grade 1c | #108 |
| noncancer patients | #108 |
| specific subgroups | #108 |
| human volunteers | #108 |
| cardiovascular death stroke | #108 |
| post thrombotic syndrome | #108 |
| patients cancer | #108 |
| thrombin antithrombin | #109 |
| 500μg | #109 |
| 039 | #109 |
| routine coagulation | #109 |
| viia | #109 |
| synthetic pentasaccharide | #109 |
| 1235 | #109 |
| embolism treatment | #109 |
| anticoagulants cohort | #109 |
| factor mutation | #109 |
| evaluation studies | #109 |
| embolism quality | #110 |
| thrombosis treated | #110 |
| primary safety | #110 |
| subsequent pregnancy | #110 |
| inferiority trial | #110 |
| cancer activity | #110 |
| antiplasmin | #110 |
| vka doac | #110 |
| anticoagulants biomarkers | #111 |
| comparison control | #111 |
| obstetric complications | #111 |
| humans intermittent | #111 |
| treatment risk factors | #111 |
| negative predictive 100 | #111 |
| predefined | #111 |
| siset | #111 |
| rivaroxaban enoxaparin | #112 |
| emergency situations | #112 |
| risk rivaroxaban | #112 |
| topic guidelines | #112 |
| patients ventricular dysfunction | #112 |
| epidemiology risk factors | #112 |
| recurrence treatment | #112 |
| chromogenic | #112 |
| publication anticoagulants | #112 |
| patients 70 | #112 |
| efficacy prevention | #112 |
| thromboembolic diseases | #112 |
| lmwh risk | #113 |
| inappropriate treatment | #113 |
| metabolic response | #113 |
| heterozygous carriers | #113 |
| patients nephrotoxicity | #113 |
| nonionic contrast | #113 |
| postphlebitic syndrome | #114 |
| cancerassociated vte | #114 |
| study centre | #114 |
| total knee replacement | #114 |
| dialysers | #114 |
| patients intermediate | #114 |
| 0·0 | #114 |
| hyperhomocysteinaemia | #115 |
| fibrinogen vwf | #115 |
| 393 | #115 |
| global public | #115 |
| positive predictive values | #115 |
| patients recurrent | #115 |
| life treatment | #116 |
| agents heparin | #116 |
| computed tomography patients | #116 |
| effects tnf | #116 |
| anticoagulants arthroplasty | #116 |
| topic dabigatran | #116 |
| major bleeding 95 | #116 |
| vte data | #116 |
| heparin warfarin | #116 |
| women severe preeclampsia | #116 |
| reference standard | #116 |
| fibrinolytic parameters | #117 |
| protein resistance | #117 |
| arthroscopies | #117 |
| 2460 | #117 |
| protein inhibitor pci | #117 |
| vte children | #117 |
| women caesarean | #117 |
| vte complications | #117 |
| patients extensive | #118 |
| autopsyconfirmed | #118 |
| proximal dvt | #118 |
| 2744 | #118 |
| 4118 | #118 |
| arterial thrombosis patients | #118 |
| compression stockings | #119 |
| compared warfarin | #119 |
| incidence pulmonary embolism | #119 |
| humans leg | #119 |
| patients doac | #119 |
| acquired deficiency | #120 |
| mortality diseases | #120 |
| rivaroxaban patients | #120 |
| months follow | #120 |
| previous vte | #120 |
| dabigatran factor | #120 |
| lactoferrin leukocyte | #120 |
| healthy humans | #120 |
| thrombosis study | #120 |
| risk thromboembolism | #120 |
| thrombocytopenia thrombosis | #121 |
| patients prostatic cancer | #121 |
| patients 6 | #122 |
| oral hormonal | #122 |
| studies venous | #122 |
| fatal pulmonary embolism | #122 |
| anti factor | #122 |
| 100 patients | #123 |
| factor xia | #123 |
| acute infection | #123 |
| venous thromboembolism pregnancy | #123 |
| heparin hirudin | #123 |
| minor bleeding | #123 |
| early dynamics | #123 |
| placebo standard | #123 |
| heparin | #123 |
| ft4 levels | #124 |
| statin risk | #124 |
| vte lmwh | #124 |
| atherogenic lipid profile | #124 |
| treatment data | #124 |
| thrombophilia pregnancy | #124 |
| association level | #124 |
| nonsignificantly | #125 |
| bayer | #125 |
| treatment indication | #125 |
| skin perfusion | #125 |
| intravenous heparin | #125 |
| diseases mortality | #125 |
| fibrinolysis inhibitor | #125 |
| incidence thrombosis | #125 |
| elevated liver enzymes | #125 |
| puerperal disorders | #125 |
| thromboembolism recurrence | #125 |
| peripheral arterial disease | #125 |
| doacs treatment | #126 |
| distal dvt | #126 |
| upper extremity | #126 |
| unacceptably | #127 |
| marder | #127 |
| performance scores | #127 |
| thromboprophylaxis lmwh | #127 |
| patients permanent | #127 |
| occurrence vte | #127 |
| patients ventilation | #127 |
| direct factor | #128 |
| prevention | #128 |
| 50 age | #128 |
| treatment months | #128 |
| development vte | #128 |
| patients conventional therapy | #128 |
| venous thromboembolism risk | #128 |
| resistance apc | #128 |
| elevated biomarkers | #129 |
| mortality cancer patients | #129 |
| 060 | #129 |
| ctrough | #129 |
| 1041 | #129 |
| riete registry | #129 |
| plaster cast | #130 |
| patients episode | #130 |
| 194 patients | #130 |
| 220 | #130 |
| internists | #130 |
| hospital discharge records | #130 |
| day 10 | #130 |
| anticoagulants antithrombins | #130 |
| long‐term clinical outcomes | #131 |
| linear interpolation | #131 |
| obviating | #131 |
| pooled incidence | #131 |
| tests specificity | #131 |
| 05 patients | #131 |
| rivaroxaban versus | #132 |
| hypocoagulability | #132 |
| hoc analysis | #132 |
| postpartum period women | #132 |
| started | #133 |
| cha2ds2vasc | #133 |
| fxa inhibitors | #133 |
| 80 anticoagulants | #133 |
| enoxaparin treatment | #133 |
| avidin | #133 |
| direct inhibitors | #133 |
| risk pad | #134 |
| embolism acute | #134 |
| rco vwf | #134 |
| instituted | #134 |
| pulmonary angiography patients | #134 |
| selectin levels | #134 |
| activator plasminogen | #135 |
| bnp concentration | #135 |
| anticoagulant prophylaxis | #135 |
| prevalence dvt | #135 |
| 0056 | #136 |
| thrombotic syndrome | #136 |
| clinical prediction | #136 |
| apixaban edoxaban | #136 |
| followup patients | #136 |
| months anticoagulation | #136 |
| east asian patients | #136 |
| severe pph | #136 |
| sequential application | #137 |
| phase 3 trials | #137 |
| 2283 | #137 |
| acquired thrombophilia | #137 |
| factor prothrombin | #137 |
| point‐of‐care | #137 |
| diagnostic work | #137 |
| 99 patients | #137 |
| studies mortality | #138 |
| national guidelines | #138 |
| intravascular coagulation dic | #138 |
| antidote | #138 |
| enhanced factor | #138 |
| complete inhibition | #138 |
| bleeding warfarin | #138 |
| direct inhibitor | #139 |
| 3 weeks | #139 |
| patients comparison | #139 |
| 95 major bleeding | #139 |
| 2465 | #139 |
| factor viii factor | #139 |
| reproducibility risk | #139 |
| oral anticoagulant treatment | #139 |
| risk fatal | #139 |
| dvt incidence | #140 |
| 12 95 | #140 |
| human activated | #140 |
| ottawa | #140 |
| 80 cohort | #140 |
| 20 iu | #140 |
| 0114 | #140 |
| vwf rco | #140 |
| distal deep | #140 |
| thromboembolic disorders | #141 |
| pharmacy records | #141 |
| antidotes | #141 |
| thrombin potential | #142 |
| carriership | #142 |
| jugular veins | #143 |
| escherichia humans | #143 |
| active malignancy | #143 |
| warfarin administration | #143 |
| ischaemic events | #143 |
| geneva | #143 |
| points 95 | #143 |
| treatment pulmonary | #143 |
| doac treatment | #144 |
| topic practice patterns | #144 |
| pregnancy female humans | #144 |
| compared treatment | #144 |
| fatal pulmonary | #144 |
| management vte | #144 |
| postoperative venous | #144 |
| serial testing | #145 |
| dose rivaroxaban | #145 |
| hyperthyroxinemia | #145 |
| thrombosis model | #145 |
| filters venous | #145 |
| referred patients | #145 |
| patient populations | #145 |
| death cancer patients | #146 |
| protein factor | #146 |
| derived microvesicles | #146 |
| months treatment | #146 |
| tissue factor pathway | #147 |
| personal fees | #147 |
| rebuttal | #148 |
| 2076 | #148 |
| intention treat | #148 |
| 10 years patients | #148 |
| antithrombotic drugs | #148 |
| acute medical illness | #148 |
| embolism diagnosis | #148 |
| partial thromboplastin | #148 |
| long‐acting | #148 |
| 0·45 | #149 |
| risk subgroups | #149 |
| vte hospitalization | #149 |
| thrombocyte | #149 |
| relevant publications | #149 |
| procoagulant | #149 |
| diagnostic score | #149 |
| individual patient data | #149 |
| dimer level | #150 |
| additional imaging | #151 |
| coagulation dic | #151 |
| humans injections | #151 |
| enoxaparin unfractionated heparin | #151 |
| patients primary outcome | #152 |
| longterm treatment | #152 |
| bleeding patients | #152 |
| patient eligibility | #152 |
| continuous venovenous | #152 |
| extracorporeal circuit | #153 |
| thrombosis prevention | #153 |
| hypercoagulable state | #153 |
| point systems | #153 |
| cardiopulmonary bypass surgery | #153 |
| thrombosis factor | #154 |
| dimer levels | #154 |
| active cancer | #154 |
| angioplasty patients | #154 |
| activity mortality | #154 |
| bleeding scores | #154 |
| direct thrombin | #154 |
| warfarin apixaban | #155 |
| drug factor | #155 |
| tomography patients | #155 |
| fiia | #155 |
| curve sensitivity | #155 |
| states venous | #155 |
| thromboembolic event | #155 |
| patients gastrointestinal | #156 |
| daily oral | #156 |
| coagulant activity | #156 |
| stockings | #156 |
| vte treatment | #156 |
| 09 | #156 |
| enoxaparin dose | #156 |
| fvl | #156 |
| recurrent symptoms | #156 |
| hemodynamically | #157 |
| increased thrombin | #157 |
| prophylaxis patients | #157 |
| cross‐sectional survey | #157 |
| 97 | #158 |
| 2126 | #158 |
| duration anticoagulation | #158 |
| dfl | #158 |
| months chemotherapy | #158 |
| underlying malignancy | #158 |
| increased risk thrombosis | #159 |
| adjusted relative risk | #159 |
| plasma dimer | #160 |
| antithrombotic efficacy | #160 |
| guidelines prevention | #160 |
| 145 patients | #160 |
| 120 minutes | #160 |
| thrombotic disorders | #160 |
| schering | #160 |
| children fh | #160 |
| prophylactics | #161 |
| pvo | #161 |
| antagonists patients | #161 |
| lysine analogues | #162 |
| women time | #162 |
| 2206 | #162 |
| incidence vte | #162 |
| patients imaging | #162 |
| 198 patients | #163 |
| strain gauge | #163 |
| increased plasma levels | #163 |
| factors bleeding | #163 |
| imaging test | #163 |
| lmwh therapy | #163 |
| coagulation blood | #163 |
| rates vte | #163 |
| venous thrombus | #163 |
| 028 | #164 |
| age comorbidity | #164 |
| justified | #164 |
| observer variability | #164 |
| inborn humans | #164 |
| relatives patients | #165 |
| patients enoxaparin | #165 |
| mutation factor | #165 |
| subhazard | #165 |
| management venous thromboembolism | #166 |
| viii factor | #166 |
| microvascular thrombosis | #166 |
| pravastatin therapy | #166 |
| strategies patients | #166 |
| phlebography | #166 |
| stockings compression | #166 |
| ankle brachial abi | #167 |
| recurrent thrombosis | #167 |
| thrombin venous | #167 |
| 3658 | #167 |
| syndrome pts | #168 |
| cstatistics | #168 |
| treatment 3 months | #168 |
| recurrent acute | #168 |
| warfarin | #168 |
| cvcs | #168 |
| double heterozygosity | #168 |
| current clinical practice | #168 |
| postthrombotic syndrome pts | #169 |
| therapeutic range | #169 |
| preexistent | #169 |
| patients infections | #169 |
| risk profile | #169 |
| fold increased | #169 |
| 3 12 | #169 |
| heavy menstrual bleeding | #170 |
| interobserver agreement | #170 |
| postoperative blood loss | #170 |
| thrombosis cancer | #170 |
| cart patients | #170 |
| recombinant factor | #171 |
| adamts‐13 | #171 |
| aged algorithms | #171 |
| venous thrombotic events | #171 |
| 57 years | #171 |
| clinical trials patients | #172 |
| lmw heparin | #172 |
| vaginal bleeding | #172 |
| patients blood transfusion | #172 |
| antifibrinolytic | #172 |
| risk factors patients | #172 |
| pulmonology | #172 |
| inr | #173 |
| bleeds | #173 |
| pulmonary | #173 |
| hospitalized medical patients | #173 |
| bleeding tendency | #174 |
| laboratory monitoring | #174 |
| clinically bleeding | #174 |
| arterial occlusions | #174 |
| patients initial | #174 |
| arterial venous | #175 |
| fragment 1 | #175 |
| vte common | #175 |
| data control | #175 |
| reocclusion | #175 |
| picotamide | #177 |
| mitsubishi | #177 |
| prothrombin | #177 |
| intention analysis | #178 |
| short‐ | #178 |
| 122 | #178 |
| hyperthyroidism hypothyroidism | #178 |
| aspirin ticlopidine | #178 |
| baseline day | #179 |
| vte event | #179 |
| concomitance | #179 |
| oral female humans | #179 |
| noninferior | #179 |
| isth | #180 |
| referral bias | #180 |
| thromboplastin time | #180 |
| patients deficiency | #180 |
| ventilation perfusion | #180 |
| additional risk factors | #180 |
| aged partial | #181 |
| testing patients | #182 |
| antithrombin | #182 |
| acute episode | #182 |
| painkillers | #182 |
| biological variation | #183 |
| hyperhomocysteinemic | #183 |
| 2–4 | #183 |
| patients major | #183 |
| subsequent diagnosis | #184 |
| antithrombin iii atiii | #184 |
| 4150 | #184 |
| n110 | #184 |
| treat analysis | #184 |
| risk bleeding | #184 |
| coagulation factors | #184 |
| thromboinflammation | #184 |
| incidental | #184 |
| pregnancy vte | #184 |
| prognosis pulmonary | #184 |
| vte age | #185 |
| deficient patients | #185 |
| live birth rate | #186 |
| hemostatic effects | #186 |
| brain natriuretic | #186 |
| symptomatic | #186 |
| anticoagulated | #186 |
| studies heparin | #186 |
| patients intensive units | #186 |
| patients thromboprophylaxis | #186 |
| safety apixaban | #187 |
| risk composite | #187 |
| cutoff level | #187 |
| antifibrinolytic agents | #187 |
| patients haemophilia | #187 |
| ratio inr | #188 |
| doacs vkas | #188 |
| prevalence cancer | #188 |
| spontaneous rupture | #188 |
| humans international | #188 |
| 926 | #188 |
| absolute rate | #188 |
| riete | #189 |
| fibrinolysis | #189 |
| blood loss patients | #189 |
| patients netherlands | #189 |
| willebrand factor antigen | #189 |
| heparin administration | #189 |
| clinical validity | #189 |
| 64slice | #189 |
| viia female | #189 |
| ccus | #190 |
| thrombosis patients | #190 |
| current views | #190 |
| anticoagulant drugs | #190 |
| ischemic event | #190 |
| gogh | #191 |
| acute thrombosis | #191 |
| 07 | #191 |
| venous outflow | #191 |
| attending physicians | #191 |
| score patients | #191 |
| 058 | #192 |
| 1495 | #192 |
| stroke systemic | #192 |
| endothelial cell activation | #193 |
| coagulation assays | #193 |
| anticoagulation | #194 |
| blood coagulation | #194 |
| heparin patients | #194 |
| 070 | #194 |
| prothrombin activation | #194 |
| antagonist treatment | #195 |
| 65 months | #195 |
| antixa levels | #195 |
| risk major | #195 |
| recurrent ischemic events | #195 |
| target range | #195 |
| complications cardiovascular | #196 |
| abnormal test | #196 |
| 29 95 | #196 |
| coagulation status | #196 |
| treatment groups patients | #198 |
| vii rfviia | #198 |
| vwf adamts13 | #198 |
| ate | #198 |
| sew2871 | #198 |
| difference treatment | #198 |
| cachectin | #199 |
| coagulation monitoring | #199 |
| patient diagnosis | #199 |
| screening patients | #200 |
| obese controls | #200 |
| patients 12 months | #200 |
| incidence cardiovascular events | #200 |
| thrombin factor | #201 |
| vte incidence | #201 |
| validation sets | #201 |
| thromboembolic disease | #201 |
| patients abnormal | #201 |
| johnson | #202 |
| peritoneovenous | #202 |
| 17 95 | #202 |
| arterial thrombosis | #202 |
| worldwide survey | #203 |
| induced activation | #203 |
| symptomatic pad | #203 |
| invitees | #203 |
| heparin dose | #203 |
| antithrombotic agents | #204 |
| levonorgestrel | #204 |
| period time | #205 |
| 0 95 | #205 |
| thrombophilia risk | #205 |
| extended thromboprophylaxis | #205 |
| low incidence | #205 |
| stroke systemic embolism | #205 |
| fgt | #206 |
| patients anticoagulant therapy | #206 |
| varese | #206 |
| venous ultrasonography | #206 |
| data synthesis | #206 |
| systematic review studies | #207 |
| algorithms anticoagulants | #207 |
| 06 | #207 |
| methods consecutive | #207 |
| fviii | #207 |
| desogestrel | #207 |
| imt patients | #207 |
| cardiologist | #207 |
| objectively | #207 |
| death female humans | #207 |
| platelet activation patients | #207 |
| bleeding compared | #208 |
| thrombocythaemia | #208 |
| patients hypothyroidism | #208 |
| deficiency risk | #209 |
| free protein | #209 |
| hirudins | #210 |
| tgt | #210 |
| women frequency | #210 |
| antixa activity | #210 |
| toxaemia | #211 |
| ioxaglate | #211 |
| systemic embolism patients | #211 |
| stocking | #211 |
| atrial fibrillation study | #212 |
| anticoagulation management | #212 |
| plasminogen activator activity | #213 |
| heparitin sulfate | #213 |
| correct interpretation | #214 |
| topic practice | #214 |
| dabigatran dose | #214 |
| studies rivaroxaban | #215 |
| factors vte | #215 |
| standard duration | #215 |
| current developments | #215 |
| thrombin inhibition | #215 |
| deamino | #216 |
| duplex venous | #216 |
| warfarin stroke | #216 |
| betatg | #216 |
| community hospital | #216 |
| mildest | #217 |
| undergoing total | #217 |
| obviates | #217 |
| diagnostic algorithm | #217 |
| studies difference | #217 |
| npv 100 | #218 |
| conclusive evidence | #218 |
| cstatistic | #218 |
| g20210a | #218 |
| plasminogen activator inhibitor | #218 |
| 077 95 | #219 |
| patients cart | #219 |
| deamino arginine | #219 |
| cancer | #219 |
| data extraction | #220 |
| vii factor | #220 |
| hip replacement surgery | #220 |
| viii female | #220 |
| techniques female | #220 |
| healthy human subjects | #221 |
| preventive measures | #221 |
| hmvec | #221 |
| postoperative vte | #221 |
| heparin humans | #221 |
| apc resistance | #222 |
| proximally | #222 |
| vte events | #222 |
| substantial proportion | #223 |
| engl | #223 |
| 1 january | #223 |
| 1541 | #223 |
| pulmonologists | #223 |
| subsequent cancer | #224 |
| protein pathway | #224 |
| thromboendarterectomy | #224 |
| topic factor | #224 |
| neoplasms prospective | #225 |
| balloon coronary anticoagulants | #225 |
| thrombosis warfarin | #225 |
| kruskalwallis | #225 |
| org | #225 |
| 16 95 | #226 |
| vascular events patients | #226 |
| extremity amputation | #226 |
| 0·67 | #226 |
| inr monitoring | #226 |
| tests diagnosis | #227 |
| acute medical | #227 |
| haemostasis | #227 |
| 35 ± | #227 |
| mild hyperhomocysteinemia | #228 |
| ipe | #228 |
| cgp | #229 |
| dalteparin | #229 |
| residual thrombus | #229 |
| scant | #229 |
| advocated | #230 |
| 037 | #230 |
| 6 studies | #231 |
| urosepsis | #231 |
| thiazoles | #231 |
| ft4 | #231 |
| patients discontinuation | #231 |
| resource utilisation | #231 |
| equinox | #231 |
| major orthopaedic surgery | #231 |
| severe preeclampsia | #231 |
| habitual abortion | #231 |
| aspirin dipyridamole | #232 |
| patients warfarin | #232 |
| endogenous thrombin potential | #233 |
| anticoagulant effects | #233 |
| cancer prevalence | #233 |
| surgical embolectomy | #233 |
| dimer | #233 |
| recurrence risk factors | #233 |
| humans netherlands | #233 |
| effective alternative | #234 |
| prothrombotic state | #235 |
| graduated compression | #235 |
| doac | #235 |
| humans meta | #236 |
| venous thromboembolic events | #236 |
| brain natriuretic peptide | #236 |
| oral anticoagulants | #237 |
| myocardial infarction 95 | #237 |
| treatment continuation | #237 |
| 009 | #238 |
| patients vkas | #238 |
| 6500 | #238 |
| predictive tests | #238 |
| anticoagulants aspirin | #239 |
| factor tnf | #239 |
| crossover study | #239 |
| factor viii fviii | #239 |
| rational approach | #239 |
| arterial venous thrombosis | #240 |
| patients initial treatment | #240 |
| 045 | #241 |
| hip knee arthroplasty | #241 |
| aspirin heparin | #241 |
| time therapeutic range | #242 |
| bleeding incidence | #242 |
| patients intermittent claudication | #243 |
| prothrombin fragment | #243 |
| pivotal trials | #243 |
| iohexol | #244 |
| vte risk factors | #245 |
| n89 | #245 |
| vte cases | #246 |
| thrombogenesis | #246 |
| casecontrol | #246 |
| children neonates | #246 |
| lipoproteina levels | #247 |
| warfarin aged | #247 |
| 23 95 | #247 |
| antithrombotic | #247 |
| patients solid tumours | #248 |
| coronary anticoagulants | #248 |
| treatment compared | #248 |
| anti activity | #248 |
| committees | #248 |
| bleeding rates | #249 |
| score risk | #249 |
| multiple comorbidities | #249 |
| diagnostic models | #249 |
| ischemic strokes | #250 |
| protein risk | #250 |
| ioxaglic | #250 |
| fv leiden | #250 |
| microthrombosis | #251 |
| 8595 | #251 |
| finalized | #251 |
| patients contraindications | #251 |
| simplification | #252 |
| vkas doacs | #252 |
| somit | #252 |
| thrombin thrombosis | #253 |
| incidence | #253 |
| treatment duration | #254 |
| agents anticoagulants | #254 |
| fibrinolytic activity | #255 |
| palga | #255 |
| medea | #256 |
| haul | #256 |
| activation humans | #256 |
| continuous intravenous | #257 |
| activity assay | #257 |
| bleeding risk | #257 |
| cost‐effectiveness | #257 |
| clinical utility | #257 |
| q24h | #257 |
| ctpa | #258 |
| patient subgroups | #258 |
| fibrin degradation | #258 |
| 30 50 | #259 |
| unpublished data | #259 |
| sspe | #260 |
| dvt risk | #260 |
| thrombus size | #261 |
| toxicosis | #261 |
| noncarriers | #261 |
| heparin dosing | #261 |
| patients hospitalization | #262 |
| optimal duration | #263 |
| risk pulmonary | #263 |
| blind study | #264 |
| graft type | #265 |
| 400 patients | #266 |
| pbac | #267 |
| einstein | #267 |
| statins risk | #268 |
| endotoxaemia | #268 |
| relation time | #269 |
| versus aspirin | #269 |
| propeptide | #269 |
| lysis time | #269 |
| randomised cross | #269 |
| malignancy patients | #269 |
| discontinuing | #270 |
| single test | #270 |
| exclusion | #270 |
| protein patients | #270 |
| hormonal replacement therapy | #271 |
| platelet serotonin | #271 |
| thrombosis inflammation | #271 |
| protein apc | #271 |
| orthopaedic patients | #271 |
| 3·0 | #271 |
| groups levels | #272 |
| vte recurrence | #272 |
| patients combination | #272 |
| clopidogrel ticlopidine | #272 |
| bleeding patient | #272 |
| ankle brachial | #273 |
| efficacy analysis | #273 |
| prevalence pad | #274 |
| risk levels | #274 |
| cleavage sites | #274 |
| months 12 | #274 |
| performance score | #275 |
| international normalized | #275 |
| parenteral nutrition patients | #275 |
| antithrombotic agent | #276 |
| fourth quartile | #276 |
| time aptt | #277 |
| smoking hypertension | #277 |
| imaging sensitivity | #278 |
| normalized ratio | #278 |
| dose reduction | #278 |
| aptt | #279 |
| blood test | #279 |
| rco | #279 |
| propositi | #280 |
| partial thromboplastin time | #280 |
| intracranial hemorrhage patients | #280 |
| hospitalized medical | #280 |
| obviate | #280 |
| exclusion criteria | #280 |
| patients presence | #281 |
| diagnostic test | #282 |
| thromboplastin | #282 |
| puerperal | #283 |
| diagnostic sensitivity | #283 |
| thyroid diseases | #283 |
| presentation patients | #283 |
| neutrophil degranulation | #283 |
| favor | #284 |
| noninferiority margin | #284 |
| outpatient treatment | #284 |
| animals anticoagulants | #284 |
| departments | #284 |
| test characteristics | #284 |
| major orthopaedic | #285 |
| plasma bnp | #286 |
| 2630 | #286 |
| patients apixaban | #286 |
| gentamicin treatment | #286 |
| patients pancreatic cancer | #287 |
| subdistribution | #287 |
| disseminated intravascular | #287 |
| levels measured | #287 |
| clinically | #287 |
| md patients | #288 |
| 227 | #288 |
| oral combined | #288 |
| premature atherosclerosis | #288 |
| cvt patients | #289 |
| clot lysis | #289 |
| vte rates | #289 |
| vte women | #289 |
| substantiation | #289 |
| thrombin time | #290 |
| 0·50 | #290 |
| n59 | #290 |
| current clinical | #291 |
| extracted data | #291 |
| carriers mutation | #291 |
| oral contraceptives | #291 |
| 016 | #291 |
| 2 studies | #292 |
| 1603 | #292 |
| activator inhibitor | #292 |
| willebrand disease vwd | #292 |
| pentasaccharide | #293 |
| adverse outcome patients | #293 |
| 1000 personyears | #293 |
| plasmin activity | #293 |
| patients dabigatran | #293 |
| patients rivaroxaban | #294 |
| lower extremities | #294 |
| tissuetype plasminogen activator | #294 |
| cardiac troponin ctnt | #294 |
| scenario analysis | #295 |
| 1025 | #295 |
| extremity dvt | #295 |
| peripheral vascular | #296 |
| classified | #296 |
| coagulation factor viii | #296 |
| observer agreement | #297 |
| routine monitoring | #297 |
| thrombocytes | #298 |
| episode patients | #298 |
| recurrent miscarriage | #298 |
| specificity npv | #298 |
| patients inr | #299 |
| inferiority | #300 |
| 041 | #301 |
| heparitin | #301 |
| aged neoplasms | #302 |
| toxemia | #302 |
| subclinical thyroid dysfunction | #302 |
| 155 patients | #302 |
| thromboglobulin | #302 |
| 1214 | #304 |
| absolute difference | #304 |
| rivaroxaban dabigatran | #305 |
| medline embase | #306 |
| prophylactic administration | #306 |
| chimpanzees | #307 |
| noninvasive testing | #308 |
| complex concentrate | #309 |
| hematologic pregnancy | #310 |
| vte pregnancy | #310 |
| thrombotic | #310 |
| surgery day | #310 |
| antithrombins blood | #311 |
| patients 100 | #311 |
| clinical presentation | #311 |
| percentage points | #311 |
| 105 patients | #311 |
| 598 | #312 |
| leg male | #312 |
| hereditary thrombophilia | #313 |
| vte 95 | #313 |
| obesity risk factor | #313 |
| negative reactions | #313 |
| diagnosis | #314 |
| cardiologists | #315 |
| postpartum haemorrhage | #315 |
| funding | #315 |
| heparin aspirin | #315 |
| puerperium | #315 |
| apixaban versus | #316 |
| therapeutic dose | #316 |
| patients followup | #317 |
| adjudicators | #317 |
| deciding | #318 |
| 0·92 | #318 |
| decision model | #319 |
| failure rates | #319 |
| safety outcomes | #319 |
| influenza infections | #320 |
| combined administration | #320 |
| patients pregnancy | #320 |
| bnp levels | #320 |
| 1731 | #320 |
| catheter thrombosis | #320 |
| ventricular dysfunction patients | #321 |
| intermediate phenotype | #322 |
| additional data | #322 |
| patients noacs | #322 |
| difference risk | #322 |
| peripheral arterial | #324 |
| glaxosmithkline | #324 |
| inrs | #324 |
| convincing evidence | #325 |
| mortality odds ratio | #325 |
| 122 patients | #326 |
| pulmonary embolus | #326 |
| blood coagulation factor | #326 |
| mechanical heart valves | #326 |
| surgery trauma | #327 |
| clinical | #327 |
| association vte | #329 |
| thrombotic event | #331 |
| vitamin administration | #331 |
| incidence bleeding | #331 |
| pregnancy outcome women | #331 |
| new oral | #332 |
| 95 percent | #333 |
| n69 | #333 |
| embase databases | #333 |
| analysis trials | #333 |
| complicate | #334 |
| incidences | #334 |
| 95 confidence limits | #334 |
| minor effects | #334 |
| patients healthy volunteers | #335 |
| fibrillation benzimidazoles | #335 |
| rationale design | #335 |
| pulmonary perfusion | #336 |
| septicaemia | #336 |
| central venous catheter | #336 |
| 065 | #337 |
| recurrent | #337 |
| 035 | #337 |
| total hip replacement | #337 |
| 2 points | #337 |
| plethysmographic | #337 |
| outpatient management | #338 |
| fatal bleeding | #338 |
| coagulation abnormalities | #338 |
| aged netherlands | #338 |
| prospective clinical study | #339 |
| placebo trials | #339 |
| noacs warfarin | #339 |
| 024 | #340 |
| antithrombotic effects | #340 |
| patients 12 | #340 |
| activatable | #341 |
| 217 | #341 |
| coagulation markers | #341 |
| knee arthroscopy | #342 |
| noac patients | #342 |
| pretest | #344 |
| patients covid19 infection | #344 |
| antithrombotic strategies | #345 |
| rfviia | #345 |
| vte prevention | #345 |
| splanchnic vein thrombosis | #345 |
| diagnosis vte | #346 |
| embolisms | #346 |
| activated protein resistance | #347 |
| patients thrombosis | #347 |
| 073 | #347 |
| 044 | #348 |
| cochrane central | #348 |
| bsf | #349 |
| chads2 | #349 |
| 2575 | #349 |
| tafia | #350 |
| randomized studies | #350 |
| trousseau | #350 |
| brain predictive | #350 |
| factor viii | #351 |
| 013 | #351 |
| versus warfarin | #351 |
| selection bias | #352 |
| anticoagulants noacs | #352 |
| factor activation | #352 |
| dermatan sulphate | #352 |
| 5075 | #353 |
| 1590 | #353 |
| vein | #353 |
| relative efficacy | #353 |
| oral anticoagulant therapy | #353 |
| international normalized ratio | #354 |
| aged pulmonary | #354 |
| patients gp | #355 |
| studies diagnostic accuracy | #355 |
| protein deficiency | #356 |
| intestinal microbiome | #357 |
| categorised | #357 |
| post hoc | #357 |
| tests prospective studies | #357 |
| 127 patients | #358 |
| sucra | #360 |
| pilots | #360 |
| intermittent claudication | #361 |
| consensus agreement | #362 |
| treatment risk | #362 |
| anticoagulation patients | #364 |
| humans risk | #365 |
| conventional therapy | #365 |
| bleeding rate | #366 |
| topic female | #366 |
| prediction models | #367 |
| patients 3 | #368 |
| time recurrence | #368 |
| infrainguinal | #368 |
| thrombin inhibitor | #369 |
| 6week | #370 |
| patients acl reconstruction | #370 |
| influenza infection | #370 |
| endotoxin infusion | #371 |
| venous stasis | #371 |
| 055 | #372 |
| 803 | #372 |
| patients svt | #373 |
| recombinant activated | #373 |
| clinical suspicion | #373 |
| knee surgery | #373 |
| aprotinin blood | #373 |
| human cytomegalovirus infection | #374 |
| patients scores | #374 |
| helical computed tomography | #374 |
| hmb | #375 |
| subcutaneous | #375 |
| lyg | #377 |
| subclinical hyperthyroidism | #378 |
| contraceptives oral | #380 |
| stroke venous | #380 |
| tafi | #381 |
| ethinyloestradiol | #381 |
| antitnf | #382 |
| prefilter | #383 |
| multivariate regression analysis | #384 |
| standardized questionnaire | #384 |
| 0·8 | #384 |
| reassessed | #384 |
| thromboembolic complications | #384 |
| systemic activation | #385 |
| alpha2m | #385 |
| bleeding events | #386 |
| conference proceedings | #386 |
| surrogate outcome | #386 |
| antithrombins | #387 |
| sensitivity npv | #387 |
| cumulative incidences | #387 |
| delegates | #388 |
| major orthopedic | #388 |
| safety rivaroxaban | #389 |
| systemic embolism | #389 |
| referred | #389 |
| 880 | #389 |
| vitt | #390 |
| tinzaparin | #390 |
| apixaban warfarin | #390 |
| comparison patients | #391 |
| drug prescription | #391 |
| biosis | #391 |
| postop | #391 |
| abi | #391 |
| increased bleeding | #391 |
| topic female humans | #392 |
| patients chest | #392 |
| time presentation | #392 |
| kappa values | #393 |
| factors thrombosis | #393 |
| background patients | #394 |
| pulmonary emboli | #394 |
| clinical score | #394 |
| injections intravenous | #394 |
| 007 | #395 |
| popliteal | #396 |
| 95 12 | #396 |
| bleeding event | #396 |
| embolic events | #397 |
| hirudins humans | #397 |
| 665 | #397 |
| factors factor | #397 |
| replacement surgery | #397 |
| risk score patients | #399 |
| heparin induced | #400 |
| patients risk | #400 |
| echography | #400 |
| risk factors asthma | #400 |
| hemostatic parameters | #401 |
| fibrinolytic agents | #402 |
| dabigatran | #403 |
| increased risk vte | #403 |
| controversy | #403 |
| massive pulmonary embolism | #405 |
| 075 | #406 |
| 2215 | #406 |
| treatment patient | #406 |
| thrombolytic agents | #406 |
| oral anticoagulant | #408 |
| factor levels | #408 |
| biologic effects | #410 |
| fviii levels | #411 |
| safety combination | #411 |
| patients assigned | #411 |
| noacs patients | #411 |
| transfusion patients | #412 |
| major risk factor | #412 |
| 20 microg | #412 |
| euthyroidism | #414 |
| maastricht | #414 |
| coagulation patients | #414 |
| xii | #415 |
| hypocortisolism | #415 |
| aged odds | #415 |
| intravascular coagulation | #416 |
| pai1 levels | #416 |
| deserve | #416 |
| dose heparin | #416 |
| comparable | #417 |
| data risk | #417 |
| 95 10 | #417 |
| pretest probability | #418 |
| 95 | #418 |
| carotid femoral | #418 |
| risk factors thrombosis | #419 |
| dermatan | #419 |
| 269 | #419 |
| xia | #420 |
| ototoxicity | #420 |
| fibrillation risk | #421 |
| fibrillation clinical | #422 |
| 1989 | #422 |
| tests radiography | #422 |
| 2850 | #422 |
| fibrinolysin | #423 |
| fviia | #424 |
| subanalysis | #424 |
| prevalence patients | #425 |
| adjunct | #426 |
| randomised double | #426 |
| fii | #426 |
| cancer cohort | #426 |
| consecutive | #427 |
| activated factor | #427 |
| plg | #428 |
| conferences | #428 |
| excessive bleeding | #428 |
| daily practice | #428 |
| daily clinical practice | #429 |
| idiopathic myelofibrosis | #429 |
| prolactin levels | #429 |
| undergoing elective | #429 |
| patients testing | #429 |
| 1904 | #430 |
| rule | #431 |
| heparinoids | #431 |
| bleeding complications | #431 |
| 04 | #432 |
| outpatients | #433 |
| incidence length | #433 |
| ncb | #434 |
| patients systematic review | #434 |
| firstdegree relatives patients | #436 |
| blood cultures | #436 |
| 059 | #437 |
| bolus injection | #437 |
| composite point | #439 |
| dose adjustment | #439 |
| proven | #439 |
| prostatic cancer | #439 |
| women compared | #439 |
| highrisk populations | #441 |
| concomitant medications | #441 |
| 074 | #442 |
| rate vte | #442 |
| standard therapies | #444 |
| –control study | #444 |
| prespecified | #445 |
| febrile patients | #446 |
| patients atrial fibrillation | #446 |
| female fibrinolytic | #447 |
| hellp | #449 |
| 58 | #449 |
| utrecht | #449 |
| patients parenteral nutrition | #449 |
| prevalence distribution | #450 |
| 3 12 months | #450 |
| stigmatisation | #451 |
| category | #451 |
| pipecolic | #452 |
| noninvasive tests | #453 |
| fatal disease | #453 |
| aspirin risk | #453 |
| thrombin generation | #453 |
| factor xii | #454 |
| portal blood | #454 |
| 30 40 | #454 |
| placebo day | #454 |
| microthrombi | #455 |
| 026 | #455 |
| 12week | #455 |
| dichotomized | #456 |
| fviii vwf | #456 |
| onwards | #457 |
| dicumarol | #457 |
| squibb | #457 |
| hazard ratio 95 | #458 |
| iii complexes | #458 |
| anti levels | #458 |
| svt | #460 |
| recommend | #460 |
| plasma lipoprotein | #460 |
| gastrointestinal cancer | #461 |
| factor fxa | #461 |
| expert consensus document | #462 |
| curve biomarkers | #462 |
| hip arthroplasty replacement | #462 |
| guidelines patients | #463 |
| haemolysis | #463 |
| gp iib | #464 |
| patients values | #464 |
| studies ultrasonography | #464 |
| month follow | #465 |
| diabetes stroke | #466 |
| cancerassociated thrombosis | #466 |
| accuracy detection | #467 |
| thrombin formation | #467 |
| intimamedia thickness | #468 |
| patients nsaids | #468 |
| prophylaxis | #468 |
| bmi≥30 | #469 |
| teaching hospitals | #469 |
| eligible studies | #469 |
| hemihepatectomy | #470 |
| inr patients | #470 |
| 077 | #470 |
| test probability | #470 |
| roc analysis | #470 |
| placebo recipients | #471 |
| case control study | #472 |
| prophylactic anticoagulation | #472 |
| hypercoagulability | #472 |
| cardiovascular risk assessment | #473 |
| thrombophilia testing | #474 |
| intermittent pneumatic | #475 |
| endotoxemia | #475 |
| heterozygote humans | #475 |
| patients heparin | #475 |
| 15 95 | #475 |
| plethysmograph | #475 |
| atria | #477 |
| haemophiliacs | #479 |
| 08 | #479 |
| patients score | #479 |
| versus standard | #480 |
| thrombosis cvt | #481 |
| acutely | #481 |
| hit patients | #481 |
| postoperative blood | #482 |
| 1162 | #482 |
| advisory | #482 |
| transportability | #482 |
| thrombin inhibitors | #483 |
| events mortality | #484 |
| diagnostic efficacy | #485 |
| patients hematologic malignancies | #485 |
| awaited | #486 |
| secondary prophylaxis | #487 |
| composite scores | #487 |
| silent | #488 |
| travel | #488 |
| activity patients | #489 |
| 98 | #490 |
| blinded | #491 |
| residual risk | #493 |
| hemophilic | #493 |
| pan troglodytes | #493 |
| treatment period | #493 |
| new therapy | #493 |
| p00007 | #493 |
| vcf | #494 |
| activated protein | #495 |
| favour | #496 |
| replacement hip arthroplasty | #496 |
| dose oral | #496 |
| heterozygote | #496 |
| 271 | #497 |
| topic risk factors | #497 |
| discriminative ability | #498 |
| blockages | #498 |
| risk factors stroke | #498 |
| willebrand disease | #498 |
| hip knee | #501 |
| nri | #502 |
| ptp | #502 |
| ft4 tsh | #503 |
| subcategories | #503 |
| deficiencies | #503 |
| rapid decrease | #504 |
| patients referred | #505 |
| 1107 | #505 |
| complications pulmonary | #505 |
| nondiagnostic | #505 |
| net clinical | #506 |
| 310 | #506 |
| day surgery | #507 |
| nonionic | #507 |
| oftentimes | #507 |
| inhibitors rivaroxaban | #508 |
| contraceptives | #509 |
| coagulation tests | #509 |
| aminocaproates | #509 |
| 13 95 | #509 |
| guidelines diagnosis | #509 |
| degradation products | #510 |
| angiography patients | #510 |
| thrombosis animals | #510 |
| new oral anticoagulants | #510 |
| viii fviii | #511 |
| 019 | #512 |
| epiphenomenon | #512 |
| serial | #513 |
| 056 | #514 |
| interim analysis | #514 |
| highintensity | #514 |
| daycare | #515 |
| safety | #516 |
| crcl | #517 |
| bleeding outcomes | #518 |
| protein antithrombin | #518 |
| thrombophilia thrombosis | #518 |
| sensitivity diagnosis | #518 |
| thrombotic diseases | #518 |
| treatment cancer patients | #519 |
| groups treatment | #519 |
| study sensitivity | #520 |
| duration intensity | #521 |
| 1599 | #521 |
| 8090 | #521 |
| warfarin therapy | #524 |
| general practitioner | #525 |
| fixed doses | #525 |
| 062 | #527 |
| cancer age | #528 |
| cindices | #528 |
| convincing | #529 |
| 378 | #529 |
| 923 | #529 |
| 051 | #529 |
| health female | #530 |
| fatal | #530 |
| medically patients | #531 |
| humans postoperative | #531 |
| thrombosis hemostasis | #531 |
| betaalanine | #531 |
| 068 | #532 |
| intensive units icu | #532 |
| thrombosis risk | #532 |
| ≥50 years | #532 |
| factor thrombin | #534 |
| therapy cancer | #534 |
| 730 | #536 |
| factor pathway | #537 |
| humans neoplasms | #538 |
| 449 | #538 |
| patients idiopathic | #538 |
| ddavp | #539 |
| comprehensive search | #539 |
| cbo | #539 |
| concise | #539 |
| clinical review | #540 |
| diagnosis acute | #540 |
| diagnostic accuracy studies | #540 |
| bleeding episodes | #543 |
| vascular obstruction | #543 |
| conventional treatment | #543 |
| thrombotic risk | #543 |
| patients eligible | #543 |
| 234 | #543 |
| jak2 mutation | #544 |
| 00 | #544 |
| coagulative | #544 |
| pad abi | #544 |
| prospective cohort study | #545 |
| perc | #545 |
| v617f | #545 |
| hellp syndrome | #545 |
| screening strategies | #546 |
| association statin | #546 |
| prothrombin complex | #547 |
| bureau | #547 |
| primary | #548 |
| 95 difference | #549 |
| overt | #549 |
| adequate | #549 |
| platelet inhibitors | #550 |
| reviewers | #550 |
| cancer type | #550 |
| conduction anesthesia | #550 |
| 1103 | #550 |
| percent patients | #550 |
| 500 patients | #552 |
| management bleeding | #552 |
| studies sensitivity | #552 |
| amsterdam | #552 |
| careful | #552 |
| day patients | #552 |
| femoral arteries | #553 |
| general population patients | #554 |
| ttr | #556 |
| humans infusions | #557 |
| factor vii | #558 |
| vivo treatment | #558 |
| 66 patients | #558 |
| bleeding time | #559 |
| orthopedic surgery | #559 |
| limulus | #561 |
| risk development | #563 |
| female humans tests | #563 |
| patients transfusion | #563 |
| board directors | #563 |
| appears | #564 |
| hip replacement | #564 |
| anamnesis | #564 |
| hyperfibrinolysis | #565 |
| increasing risk | #565 |
| cardiac troponins | #566 |
| withholding | #566 |
| solid tumours | #566 |
| roc curves | #568 |
| patients 2 years | #568 |
| n46 | #568 |
| levothyroxine | #571 |
| alpha1antitrypsin | #571 |
| aggravation | #572 |
| ctnt | #573 |
| revascularization procedures | #574 |
| menstrual bleeding | #574 |
| cutoff point | #574 |
| women proportion | #575 |
| major bleedings | #575 |
| subcutaneously | #575 |
| progression cancer | #577 |
| endothelial barrier | #578 |
| patients vka | #578 |
| thiophenes | #579 |
| pharma | #579 |
| endotoxin | #579 |
| notice | #580 |
| 99 | #580 |
| diagnostic tools | #580 |
| cancer thrombosis | #581 |
| subgroups patients | #583 |
| dummy | #584 |
| unselected patients | #584 |
| coagulation disorders | #585 |
| 094 | #585 |
| chondroitin sulfates | #586 |
| feasibility safety | #588 |
| major orthopedic surgery | #588 |
| helminth proteins | #589 |
| beta alanine | #590 |
| healthy human | #590 |
| reversal agents | #590 |
| malignancy | #590 |
| thrombophilias | #590 |
| massive pulmonary | #592 |
| doppler ultrasound | #592 |
| conventional management | #592 |
| bmi30 | #594 |
| factor fv | #595 |
| patency rates | #597 |
| replacement knee | #597 |
| ldf | #597 |
| major hemorrhage | #597 |
| severe bleeding | #597 |
| infusions intravenous | #598 |
| analysis topic | #599 |
| loss surgical | #600 |
| tests sensitivity | #600 |
| 046 | #601 |
| association patients | #602 |
| vwd | #603 |
| comorbid conditions | #604 |
| events occurred | #604 |
| clinical characteristics patients | #604 |
| diagnostic studies | #606 |
| initial increase | #607 |
| activated coagulation | #607 |
| 0·3 | #607 |
| patients antibodies | #607 |
| treatment acute | #608 |
| tissue factor | #609 |
| arbitrage | #609 |
| pfizer | #609 |
| benefit risk | #610 |
| 100 years | #610 |
| patients death | #610 |
| airline | #610 |
| clinical evaluation | #611 |
| ultrasonography | #613 |
| coagulation inflammation | #614 |
| reluctant | #615 |
| leg | #615 |
| patients bariatric surgery | #615 |
| complications risk | #616 |
| treatment rivaroxaban | #617 |
| arterial disease | #617 |
| 467 | #618 |
| stroke atrial fibrillation | #618 |
| occurred | #618 |
| fh patients | #620 |
| compared placebo | #620 |
| patients elevated | #621 |
| advisory committees | #621 |
| 1002 | #622 |
| sgs | #623 |
| thyrotoxic | #623 |
| thrombocytopenia hit | #623 |
| peptide bnp | #625 |
| cochrane central register | #625 |
| topic practice guidelines | #626 |
| stopped | #626 |
| stroke warfarin | #627 |
| 5000 | #628 |
| 66 | #628 |
| women risk factors | #628 |
| warfarin risk | #628 |
| human subjects | #629 |
| physical training | #629 |
| diagnostic algorithms | #629 |
| referral patients | #629 |
| sanofi | #630 |
| absolute | #630 |
| atiii | #632 |
| risk treatment | #633 |
| screening strategy | #634 |
| uneventful | #635 |
| outweigh | #635 |
| pentoxifylline | #637 |
| travelling | #638 |
| 95 allcause mortality | #640 |
| 14 95 | #640 |
| study quality | #641 |
| proceedings | #641 |
| 3050 | #642 |
| predictive performance | #642 |
| neutrophilia | #643 |
| threatening bleeding | #643 |
| association mortality | #647 |
| primary outcome measure | #647 |
| statin treatment | #648 |
| necessitating | #648 |
| studies efficacy | #648 |
| thrombolysis patients | #651 |
| 036 | #651 |
| fixed | #651 |
| organisations | #652 |
| troglodytes | #652 |
| fxa | #653 |
| hemorrhagic stroke | #653 |
| 127 | #655 |
| patients review | #657 |
| 69 | #659 |
| coronary stent implantation | #659 |
| bleeding death | #659 |
| haematoma | #660 |
| physical examination | #661 |
| tertiles | #661 |
| coagulation proteins | #661 |
| clinical presentations | #662 |
| haemophilia | #662 |
| 95 studies | #663 |
| 1028 | #663 |
| provoked | #664 |
| long term treatment | #664 |
| sepsis shock | #665 |
| phase iii studies | #666 |
| deep | #666 |
| guideline adherence | #667 |
| presence patients | #667 |
| onethird | #667 |
| patients completed | #667 |
| male medical | #668 |
| 8 wk | #669 |
| 1110 | #671 |
| phenprocoumon | #672 |
| patients cteph | #673 |
| elevated plasma | #673 |
| managing | #674 |
| hospitalization hf | #674 |
| clotting factors | #675 |
| inhibitor 1 | #675 |
| il6 levels | #675 |
| prothrombotic | #676 |
| highincome countries | #676 |
| asymptomatic subjects | #677 |
| favourably | #678 |
| jugular | #679 |
| pulmonary endarterectomy | #681 |
| medicine humans | #681 |
| suspicion | #682 |
| conclude | #687 |
| apolipoproteina | #688 |
| efficacy safety | #690 |
| patients bleeding | #692 |
| ambulatory patients | #692 |
| activator pa | #693 |
| graduated | #693 |
| myocardial infarctions | #693 |
| composite outcome | #694 |
| intracranial bleeding | #694 |
| administer | #694 |
| precise mechanisms | #694 |
| 1718 | #695 |
| stroke prevention patients | #696 |
| combined oral contraceptives | #696 |
| moyamoya | #696 |
| ratio male | #698 |
| difference 95 | #698 |
| participant data | #698 |
| episode | #700 |
| compression devices | #700 |
| therapeutic management | #702 |
| diagnostic errors | #702 |
| prothrombin gene | #702 |
| veins venous | #703 |
| patients confirmed | #703 |
| surgery risk | #703 |
| willebrand | #704 |
| data incidence | #706 |
| subclinical hypothyroidism | #708 |
| clinical expression | #709 |
| directors | #709 |
| starters | #711 |
| gastrointestinal bleeding | #712 |
| gynaecology | #712 |
| 048 | #712 |
| medical patients | #712 |
| radionuclide imaging | #713 |
| 1098 | #714 |
| rate death | #714 |
| neurosurgical patients | #714 |
| intravenous bolus | #715 |
| rivaroxaban stroke | #716 |
| menstrual period | #716 |
| cancer groups | #717 |
| adequately | #717 |
| 10 30 | #718 |
| solid cancer | #718 |
| falsely | #718 |
| plasminogen | #719 |
| reagent kits | #719 |
| pulmonary medicine | #720 |
| nordisk | #721 |
| pyrazoles pyridines | #721 |
| accp | #721 |
| clinical judgment | #721 |
| s1p1 | #722 |
| 95 hazard ratio | #724 |
| abnormal | #726 |
| follow period | #726 |
| gentamicins | #727 |
| 59 patients | #727 |
| orthopaedic surgery | #728 |
| diagnostic therapeutic | #728 |
| diagnostic tests | #730 |
| leeches | #732 |
| gentamicin | #732 |
| oral contraception | #733 |
| tumor necrosis factor | #733 |
| relative risk 95 | #734 |
| hull | #735 |
| disease pad | #735 |
| patients levels | #735 |
| atrial fibrillation risk | #736 |
| clinical prediction rule | #736 |
| tests retrospective studies | #736 |
| post hoc analysis | #739 |
| 6 12 | #739 |
| anti tnf | #740 |
| evaluable patients | #741 |
| unclear | #742 |
| 040 | #742 |
| early pregnancy loss | #742 |
| topic predictive | #743 |
| betathromboglobulin | #744 |
| illness time factors | #744 |
| molecular weight | #744 |
| patients 50 years | #746 |
| 285 | #746 |
| antithrombin activity | #746 |
| etp | #746 |
| leukocyte activation | #748 |
| thrombolytic therapy | #749 |
| hospitalization heart failure | #750 |
| indication | #752 |
| advisable | #754 |
| fibrin formation | #754 |
| primary patients | #755 |
| pneumatic compression | #756 |
| answer | #756 |
| 95 combination | #756 |
| 95 risk factors | #756 |
| hf risk | #756 |
| venovenous | #757 |
| 1·7 | #758 |
| 85 | #759 |
| loe | #759 |
| inflammation coagulation | #760 |
| patients peripheral | #761 |
| proportion women | #763 |
| 435 | #763 |
| start treatment | #764 |
| cprs | #764 |
| hip surgery | #765 |
| aspirin clopidogrel | #767 |
| 689 | #767 |
| risk pregnancy | #767 |
| 732 | #768 |
| method drug | #769 |
| groups patients | #770 |
| relevant | #770 |
| 566 | #770 |
| baseline values | #772 |
| graft patency | #772 |
| patients criteria | #773 |
| bmi patients | #774 |
| subcutaneous injections | #774 |
| 1·5 | #776 |
| 992 | #777 |
| patients 65 years | #778 |
| study groups | #778 |
| dose intravenous | #778 |
| dose warfarin | #778 |
| miscarriage | #779 |
| 066 | #780 |
| thromboembolism prophylaxis | #780 |
| plasmin generation | #780 |
| patients hyperthyroidism | #780 |
| age ≥ | #782 |
| factor ixa | #785 |
| onefifth | #785 |
| abnormalities patients | #786 |
| 100 personyears | #787 |
| topic disease models | #787 |
| polypharmacy | #787 |
| cteph | #787 |
| general practitioners | #787 |
| preferable | #788 |
| secondary outcome | #791 |
| recombinant tissue | #793 |
| mechanical heart | #793 |
| risk factors risk | #795 |
| inactivators | #795 |
| 047 | #795 |
| patient years | #796 |
| patency | #796 |
| eligible | #797 |
| netherlands | #797 |
| studies prevalence | #797 |
| femoropopliteal | #798 |
| lupus anticoagulant | #798 |
| estrogen therapy | #799 |
| theme | #799 |
| patients lower | #799 |
| hemophilia patients | #800 |
| willebrand factor | #802 |
| randomized patients | #804 |
| subclinical | #804 |
| anticoagulant agents | #805 |
| microvesicles | #805 |
| adverse outcomes patients | #806 |
| fibrillation blood | #806 |
| stroke risk factors | #807 |
| ventricular dysfunction | #808 |
| hypertension cteph | #809 |
| efficacy patients | #809 |
| activator inhibitor1 | #810 |
| 069 | #811 |
| model patients | #813 |
| primary aim | #814 |
| factor vwf | #816 |
| flights | #816 |
| 0·4 | #818 |
| vehicle control | #820 |
| irrespective | #820 |
| health predictive | #820 |
| abruptio | #821 |
| neuroradiologist | #822 |
| reduction mortality | #823 |
| prevention patients | #823 |
| coc | #824 |
| single administration | #824 |
| risk benefit | #825 |
| study incidence | #827 |
| gp | #828 |
| cardioembolic stroke | #828 |
| patients anticoagulants | #830 |
| cava filters | #832 |
| antithrombotic treatment | #833 |
| myers | #833 |
| 93 | #833 |
| abortion habitual | #835 |
| plough | #836 |
| oral adult | #836 |
| noac | #837 |
| versus placebo | #837 |
| 87 | #838 |
| 057 | #839 |
| genetic defect | #841 |
| risk scores | #844 |
| antithrombotic therapy | #846 |
| 49 | #846 |
| 072 | #847 |
| multidetector row | #847 |
| advise | #848 |
| recurrence risk | #849 |
| caesarean | #850 |
| patients diagnosis | #850 |
| area roc curve | #852 |
| pre‐eclampsia | #853 |
| 30 patients | #853 |
| reference method | #853 |
| advanced prostate | #854 |
| clopidogrel aspirin | #855 |
| fibrin | #855 |
| patients mutation | #859 |
| ultrafiltrate | #860 |
| dutch population | #861 |
| microg | #862 |
| cardiometabolic disease | #863 |
| 090 | #865 |
| placebo study | #866 |
| diagnostic methods | #868 |
| 1046 | #869 |
| pyridones | #870 |
| 6 month | #870 |
| longterm clinical outcomes | #872 |
| individual participant | #872 |
| favoring | #873 |
| tasman | #873 |
| thromboembolic pulmonary | #874 |
| imaging reproducibility | #874 |
| targeted inhibition | #874 |
| titles | #875 |
| plasminogen activation | #875 |
| n15 | #876 |
| cha2ds2 | #877 |
| dabigatran rivaroxaban | #878 |
| risk thromboembolic | #878 |
| 57 | #879 |
| anticoagulants atrial | #879 |
| oral | #881 |
| angiograms | #882 |
| control trial | #883 |
| 92 | #884 |
| imaging tests | #885 |
| prostate turp | #888 |
| handbook | #890 |
| domiciliary | #894 |
| 084 | #894 |
| male mexico | #894 |
| loading dose | #896 |
| p011 | #896 |
| repeatedly | #897 |
| uln | #901 |
| indefinite | #902 |
| bleedings | #904 |
| vkorc1 | #905 |
| wml | #906 |
| 064 | #908 |
| factor activity | #908 |
| subcutaneous administration | #909 |
| documented | #911 |
| patients clinical trials | #911 |
| initially | #912 |
| haemostatic | #912 |
| impedance | #913 |
| specificity sensitivity | #914 |
| combined approach | #916 |
| haemodialysis patients | #916 |
| 317 | #917 |
| 022 | #918 |
| thromboembolic events | #918 |
| chronic thromboembolic | #919 |
| antagonist oral | #920 |
| standard patients | #920 |
| randomeffects model | #920 |
| optimal dose | #921 |
| loss patients | #921 |
| ultrasound examination | #921 |
| practise | #923 |
| estimate male | #923 |
| multifactorial disease | #925 |
| study medication | #925 |
| total hip | #926 |
| safer | #928 |
| 902 | #928 |
| 004 | #929 |
| recurrent events | #930 |
| fxi | #931 |
| wording | #934 |
| treatment placebo | #934 |
| 84 | #936 |
| publication clinical trials | #937 |
| subgroup patients | #938 |
| 60 patients | #938 |
| rrr | #940 |
| families patients | #941 |
| teaching hospital | #943 |
| echocardiographically | #944 |
| stroke atrial | #944 |
| women preeclampsia | #944 |
| emboli | #945 |
| predictive values | #946 |
| ssc | #946 |
| anticoagulation treatment | #947 |
| extensive disease | #948 |
| diagnostic | #948 |
| knee replacement | #948 |
| previous diagnosis | #951 |
| adjudication | #954 |
| dic | #956 |
| cancer humans | #956 |
| registro | #956 |
| network metaanalysis | #956 |
| reassuring | #957 |
| venous insufficiency | #957 |
| day1 | #958 |
| efficacy | #958 |
| retropubic | #961 |
| combined oral | #961 |
| guidelines recommend | #962 |
| 3 months | #963 |
| blood product | #964 |
| travellers | #965 |
| reference lists | #966 |
| inhibitor1 | #966 |
| peaking | #969 |
| greater risk | #970 |
| allogeneic blood | #971 |
| antiplatelet | #973 |
| prevalence characteristics | #973 |
| risk allcause mortality | #973 |
| hoc | #973 |
| segmental | #974 |
| patients anticoagulation | #975 |
| vascular humans | #976 |
| female fibrinogen | #976 |
| fvii | #978 |
| false negative | #979 |
| 50 100 | #980 |
| onset aged aged | #980 |
| 071 | #980 |
| early gestation | #984 |
| 426 | #986 |
| prophylactic treatment | #987 |
| randomised trials | #987 |
| patients safety | #988 |
| vascular patency | #989 |
| study treatment | #990 |
| rises | #991 |
| missed | #991 |
| academic medical center | #992 |
| seminar | #992 |
| counteracted | #993 |
| normal lung | #993 |
| treatment bleeding | #994 |
| aged | #999 |
| 226 | #999 |
| justification | #1000 |
| lower extremity | #1000 |
| thromboembolic risk | #1000 |
| tissue type | #1001 |
| parenteral administration | #1002 |
| rivaroxaban apixaban | #1002 |
| eclamptic | #1003 |
| hyperprolactinaemia | #1005 |
| interleukin 6 | #1005 |
| extended | #1005 |
| pyridines | #1006 |
| 50 patients | #1007 |
| orthosis | #1007 |
| easier | #1007 |
| valsalva maneuver | #1009 |
| venous catheter | #1011 |
| individual participant data | #1012 |
| weighing | #1014 |
| ticlopidine | #1018 |
| pounds | #1018 |
| clotting time | #1019 |
| prostatic carcinoma | #1020 |
| 200 patients | #1022 |
| cha2ds2 vasc | #1023 |
| years risk | #1023 |
| international prospective | #1024 |
| humans randomized | #1024 |
| 076 | #1025 |
| diagnostic challenge | #1026 |
| prothrombin time | #1027 |
| firstdegree relatives | #1030 |
| decision analysis | #1030 |
| ixa | #1031 |
| prolactin | #1032 |
| risk hemorrhage | #1033 |
| cardiovascular event | #1033 |
| relatives | #1033 |
| 052 | #1035 |
| graft occlusion | #1037 |
| male netherlands | #1037 |
| 2 hours | #1039 |
| detect | #1040 |
| 025 | #1041 |
| 3 6 months | #1046 |
| patients severe asthma | #1047 |
| vwf levels | #1047 |
| patients massive | #1050 |
| examiner | #1050 |
| continuation | #1052 |
| patients analysis | #1053 |
| 221 | #1054 |
| mean±sd | #1054 |
| free triiodothyronine | #1056 |
| diseases liver | #1057 |
| 179 | #1060 |
| coagulant | #1060 |
| birth rate | #1060 |
| pad | #1061 |
| 610 | #1061 |
| published literature | #1062 |
| primary data | #1062 |
| false | #1064 |
| 150 | #1065 |
| prekallikrein | #1065 |
| 00008 | #1066 |
| live birth | #1066 |
| 101 | #1066 |
| lysosphingolipid | #1067 |
| cut | #1067 |
| pmol | #1068 |
| 95 increased risk | #1070 |
| register controlled | #1070 |
| observer variation | #1071 |
| specialties | #1072 |
| continued | #1073 |
| laboratory diagnosis | #1074 |
| thorax | #1074 |
| systematic search | #1078 |
| 063 | #1080 |
| advocate | #1080 |
| drawbacks | #1082 |
| longterm therapy | #1087 |
| f1 | #1087 |
| bandages | #1089 |
| stopping | #1095 |
| clarifications | #1095 |
| diagnostic utility | #1096 |
| mandated | #1096 |
| idarucizumab | #1096 |
| 1223 | #1099 |
| 083 | #1099 |
| 62 | #1102 |
| 96 | #1104 |
| fourfold | #1105 |
| blueprint | #1105 |
| clinical protocols | #1107 |
| peptide brain | #1107 |
| pending | #1111 |
| incidence pulmonary | #1112 |
| assigned | #1113 |
| diagnostic approach | #1115 |
| haemodialysis | #1116 |
| bypass grafts | #1116 |
| 252 | #1117 |
| qualified | #1118 |
| sensitivity specificity | #1119 |
| critical appraisal | #1120 |
| randomized controlled trials | #1122 |
| probands | #1123 |
| resistance factor | #1123 |
| new developments | #1124 |
| advised | #1125 |
| new perspectives | #1126 |
| 445 | #1126 |
| cip | #1127 |
| heparininduced thrombocytopenia | #1127 |
| patients pad | #1128 |
| discretion | #1132 |
| judged | #1132 |
| ≤10 | #1133 |
| statistic | #1133 |
| 95 confidence interval | #1134 |
| pulse rate | #1135 |
| gram negative | #1137 |
| 1043 | #1139 |
| disseminated | #1140 |
| 635 | #1141 |
| superior efficacy | #1141 |
| 86 | #1143 |
| 734 | #1145 |
| 844 | #1147 |
| refusal | #1150 |
| roc curve | #1150 |
| medline | #1151 |
| medical records | #1151 |
| embolectomy | #1153 |
| longterm complications | #1154 |
| risk recurrence | #1155 |
| patients influenza | #1156 |
| anticoagulation therapy | #1156 |
| blood loss | #1156 |
| prophylaxis treatment | #1157 |
| 3040 | #1158 |
| patients increased | #1159 |
| extension study | #1161 |
| cvc | #1162 |
| published guidelines | #1163 |
| bristol | #1163 |
| viii | #1164 |
| stable angina | #1164 |
| safety concerns | #1164 |
| intermittent | #1164 |
| hyperhomocysteinemia | #1164 |
| age 65 years | #1165 |
| thromboembolism risk | #1165 |
| angiogram | #1167 |
| perioperative bleeding | #1172 |
| glucocorticoid treatment | #1172 |
| atherosclerotic disease | #1172 |
| crossover design | #1172 |
| occlusive diseases | #1173 |
| practice guideline | #1173 |
| 5 years patients | #1176 |
| macroglobulin | #1176 |
| findings patients | #1178 |
| analysis studies | #1178 |
| 79 | #1179 |
| concealed | #1181 |
| conceive | #1181 |
| patients obesity | #1182 |
| unaware | #1182 |
| hospitalized patients | #1182 |
| conclusive | #1186 |
| combined therapy | #1186 |
| occult | #1189 |
| degree relatives | #1189 |
| adult analysis | #1191 |
| cus | #1194 |
| administration oral | #1195 |
| 21 patients | #1197 |
| cardiotonic agents | #1199 |
| mandate | #1199 |
| international society | #1199 |
| hypercortisolism | #1200 |
| 83 | #1203 |
| quantitative trait locus | #1204 |
| 015 | #1204 |
| categorized | #1204 |
| increase plasma | #1205 |
| 31 | #1207 |
| biomarkers blood | #1210 |
| 56 patients | #1212 |
| pph | #1214 |
| multicenter randomized | #1214 |
| 103 | #1218 |
| patient treatment | #1221 |
| scores patients | #1221 |
| warranted | #1221 |
| ultrasound screening | #1222 |
| 6months | #1223 |
| peak levels | #1224 |
| 64 patients | #1224 |
| vasc | #1225 |
| 16 patients | #1226 |
| sixfold | #1227 |
| blind | #1227 |
| metabolic syndrome patients | #1228 |
| consensus guidelines | #1228 |
| peptide hydrolases | #1229 |
| trial background | #1229 |
| radionuclide | #1229 |
| 65 patients | #1230 |
| rules | #1232 |
| doubles | #1232 |
| aspirin | #1234 |
| milliliter | #1238 |
| coronary angiography patients | #1238 |
| postoperative hemorrhage | #1238 |
| humans length | #1240 |
| clinical criteria | #1241 |
| patients fh | #1242 |
| vte prophylaxis | #1244 |
| neurohormone | #1245 |
| multinational | #1246 |
| thrombolytic | #1247 |
| knee arthroplasty | #1248 |
| intermediate risk | #1250 |
| subgroups | #1252 |
| ml1 | #1252 |
| matter lesions | #1252 |
| artery pulmonary | #1254 |
| extensive | #1257 |
| oral vitamin | #1257 |
| search strategy | #1257 |
| prospective cohort | #1258 |
| symptomatic patients | #1259 |
| major surgery | #1262 |
| entity | #1266 |
| visiting | #1266 |
| troponins | #1266 |
| macroglobulins | #1267 |
| 172 | #1270 |
| amputations | #1273 |
| equally | #1274 |
| intensive patients | #1274 |
| design study | #1276 |
| antiplatelet agents | #1278 |
| proportionally | #1279 |
| statin users | #1281 |
| 75 years | #1281 |
| routine screening | #1281 |
| factors ultrasonography | #1285 |
| thyroxine | #1287 |
| 050 | #1288 |
| blockers | #1290 |
| dermatan sulfate | #1292 |
| janssen | #1295 |
| scan | #1295 |
| perfusion defects | #1295 |
| hemofiltration | #1297 |
| predictive | #1297 |
| insufficiently | #1298 |
| low prevalence | #1299 |
| cardiovascular complications | #1299 |
| dutch | #1300 |
| prolong | #1302 |
| 61 | #1303 |
| pf4 | #1303 |
| pulmonary circulation | #1304 |
| scores | #1305 |
| 95 mortality | #1307 |
| apoa | #1312 |
| 1st | #1312 |
| cyproterone | #1312 |
| risk difference | #1312 |
| adamts13 activity | #1313 |
| current strategies | #1314 |
| 0·7 | #1314 |
| tests severity | #1314 |
| atrial fibrillation | #1316 |
| claudication | #1316 |
| carotid imt | #1317 |
| international guidelines | #1318 |
| replacement hip | #1320 |
| study time | #1321 |
| coagulation factor | #1322 |
| vienna | #1323 |
| increases risk | #1324 |
| lipoproteina | #1325 |
| glycoprotein gpiib | #1325 |
| patients coronavirus disease | #1326 |
| vascular diseases | #1329 |
| antibodies monoclonal antibodies | #1329 |
| beneficial | #1329 |
| low moderate | #1330 |
| thyroid disorders | #1330 |
| plasminogen activators | #1330 |
| coagulation cascade | #1331 |
| 6 months patients | #1331 |
| 77 | #1331 |
| 126 | #1332 |
| frequent complication | #1333 |
| adjusted age | #1335 |
| transurethral resection | #1336 |
| 91 | #1342 |
| venous catheters | #1342 |
| likelihood ratio | #1342 |
| blood sample | #1343 |
| daily patients | #1344 |
| antitrypsin | #1347 |
| surgical trauma | #1347 |
| patients relatives | #1351 |
| neurosurgery | #1355 |
| arthroplasty patients | #1356 |
| patients stable angina | #1357 |
| experimental model | #1359 |
| allcause mortality 95 | #1359 |
| 15 patients | #1359 |
| vwf | #1363 |
| limb salvage | #1363 |
| arsenal | #1363 |
| vtes | #1365 |
| 95 patients | #1366 |
| operatively | #1367 |
| 12 month | #1369 |
| heart valves | #1370 |
| starting | #1372 |
| ethinyl | #1373 |
| acetylsalicylic | #1375 |
| costeffectiveness analysis | #1376 |
| utmost | #1378 |
| consented | #1382 |
| management patients | #1383 |
| gps | #1384 |
| noninferiority | #1385 |
| dl1 | #1385 |
| 224 | #1385 |
| disorders blood | #1386 |
| ivt | #1389 |
| patients cvd | #1392 |
| substitute | #1394 |
| screening tests | #1399 |
| record linkage | #1400 |
| patients control subjects | #1400 |
| equipoise | #1402 |
| 82 | #1402 |
| antisense oligonucleotide | #1402 |
| mandatory | #1403 |
| clinical challenges | #1404 |
| 1886 | #1405 |
| patients advanced cancer | #1405 |
| pregnancy loss | #1406 |
| obese patients | #1406 |
| categories | #1408 |
| 515 | #1408 |
| 994 | #1409 |
| reflected | #1410 |
| inception | #1411 |
| tranexamic | #1413 |
| adamts13 | #1417 |
| 0·1 | #1418 |
| 7 weeks | #1419 |
| thrombotic complications | #1419 |
| 3 6 | #1419 |
| 6 weeks | #1419 |
| total knee | #1420 |
| 95 0 | #1421 |
| university hospitals | #1422 |
| followup data | #1422 |
| ≥55 | #1424 |
| daily | #1424 |
| 061 | #1424 |
| eightfold | #1425 |
| randomised controlled trials | #1427 |
| 080 | #1427 |
| casecontrol study | #1430 |
| rgs | #1430 |
| outcome pregnancy | #1438 |
| 096 | #1439 |
| imaging radiopharmaceuticals | #1439 |
| 78 | #1443 |
| principal | #1443 |
| 1123 | #1445 |
| drug levels | #1446 |
| weight bmi | #1446 |
| outcome studies | #1446 |
| underreporting | #1451 |
| support systems | #1452 |
| confusion | #1454 |
| population patients | #1454 |
| platelet factor | #1455 |
| aged blood | #1455 |
| dip | #1456 |
| mbe | #1457 |
| conclusions patients | #1459 |
| prospectively | #1460 |
| multicenter studies | #1461 |
| humans | #1463 |
| inaccuracy | #1464 |
| actual | #1466 |
| funded | #1466 |
| avoided | #1468 |
| 0·9 | #1468 |
| 26 patients | #1469 |
| heart failure hf | #1469 |
| groin | #1471 |
| risk factors mortality | #1472 |
| 1215 | #1473 |
| prevalences | #1473 |
| centrally | #1474 |
| systemic infection | #1477 |
| probability | #1477 |
| lowest tertile | #1478 |
| remained | #1480 |
| atherothrombotic | #1481 |
| undetermined | #1482 |
| dysfunction patients | #1483 |
| analysis randomized | #1485 |
| cushing syndrome | #1485 |
| phase iii trials | #1486 |
| methodologic | #1486 |
| general practice | #1491 |
| procoagulant activity | #1495 |
| patients control | #1495 |
| randomly | #1496 |
| 64 | #1498 |
| aged natriuretic | #1499 |
| exposing | #1501 |
| imt | #1507 |
| fracture surgery | #1510 |
| specificity 100 | #1512 |
| odds ratio 95 | #1513 |
| growing body | #1514 |
| adverse outcome | #1514 |
| proximal | #1516 |
| pregnancy postpartum | #1520 |
| ganz | #1520 |
| patients 10 | #1520 |
| subgroup | #1521 |
| factor deficiency | #1522 |
| gsk | #1524 |
| chills | #1526 |
| contraindicated | #1527 |
| thrombotic events | #1527 |
| time study | #1529 |
| score | #1529 |
| oral contraceptive | #1534 |
| mechanical compression | #1536 |
| immobilisation | #1539 |
| comparator | #1540 |
| patients life | #1541 |
| humans neoplasm | #1542 |
| hemostatics humans | #1545 |
| 089 | #1548 |
| tsh levels | #1551 |
| live births | #1552 |
| patients severe sepsis | #1552 |
| 23 | #1554 |
| vascular thrombosis | #1555 |
| fees | #1556 |
| neonatal period | #1558 |
| patients year | #1559 |
| discriminatory | #1562 |
| hypothyroidism | #1563 |
| pfa | #1564 |
| enfermedad | #1564 |
| iii topic | #1565 |
| topic | #1566 |
| treatment prevention | #1566 |
| deficient | #1568 |
| 95ci | #1568 |
| hyperlipoproteinemia type | #1568 |
| cushings syndrome | #1568 |
| aged biomarkers | #1571 |
| 36 | #1575 |
| plasminogen activator | #1575 |
| humans platelet | #1576 |
| 012 | #1577 |
| hyperlipoproteinemia | #1580 |
| risk myocardial infarction | #1584 |
| activation markers | #1586 |
| cocs | #1586 |
| study entry | #1586 |
| thyroid dysfunction | #1586 |
| studies association | #1587 |
| adjusted hazard ratio | #1589 |
| volunteers | #1591 |
| 1·1 | #1594 |
| total mortality | #1594 |
| translates | #1597 |
| placebo | #1598 |
| noncancer | #1598 |
| exclude | #1599 |
| lmw | #1601 |
| figures | #1604 |
| paroxetine | #1606 |
| abdominal surgery | #1607 |
| complement pathway | #1609 |
| curability | #1610 |
| general surgery | #1613 |
| 162 | #1613 |
| ethinylestradiol | #1614 |
| recommending | #1615 |
| postpartum period | #1616 |
| prospective cohort studies | #1616 |
| factors tomography | #1616 |
| tests reproducibility | #1616 |
| positive effects | #1616 |
| 155 | #1618 |
| perinatal outcome | #1618 |
| female hemostasis | #1619 |
| imaging tomography | #1619 |
| cvd patients | #1619 |
| proportion | #1620 |
| uncertain | #1621 |
| 12month followup | #1621 |
| 079 | #1623 |
| competing risk | #1628 |
| isis | #1630 |
| major | #1631 |
| venous disease | #1632 |
| incidentally | #1632 |
| pa patients | #1632 |
| fresh frozen plasma | #1633 |
| clinical patients | #1633 |
| double | #1639 |
| study outcomes | #1639 |
| 029 | #1642 |
| 181 | #1643 |
| ctni | #1644 |
| stroke prevention | #1644 |
| patients hospitalized | #1647 |
| mismatched | #1648 |
| dorsiflexion | #1651 |
| 997 | #1651 |
| 35 years | #1652 |
| ≤4 | #1652 |
| studies data | #1653 |
| thrombin activity | #1653 |
| clotting | #1656 |
| remaining | #1660 |
| plasma concentration | #1661 |
| outcome data | #1663 |
| spiral | #1669 |
| homocysteine levels | #1670 |
| disease adult | #1670 |
| thrombi | #1674 |
| inpatient treatment | #1676 |
| daily dosing | #1676 |
| plasma level | #1677 |
| deficiency | #1677 |
| warfarin dose | #1680 |
| arthroscopy | #1684 |
| steroidal anti | #1686 |
| unreliable | #1686 |
| patients acs | #1687 |
| thrombin | #1690 |
| severe renal | #1694 |
| patients brain metastases | #1695 |
| prospective | #1702 |
| necrosis factor | #1705 |
| highest risk | #1707 |
| cancer screening | #1708 |
| awaiting | #1710 |
| yielded | #1712 |
| 033 | #1712 |
| intravenous | #1715 |
| hemorheology | #1715 |
| bronchospasm | #1720 |
| hematologic malignancies | #1720 |
| female femoral | #1721 |
| mb | #1721 |
| diagnostic evaluation | #1721 |
| cardioembolic | #1722 |
| cumulative incidence | #1723 |
| laser doppler | #1724 |
| 107 | #1726 |
| conference | #1726 |
| derived microparticles | #1729 |
| volunteer | #1730 |
| 021 | #1730 |
| 161 | #1733 |
| percentage patients | #1734 |
| clinical scores | #1735 |
| east asian | #1735 |
| patients icu | #1736 |
| rico | #1737 |
| 500 | #1738 |
| minor | #1739 |
| revised | #1744 |
| table | #1745 |
| 691 | #1745 |
| patients ventricular | #1745 |
| profession | #1746 |
| hyperinsulinaemia | #1747 |
| risk cardiovascular events | #1747 |
| apc | #1749 |
| turp | #1749 |
| homozygosity | #1750 |
| replacement | #1750 |
| pselectin | #1750 |
| 128 | #1752 |
| 133 | #1753 |
| intracranial hemorrhages | #1753 |
| 3 studies | #1755 |
| spontaneous | #1756 |
| arterial occlusive | #1758 |
| patients randomized | #1759 |
| audiometry | #1760 |
| treatment recommendations | #1760 |
| assessor | #1760 |
| current treatment | #1761 |
| primary setting | #1762 |
| long‐term | #1763 |
| human insulin | #1764 |
| fx | #1764 |
| duplicate | #1769 |
| hemorrhage | #1770 |
| arteriosclerosis | #1770 |
| initial management | #1770 |
| allcause death | #1774 |
| 2 6 | #1774 |
| 28 weeks | #1781 |
| hemostasis humans | #1782 |
| trough levels | #1785 |
| infusions | #1787 |
| ethinyl estradiol | #1789 |
| selfmanagement | #1790 |
| clinical consequences | #1790 |
| microparticle | #1793 |
| reid | #1793 |
| cardiac troponin | #1794 |
| vascular surgical | #1794 |
| healthy male volunteers | #1799 |
| 042 | #1800 |
| 020 | #1802 |
| aggregation inhibitors | #1802 |
| retrospective analysis | #1805 |
| hemophilia humans | #1808 |
| unpublished | #1810 |
| slc6a4 | #1812 |
| 95 specificity | #1812 |
| tumor necrosis | #1812 |
| overlapped | #1814 |
| 51 | #1815 |
| 078 | #1818 |
| economic evaluation | #1819 |
| conjoint | #1819 |
| interobserver | #1823 |
| awareness | #1824 |
| screening middle | #1825 |
| preference | #1825 |
| 303 | #1828 |
| placebo 95 | #1832 |
| undergoing coronary | #1834 |
| compressibility | #1837 |
| definite | #1837 |
| cushing | #1838 |
| kaplanmeier estimate | #1838 |
| severe sepsis | #1839 |
| 1 week | #1842 |
| central venous | #1842 |
| workup | #1848 |
| orthopaedic | #1849 |
| hydroxyethyl starch | #1852 |
| explanations | #1852 |
| 160 | #1854 |
| fibrinopeptide | #1862 |
| cancer therapies | #1865 |
| alpha 2 | #1867 |
| gramnegative | #1869 |
| serially | #1870 |
| humans pregnancy | #1874 |
| separately | #1876 |
| oral anticoagulation | #1880 |
| thromboses | #1892 |
| diagnostic techniques | #1892 |
| shrs | #1892 |
| lower incidence | #1893 |
| stable patients | #1895 |
| 067 | #1897 |
| 5 10 | #1897 |
| contraindications | #1900 |
| diagnostic testing | #1901 |
| extremity | #1901 |
| tnf | #1901 |
| clt | #1905 |
| plaster | #1906 |
| induced thrombocytopenia | #1906 |
| hazard ratio | #1906 |
| differential effects | #1907 |
| 95 year | #1909 |
| referral | #1910 |
| efficacy treatment | #1910 |
| random | #1911 |
| plato | #1913 |
| experimental mice mice | #1916 |
| 238 | #1918 |
| randomized | #1919 |
| 13 patients | #1920 |
| 793 | #1920 |
| administration | #1921 |
| pregnancy treatment | #1922 |
| 868 | #1923 |
| stroke 95 | #1923 |
| biotin | #1924 |
| 55 years | #1924 |
| trials patients | #1926 |
| venous pressure | #1926 |
| μg | #1927 |
| intracranial hemorrhage | #1927 |
| coronary syndromes | #1928 |
| 272 | #1929 |
| cardiovascular events patients | #1930 |
| chimpanzee | #1931 |
| adjusted | #1932 |
| glucocorticoid | #1934 |
| nonfatal | #1934 |
| 3months | #1935 |
| relative risks | #1935 |
| 17 | #1936 |
| acute | #1936 |
| thrombolytic treatment | #1937 |
| 27 | #1938 |
| randomized placebo | #1947 |
| femoral vein | #1950 |
| safety effectiveness | #1950 |
| 0·5 | #1952 |
| medical illness | #1954 |
| overtreatment | #1955 |
| prolongation | #1958 |
| intravascular | #1959 |
| major risk | #1960 |
| advanced age | #1961 |
| investigators | #1962 |
| observer | #1962 |
| 1050 | #1965 |
| permanent | #1966 |
| 80 female | #1967 |
| hyperglycaemia | #1970 |
| coronary angioplasty | #1971 |
| 48 hours | #1973 |
| surgical blood | #1973 |
| fibrin clot | #1973 |
| renewed | #1976 |
| potent inhibitor | #1976 |
| topic clinical trials | #1978 |
| specificity ultrasonography | #1981 |
| hyperaldosteronism | #1981 |
| 771 | #1981 |
| computerised | #1982 |
| patients pancreatic | #1985 |
| 1·0 | #1986 |
| treatment cancer | #1986 |
| randomized controlled | #1988 |
| coumarins | #1990 |
| 177 | #1991 |
| prospero | #1992 |
| 018 | #1992 |
| cmax | #1994 |
| drug drug therapy | #1994 |
| computerized | #1995 |
| cvt | #1995 |
| hemorrhage patients | #1996 |
| ors | #1998 |
| 602 | #1999 |
| autopsy | #2000 |
| 3 months patients | #2000 |
| clinical severity | #2000 |
| transient increase | #2000 |
| 53 | #2003 |
| 7 patients | #2006 |
| pneumonia patients | #2006 |
| pih | #2011 |
| mantel | #2013 |
| catheterization central | #2014 |
| angina unstable | #2017 |
| mongrel | #2017 |
| poc | #2019 |
| 225 | #2020 |
| type plasminogen | #2023 |
| pathophysiologic | #2024 |
| 35 | #2025 |
| patients statins | #2026 |
| annual | #2028 |
| 15th | #2031 |
| atheroma | #2032 |
| patients lung | #2033 |
| 097 | #2033 |
| pertechnetate | #2036 |
| medical record | #2041 |
| costs cost | #2041 |
| undergoing major | #2042 |
| abstracts | #2042 |
| questioned | #2043 |
| thrice | #2045 |
| prediction rule | #2045 |
| dichotomous | #2046 |
| normal | #2048 |
| superior vena cava | #2051 |
| quartiles | #2051 |
| inadequately | #2052 |
| pregnancy trimester | #2053 |
| 277 | #2053 |
| controversial | #2055 |
| adherence guidelines | #2056 |
| stent implantation | #2056 |
| hospitalized | #2057 |
| randomized comparison | #2060 |
| outpatient | #2061 |
| interobserver variability | #2062 |
| requested | #2063 |
| varies | #2063 |
| biological neoplasms | #2064 |
| clinical indications | #2064 |
| hemostatics | #2070 |
| national institute | #2074 |
| mcnemar | #2074 |
| 188 | #2074 |
| familial hypercholesterolemia | #2077 |
| unavailable | #2079 |
| searched | #2082 |
| disseminate | #2083 |
| ristocetin | #2086 |
| bypasses | #2087 |
| media thickness | #2087 |
| 03 | #2089 |
| versions | #2091 |
| 114 | #2092 |
| square distribution | #2092 |
| tissue plasminogen | #2093 |
| preformed | #2099 |
| reference range | #2099 |
| 038 | #2100 |
| 59 | #2101 |
| lifetime risk | #2101 |
| desmopressin | #2101 |
| placebos | #2102 |
| concealment | #2104 |
| hospital treatment | #2106 |
| fibrin deposition | #2107 |
| argatroban | #2108 |
| substantial | #2109 |
| 031 | #2109 |
| 1966 | #2109 |
| aged 80 | #2111 |
| debated | #2116 |
| jugular vein | #2117 |
| unnecessary | #2118 |
| independently | #2118 |
| initial | #2119 |
| exists | #2119 |
| development validation | #2120 |
| clinicaltrialsgov | #2122 |
| coronary stent | #2122 |
| 11 | #2122 |
| original | #2125 |
| acl reconstruction | #2125 |
| patients cardiovascular disease | #2127 |
| topic surveys | #2127 |
| chose | #2129 |
| controlled | #2129 |
| current recommendations | #2131 |
| odds ratios | #2132 |
| congress | #2134 |
| protamines | #2134 |
| 190 | #2136 |
| 788 | #2137 |
| hip arthroplasty | #2139 |
| heterozygous | #2141 |
| antagonists | #2142 |
| live | #2145 |
| clot | #2145 |
| bodyweight | #2146 |
| professionals | #2146 |
| pancreatic cancer patients | #2157 |
| committee | #2160 |
| oestrogens | #2160 |
| lowdose aspirin | #2163 |
| academic medical | #2167 |
| drains | #2170 |
| embase | #2171 |
| fibrinogen | #2175 |
| 1998 | #2178 |
| trimesters | #2179 |
| reproductive age | #2182 |
| advanced cancer | #2183 |
| 674 | #2183 |
| giant cell arteritis | #2185 |
| 2 × | #2185 |
| fifty | #2185 |
| patients diagnosed | #2187 |
| 631 | #2188 |
| controlled study | #2192 |
| superficial | #2194 |
| difference incidence | #2198 |
| adjust | #2202 |
| diagnostic performance | #2204 |
| increased patients | #2205 |
| pravastatin | #2205 |
| antagonist | #2206 |
| clinical implications | #2208 |
| lower limbs | #2209 |
| diagnosis differential | #2212 |
| neutrophil elastase | #2212 |
| doubled | #2213 |
| pao2 | #2219 |
| 364 | #2219 |
| insufficient | #2221 |
| comparing | #2222 |
| differential female | #2225 |
| 94 | #2225 |
| lung perfusion | #2226 |
| italian society | #2227 |
| 76 | #2233 |
| takeda | #2236 |
| nationwide cohort study | #2245 |
| clot formation | #2247 |
| congenital heart disease | #2252 |
| hemorrhages | #2253 |
| hivinfected patients | #2257 |
| clots | #2257 |
| kilogram | #2259 |
| aprotinin | #2261 |
| 8000 | #2264 |
| stroke aged | #2265 |
| hyperthyroidism | #2265 |
| 12 | #2266 |
| 6 months | #2267 |
| metaanalysis | #2267 |
| patients developed | #2273 |
| reverses | #2273 |
| arterial | #2274 |
| intrinsic pathway | #2275 |
| famine | #2278 |
| 656 | #2279 |
| ultrasonographic | #2281 |
| based case | #2284 |
| setting | #2284 |
| 14 patients | #2286 |
| ft3 | #2288 |
| case control | #2291 |
| patients heart failure | #2293 |
| aged molecular | #2295 |
| daily dose | #2296 |
| sole | #2298 |
| strategy | #2303 |
| 88 | #2308 |
| 0047 | #2310 |
| normalised | #2312 |
| metaanalysis studies | #2314 |
| tests | #2314 |
| nephelometry | #2316 |
| initial therapy | #2316 |
| obstetrics | #2317 |
| adjustments | #2319 |
| method female | #2324 |
| humans myocardial | #2324 |
| methodological | #2325 |
| 60 | #2327 |
| normalized | #2329 |
| brachial | #2332 |
| gradually | #2335 |
| random sample | #2336 |
| positive predictive | #2337 |
| transfusion requirements | #2340 |
| ultrasonography doppler | #2341 |
| 543 | #2343 |
| inhibitor | #2344 |
| lacked | #2344 |
| prescribe | #2347 |
| illness severity | #2350 |
| 20 weeks | #2351 |
| thr | #2353 |
| prefer | #2354 |
| cancer progression | #2364 |
| 053 | #2371 |
| 118 | #2372 |
| receiving | #2374 |
| risk bias | #2375 |
| 099 | #2375 |
| patients active | #2376 |
| predictable | #2377 |
| hemostasis | #2377 |
| acute coronary syndromes | #2379 |
| enrolling | #2379 |
| 187 | #2381 |
| anticardiolipin | #2382 |
| dosing regimen | #2382 |
| 145 | #2387 |
| scintigraphy | #2389 |
| 140 | #2391 |
| 244 | #2393 |
| complication rate | #2400 |
| 757 | #2401 |
| patients liver cirrhosis | #2401 |
| 086 | #2402 |
| letters | #2405 |
| curable | #2406 |
| postinjection | #2413 |
| periodicals | #2413 |
| protein | #2413 |
| risk estimates | #2414 |
| sphingosine1 | #2415 |
| 22 | #2415 |
| internal medicine | #2424 |
| study drug | #2424 |
| 32 | #2425 |
| guidelines | #2426 |
| sensitivity 100 | #2426 |
| 0048 | #2430 |
| legs | #2430 |
| coagulants | #2430 |
| 002 | #2430 |
| patients adult | #2431 |
| ci95 | #2432 |
| normal range | #2433 |
| ptca | #2434 |
| prolonging | #2434 |
| aminoglycoside | #2435 |
| cindex | #2437 |
| 030 | #2438 |
| cumulative | #2439 |
| 166 | #2441 |
| endogenous | #2445 |
| microplate | #2446 |
| 719 | #2448 |
| turbidimetry | #2448 |
| administration schedule | #2449 |
| transmigration | #2453 |
| homocysteine | #2454 |
| anticoagulant activity | #2455 |
| ≥75 | #2459 |
| extensively | #2463 |
| prognostic patients | #2464 |
| watchful | #2464 |
| potential benefits | #2466 |
| therapy acute | #2468 |
| nephrotoxic | #2468 |
| 477 | #2469 |
| comprised | #2469 |
| pharmacologic | #2473 |
| consisted | #2474 |
| cancer population | #2476 |
| current review | #2476 |
| 05 | #2481 |
| 50 | #2482 |
| 648 | #2485 |
| pathway inhibitor | #2485 |
| treatment efficacy | #2489 |
| 1015 | #2490 |
| 829 | #2490 |
| duration | #2493 |
| chest | #2493 |
| 25 | #2495 |
| illness tomography | #2503 |
| 616 | #2503 |
| bnp | #2504 |
| subsequent pregnancies | #2505 |
| 522 | #2507 |
| movie | #2508 |
| recurrence retrospective | #2509 |
| unstable angina | #2510 |
| presentation | #2512 |
| superinfection | #2513 |
| comprising | #2515 |
| 479 | #2516 |
| drug female humans | #2516 |
| sulfates | #2519 |
| 750 | #2520 |
| neutrophil extracellular traps | #2521 |
| 463 | #2521 |
| 152 | #2523 |
| accurate diagnosis | #2523 |
| treatment arms | #2524 |
| scientific | #2529 |
| establish | #2534 |
| 0046 | #2537 |
| 164 | #2537 |
| 874 | #2537 |
| nematode | #2540 |
| 67 | #2542 |
| pyrazoles | #2547 |
| arrive | #2549 |
| decided | #2552 |
| effectiveness analysis | #2553 |
| hydroxyethyl | #2560 |
| haematology | #2560 |
| hours | #2560 |
| 928 | #2565 |
| radiologist | #2566 |
| roc | #2568 |
| biologic | #2569 |
| clinical settings | #2570 |
| infrequent | #2572 |
| 73 | #2574 |
| kits | #2574 |
| humans logistic | #2574 |
| pill | #2575 |
| prevalence | #2575 |
| translate | #2577 |
| patients total | #2577 |
| 973 | #2578 |
| specificity | #2580 |
| cancer chemotherapy | #2581 |
| 374 | #2582 |
| efficacious | #2585 |
| 591 | #2585 |
| pivotal | #2588 |
| analysed | #2589 |
| bolus | #2595 |
| 657 | #2596 |
| multiple organ failure | #2599 |
| hypercholesterolaemia | #2600 |
| doppler duplex | #2602 |
| laboratory investigation | #2603 |
| manifest | #2605 |
| burden disease | #2605 |
| metaregression | #2606 |
| parenteral | #2606 |
| fatal outcome | #2608 |
| patients 2 | #2608 |
| 098 | #2610 |
| p0001 patients | #2613 |
| died | #2615 |
| 886 | #2618 |
| percent | #2619 |
| cost analysis | #2620 |
| aviation | #2620 |
| concentrate | #2621 |
| occlusive | #2622 |
| presenting | #2625 |
| assess | #2626 |
| prescribed | #2631 |
| agents steroidal | #2633 |
| trials rcts | #2635 |
| coincided | #2635 |
| chondroitin | #2635 |
| 10 day | #2637 |
| 345 | #2641 |
| attractive | #2641 |
| mutation patients | #2642 |
| greatest risk | #2643 |
| 23 patients | #2645 |
| decision | #2649 |
| risk cardiovascular disease | #2656 |
| 134 | #2659 |
| recurrence | #2660 |
| hamilton | #2661 |
| c677 | #2662 |
| benzimidazoles | #2662 |
| 679 | #2663 |
| shr | #2667 |
| quartile | #2674 |
| receive | #2675 |
| 439 | #2677 |
| valsalva | #2680 |
| trials | #2682 |
| 516 | #2683 |
| outcome ultrasonography | #2683 |
| initial dose | #2685 |
| iii | #2685 |
| inconclusive | #2686 |
| tmax | #2687 |
| mortality 95 | #2688 |
| tissue plasminogen activator | #2690 |
| 594 | #2691 |
| aso | #2691 |
| bleed | #2692 |
| schedule female | #2694 |
| stillbirth | #2698 |
| patients risk factors | #2702 |
| early discharge | #2703 |
| 14 | #2706 |
| previous stroke | #2720 |
| prematurely | #2725 |
| 897 | #2727 |
| txb2 | #2729 |
| dose low | #2732 |
| management strategies | #2732 |
| cart | #2736 |
| 595 | #2737 |
| classifications | #2739 |
| 427 | #2739 |
| therapeutic options | #2744 |
| risk ratio | #2745 |
| 848 | #2746 |
| predetermined | #2746 |
| patients asthma | #2747 |
| baseline characteristics | #2747 |
| direct comparison | #2752 |
| pan | #2755 |
| nephrotoxicity | #2758 |
| randomised trial | #2764 |
| contusions | #2765 |
| management acute | #2768 |
| 143 | #2768 |
| confounded | #2769 |
| antithyroid | #2772 |
| expert consensus | #2772 |
| alpha animals | #2772 |
| active control | #2775 |
| inpatient | #2776 |
| thrombomodulin | #2776 |
| 563 | #2777 |
| compression | #2778 |
| dosages | #2779 |
| leukocyte count | #2781 |
| mass screening | #2782 |
| 466 | #2783 |
| hemostatic | #2784 |
| primary outcomes | #2785 |
| percentiles | #2788 |
| 90th | #2789 |
| nadph2 | #2791 |
| consecutive series | #2802 |
| 402 | #2802 |
| cirrhosis patients | #2805 |
| reaching | #2805 |
| international | #2809 |
| secondary | #2811 |
| standardized | #2811 |
| embolic | #2812 |
| 406 | #2813 |
| follow studies | #2813 |
| prevalence risk factors | #2814 |
| httlpr | #2816 |
| discriminant analysis | #2817 |
| selectins | #2819 |
| consisting | #2823 |
| equivalency | #2825 |
| bid | #2826 |
| antiplatelet drugs | #2826 |
| genetic variations | #2830 |
| 557 | #2833 |
| male mass | #2834 |
| contacting | #2835 |
| recurrence rate | #2835 |
| helminth | #2836 |
| ketoprostaglandin | #2836 |
| crossover | #2839 |
| kruskal | #2839 |
| 554 | #2843 |
| partum | #2847 |
| anterior cruciate ligament | #2850 |
| carboxypeptidase | #2851 |
| iii trials | #2852 |
| doppler ultrasonography | #2852 |
| ≤2 | #2853 |
| postoperative patients | #2854 |
| new treatment | #2857 |
| post discharge | #2857 |
| specialised | #2858 |
| methods prospective | #2862 |
| 497 | #2870 |
| discontinuation | #2871 |
| 264 | #2876 |
| 628 | #2877 |
| 52 | #2879 |
| trimester pregnancy | #2880 |
| excessive | #2880 |
| hit | #2884 |
| mdct | #2885 |
| balloon angioplasty | #2886 |
| anterior cruciate | #2887 |
| 670 | #2895 |
| eligibility | #2896 |
| systematic review metaanalysis | #2897 |
| 21 | #2897 |
| central venous catheters | #2900 |
| statin | #2902 |
| slight | #2903 |
| severe asthma | #2903 |
| feasible | #2903 |
| 12 patients | #2908 |
| concomitantly | #2910 |
| supposed | #2911 |
| insulin receptors | #2914 |
| lowrisk patients | #2917 |
| leading death | #2917 |
| 39 | #2919 |
| routine clinical practice | #2920 |
| referrals | #2921 |
| older children | #2922 |
| 993 | #2928 |
| proportions | #2928 |
| clear | #2932 |
| risk stratification patients | #2934 |
| 2400 | #2934 |
| aggregation platelet | #2941 |
| control subjects patients | #2945 |
| meier estimate | #2946 |
| addison | #2952 |
| portal | #2954 |
| 100 | #2956 |
| returned | #2957 |
| 270 | #2960 |
| 010 | #2960 |
| 20 | #2961 |
| followup | #2962 |
| exercise therapy | #2962 |
| transabdominal | #2963 |
| 132 | #2974 |
| echocardiography patients | #2975 |
| 123 | #2978 |
| risk myocardial | #2981 |
| lecture | #2984 |
| declare | #2984 |
| eclampsia pregnancy | #2986 |
| glucose levels | #2987 |
| preoperatively | #2988 |
| adult blood | #2990 |
| pneumatic | #2991 |
| point | #2991 |
| n4 | #2992 |
| undefined | #2993 |
| treatable | #2996 |
| cvr | #2997 |
| microvessels | #2998 |
| 499 | #3004 |
| prostacyclin | #3012 |
| dipyridamole | #3013 |
| factors surveys | #3015 |
| antigen levels | #3015 |
| 2 patients | #3016 |
| 081 | #3019 |
| double‐blind | #3022 |
| 35 patients | #3023 |
| nested case | #3025 |
| early recognition | #3025 |
| comorbidity | #3026 |
| contraindication | #3028 |
| intention | #3035 |
| extremities | #3038 |
| 50 years | #3040 |
| 419 | #3040 |
| patients hf | #3041 |
| lymphopenia | #3043 |
| relevant articles | #3044 |
| 095 | #3045 |
| prenatal exposure | #3047 |
| summarize | #3050 |
| respondents | #3052 |
| respects | #3060 |
| subcutaneous injection | #3062 |
| nomogram | #3063 |
| 80 | #3063 |
| fourteen | #3065 |
| 95 p0001 | #3066 |
| patients data | #3067 |
| study prevalence | #3071 |
| subsequently | #3076 |
| 2 4 | #3076 |
| disease aged | #3077 |
| 524 | #3082 |
| 342 | #3083 |
| chronic renal failure | #3088 |
| angioplasty | #3088 |
| independent risk factors | #3089 |
| healthy | #3090 |
| clinical risk factors | #3098 |
| lancet | #3102 |
| reviewer | #3104 |
| practice guidelines | #3109 |
| trimester | #3110 |
| benchmark | #3110 |
| npv | #3115 |
| pregnant woman | #3119 |
| neutrophil activation | #3120 |
| wallis | #3122 |
| oac | #3122 |
| lifelong | #3122 |
| inadequacy | #3123 |
| intravenously | #3129 |
| claimed | #3132 |
| 136 | #3134 |
| 12 months | #3134 |
| meta‐analysis | #3137 |
| levels risk | #3142 |
| 082 | #3142 |
| placentae | #3143 |
| randomized clinical trial | #3145 |
| time interval | #3147 |
| arthroscopic | #3149 |
| idiopathic | #3153 |
| 507 | #3153 |
| marathon | #3155 |
| mega | #3156 |
| avoiding | #3158 |
| radiologists | #3165 |
| initial presentation | #3172 |
| seventh | #3173 |
| cornerstone | #3182 |
| test | #3184 |
| 494 | #3188 |
| revascularisation | #3191 |
| 409 | #3193 |
| pregnancy women | #3194 |
| diethylstilbestrol | #3194 |
| pacientes | #3197 |
| 945 | #3198 |
| plasmin | #3198 |
| therapy risk | #3199 |
| tenth | #3199 |
| gold standard | #3200 |
| vivo model | #3205 |
| res | #3207 |
| patient preference | #3211 |
| catheter | #3212 |
| cancer types | #3219 |
| suggested | #3219 |
| intravenous infusion | #3223 |
| 153 | #3223 |
| 72 hours | #3225 |
| 605 | #3227 |
| methodological quality | #3238 |
| observers | #3239 |
| meetings | #3241 |
| recombinant | #3241 |
| intravenous administration | #3242 |
| risk stroke | #3246 |
| alternative | #3249 |
| bivalirudin | #3251 |
| 198 | #3251 |
| 29 | #3253 |
| hypothyroid | #3253 |
| judgement | #3255 |
| scoring | #3255 |
| normotensive | #3256 |
| 054 | #3257 |
| patient preferences | #3261 |
| glargine | #3265 |
| validated | #3266 |
| patients evidence | #3267 |
| 116 | #3268 |
| immunoassay | #3271 |
| 414 | #3275 |
| 6 | #3277 |
| tranexamic acid | #3279 |
| gbd | #3280 |
| contraceptive | #3281 |
| inclusion | #3284 |
| arthroplasty replacement | #3288 |
| tumor markers | #3289 |
| coumarin | #3289 |
| replace | #3290 |
| 65 years | #3291 |
| swan | #3292 |
| recurrence rates | #3294 |
| efficacy outcomes | #3299 |
| 812 | #3314 |
| rtpa | #3315 |
| reversibility | #3316 |
| anticardiolipin antibodies | #3319 |
| discriminant | #3321 |
| vascular risk | #3322 |
| 104 | #3325 |
| hemophilia | #3328 |
| 972 | #3329 |
| 465 | #3330 |
| reduces | #3330 |
| cruciate ligament | #3331 |
| patients symptoms | #3334 |
| 74 | #3337 |
| meta | #3338 |
| acute coronary syndrome | #3339 |
| cerebrovascular disease | #3344 |
| inpatients | #3344 |
| 362 | #3349 |
| evaluating | #3349 |
| diagnosing | #3354 |
| spontaneous abortion | #3354 |
| 273 | #3355 |
| diagnosis cancer | #3356 |
| common complication | #3356 |
| 15 | #3357 |
| lysate | #3358 |
| 581 | #3359 |
| 092 | #3361 |
| miscarriages | #3365 |
| prevalent | #3371 |
| thrombolysis | #3376 |
| treatment modalities | #3377 |
| 363 | #3378 |
| 301 | #3379 |
| concluded | #3379 |
| humans lower | #3379 |
| intima media | #3380 |
| computed tomography | #3382 |
| hematomas | #3387 |
| function patients | #3389 |
| calf | #3389 |
| contraception | #3390 |
| repeated | #3394 |
| 413 | #3395 |
| p0002 | #3397 |
| cava | #3399 |
| 311 | #3400 |
| acute treatment | #3403 |
| tunica | #3403 |
| 553 | #3403 |
| humans kaplan | #3408 |
| saved | #3415 |
| differs | #3418 |
| randomisation | #3419 |
| preventive | #3419 |
| hypothesised | #3420 |
| study risk | #3420 |
| surgical patients | #3420 |
| thrombocythemia | #3422 |
| odds | #3424 |
| confirm | #3425 |
| testimony | #3430 |
| competing | #3434 |
| natriuretic | #3437 |
| 70 | #3439 |
| ease | #3443 |
| asian patients | #3444 |
| 124 | #3445 |
| 519 | #3447 |
| 487 | #3451 |
| prevalence incidence | #3452 |
| 168 | #3452 |
| evening | #3458 |
| covid19 infection | #3464 |
| differ | #3470 |
| 34 | #3470 |
| intensive chemotherapy | #3471 |
| patients receive | #3472 |
| pregnancy complications | #3472 |
| worsened | #3476 |
| induced platelet | #3479 |
| undiagnosed | #3482 |
| antiphospholipid | #3485 |
| cancer metastasis | #3485 |
| increased morbidity | #3486 |
| asymptomatic | #3487 |
| lower leg | #3487 |
| personyears | #3490 |
| paradox | #3490 |
| pacemaker | #3493 |
| statistical methods | #3494 |
| convergent validity | #3496 |
| failure hf | #3497 |
| 201 | #3504 |
| hemorrhagic complications | #3506 |
| treat | #3506 |
| inhibitors | #3506 |
| 938 | #3513 |
| tomography angiography | #3521 |
| discusses | #3522 |
| confirmed | #3522 |
| 291 | #3527 |
| quintiles | #3529 |
| 95 confidence intervals | #3530 |
| lupus | #3533 |
| human cytomegalovirus | #3533 |
| areas covered | #3537 |
| societies | #3541 |
| guidance | #3541 |
| 113 | #3544 |
| current practice | #3551 |
| gastro | #3551 |
| 10 | #3552 |
| stroke risk | #3559 |
| baboons | #3560 |
| 344 | #3562 |
| benefits risks | #3564 |
| neutralize | #3565 |
| nsaids | #3566 |
| bibliographic | #3567 |
| depends | #3571 |
| patients recurrence | #3573 |
| inconsistent | #3575 |
| safety profiles | #3580 |
| 508 | #3584 |
| evaluates | #3592 |
| prognosis prospective | #3596 |
| necessity | #3596 |
| patient management | #3598 |
| prognostic significance | #3604 |
| vitamin | #3605 |
| risk stratification | #3606 |
| consensus document | #3617 |
| platelet function | #3619 |
| treated | #3619 |
| interval | #3622 |
| platelet activation | #3622 |
| mutation | #3624 |
| lipid profiles | #3626 |
| kappa | #3629 |
| q3 | #3629 |
| organ damage | #3635 |
| analysis performed | #3640 |
| 75 | #3641 |
| undergo | #3642 |
| homozygote | #3642 |
| bypass surgery | #3642 |
| externally | #3645 |
| p006 | #3645 |
| occlusions | #3646 |
| 30 | #3649 |
| 1960 | #3649 |
| interindividual variability | #3651 |
| fibrillation | #3651 |
| coronary events | #3656 |
| atherogenic | #3658 |
| newer | #3662 |
| patients 95 | #3667 |
| optimal management | #3671 |
| outcome administration | #3671 |
| endovascular treatment | #3678 |
| blinding | #3679 |
| treatment complications | #3680 |
| limited data | #3683 |
| 68 | #3684 |
| clopidogrel | #3685 |
| mammography | #3693 |
| myalgia | #3703 |
| 478 | #3706 |
| rationale | #3707 |
| 813 | #3708 |
| rebound | #3720 |
| diagnostic process | #3721 |
| drug monitoring | #3721 |
| pharmacodynamics | #3725 |
| inhibitors humans | #3725 |
| 130 | #3729 |
| unknown | #3731 |
| patient population | #3733 |
| serine proteases | #3736 |
| 349 | #3738 |
| effective | #3739 |
| humans intracranial | #3739 |
| factor 4 | #3741 |
| 585 | #3743 |
| 299 | #3744 |
| network meta | #3746 |
| homozygous | #3747 |
| 495 | #3750 |
| practitioner | #3752 |
| deterioration | #3754 |
| randomised | #3754 |
| objectives | #3759 |
| 8 patients | #3762 |
| subgroup analyses | #3762 |
| 00001 | #3765 |
| host defense | #3769 |
| statin therapy | #3772 |
| scarce | #3773 |
| clinicians patients | #3774 |
| computed ultrasonography | #3774 |
| inherited | #3775 |
| 517 | #3778 |
| interpretable | #3778 |
| 483 | #3782 |
| aminoglycosides | #3789 |
| thyroid hormones | #3789 |
| total knee arthroplasty | #3789 |
| 525 | #3791 |
| 412 | #3795 |
| 441 | #3797 |
| life illness | #3801 |
| 333 | #3802 |
| versus | #3803 |
| vessel wall | #3804 |
| compelling | #3804 |
| preexisting | #3808 |
| outcome measure | #3814 |
| patients lung cancer | #3815 |
| 330 | #3815 |
| valid | #3816 |
| iu | #3818 |
| 55 patients | #3821 |
| fv | #3823 |
| stasis | #3824 |
| lost | #3825 |
| compares | #3830 |
| itching | #3831 |
| proved | #3834 |
| osmolar | #3837 |
| elective | #3838 |
| hydrolases | #3839 |
| patient education | #3843 |
| 197 | #3849 |
| meeting | #3856 |
| irs | #3856 |
| anaesthesia | #3857 |
| 4 patients | #3858 |
| congresses | #3859 |
| review data | #3860 |
| acquired resistance | #3860 |
| male neoplasms | #3862 |
| preferred | #3864 |
| occurring | #3867 |
| death | #3880 |
| cancer survival | #3884 |
| optimisation | #3884 |
| record | #3885 |
| sensitivity | #3885 |
| avoids | #3887 |
| calculated | #3888 |
| difference | #3890 |
| 184 | #3890 |
| 351 | #3890 |
| 10000 | #3902 |
| halflives | #3903 |
| methylamines | #3903 |
| methimazole | #3904 |
| patients time | #3905 |
| incidence prevalence | #3908 |
| specificity tomography | #3915 |
| angiography | #3915 |
| coronary thrombosis | #3918 |
| decide | #3927 |
| 474 | #3931 |
| ankle | #3932 |
| 955 | #3935 |
| 458 | #3938 |
| jak2 | #3939 |
| extravasation | #3945 |
| 405 | #3946 |
| case fatality | #3946 |
| preeclampsia | #3952 |
| neurology | #3953 |
| 56 | #3956 |
| p004 | #3961 |
| dichotomy | #3961 |
| randomized clinical trials | #3963 |
| women | #3964 |
| carboxypeptidases | #3965 |
| postoperatively | #3966 |
| clinical effectiveness | #3968 |
| risk cancer | #3970 |
| uncontrolled | #3970 |
| austrian | #3971 |
| behalf | #3971 |
| cardiovascular events | #3972 |
| data studies | #3975 |
| 2nd | #3975 |
| quality assurance | #3980 |
| pregnancy | #3982 |
| 986 | #3982 |
| continuous infusion | #3983 |
| flying | #3986 |
| unstable | #3986 |
| month | #3987 |
| 488 | #3990 |
| systematic analysis | #3994 |
| sequentially | #4006 |
| calculate | #4010 |
| lower risk | #4011 |
| limited evidence | #4014 |
| patients evaluated | #4016 |
| scored | #4023 |
| secondary prevention | #4026 |
| 538 | #4028 |
| equivalence | #4029 |
| gln | #4031 |
| meyer | #4032 |
| cerebral venous | #4041 |
| 296 | #4045 |
| introduction | #4045 |
| 423 | #4047 |
| 262 | #4051 |
| ended | #4052 |
| validating | #4058 |
| received | #4062 |
| recurrent disease | #4066 |
| cruciate | #4073 |
| elevated | #4074 |
| compare | #4075 |
| bariatric | #4077 |
| pcc | #4077 |
| avoid | #4080 |
| 429 | #4081 |
| 326 | #4083 |
| hour | #4088 |
| oligosaccharides | #4089 |
| natriuretic peptide | #4089 |
| angioplasty balloon | #4091 |
| maneuver | #4092 |
| 3000 | #4093 |
| 16 | #4098 |
| activation | #4099 |
| indications | #4099 |
| cutoff | #4099 |
| contact | #4102 |
| pharmacological | #4106 |
| infusion rate | #4109 |
| 392 | #4113 |
| 335 | #4117 |
| 6 months treatment | #4119 |
| ptm | #4120 |
| completing | #4125 |
| patients low risk | #4133 |
| 008 | #4137 |
| withdrawn | #4137 |
| 41 | #4138 |
| bms | #4146 |
| patients died | #4149 |
| medical students | #4152 |
| haemorrhagic | #4154 |
| continue | #4158 |
| study control | #4161 |
| nulliparous | #4167 |
| 2030 | #4171 |
| patients prostate cancer | #4171 |
| antitumour | #4177 |
| steroidal | #4178 |
| multidisciplinary approach | #4189 |
| direct | #4192 |
| therapy combination | #4198 |
| casts | #4200 |
| 411 | #4212 |
| 485 | #4212 |
| medical center | #4214 |
| 408 | #4215 |
| weighted | #4221 |
| additional | #4222 |
| 452 | #4223 |
| 289 | #4226 |
| 121 | #4226 |
| trough | #4229 |
| p0005 | #4230 |
| crosssectional analysis | #4230 |
| hormonal | #4234 |
| veins | #4235 |
| cox regression | #4242 |
| patients mortality | #4242 |
| 178 | #4246 |
| nsaid | #4261 |
| 263 | #4263 |
| abbreviated | #4267 |
| encountered | #4268 |
| atrial fibrillation patients | #4274 |
| fab | #4279 |
| late pregnancy | #4285 |
| pai1 | #4286 |
| rise | #4287 |
| oral aged | #4294 |
| q4 | #4296 |
| 228 | #4303 |
| share | #4304 |
| 10 patients | #4306 |
| 105 | #4310 |
| rehospitalization | #4314 |
| patients increased risk | #4315 |
| 185 | #4316 |
| tat | #4319 |
| separate | #4322 |
| concentrates | #4328 |
| intima | #4329 |
| devised | #4331 |
| 294 | #4339 |
| 102 | #4340 |
| 455 | #4340 |
| pronounced | #4342 |
| incidental findings | #4345 |
| potential risk factors | #4350 |
| managed | #4350 |
| detrimental | #4356 |
| 253 | #4359 |
| agreed | #4360 |
| young age | #4363 |
| specialist | #4379 |
| rapid | #4383 |
| minutes | #4383 |
| retrospective studies | #4384 |
| 447 | #4385 |
| cd11b | #4387 |
| 288 | #4391 |
| 170 | #4392 |
| slice | #4394 |
| concurrently | #4394 |
| risk cardiovascular | #4396 |
| steadily | #4402 |
| 239 | #4406 |
| bowel diseases | #4407 |
| 71 | #4407 |
| general | #4407 |
| negative | #4407 |
| guideline recommendations | #4408 |
| postoperative day | #4409 |
| ventilation | #4413 |
| splanchnic | #4417 |
| lacking | #4417 |
| dose aspirin | #4419 |
| immunoassays | #4419 |
| recombinant proteins | #4423 |
| 3 patients | #4426 |
| author | #4427 |
| 148 | #4428 |
| 281 | #4429 |
| primary myelofibrosis | #4430 |
| appropriateness | #4433 |
| profoundly | #4436 |
| completed | #4438 |
| platelet | #4440 |
| cellulitis | #4441 |
| sixteen | #4442 |
| concomitant | #4445 |
| assays | #4453 |
| 334 | #4458 |
| vascular surgery | #4459 |
| 192 | #4459 |
| cytomegalovirus infection | #4461 |
| proband | #4461 |
| total costs | #4474 |
| 377 | #4479 |
| 443 | #4482 |
| clinical manifestations | #4486 |
| cd18 | #4486 |
| pancreatic cancer | #4487 |
| inadequate | #4487 |
| coronavirus disease covid19 | #4489 |
| smr | #4492 |
| risk prediction | #4493 |
| bus | #4497 |
| current management | #4498 |
| 476 | #4499 |
| doubling | #4500 |
| infected patients | #4502 |
| comprises | #4503 |
| activation platelet | #4503 |
| 54 | #4513 |
| primary diagnosis | #4515 |
| alpha2 | #4516 |
| therapeutic | #4532 |
| septic | #4534 |
| 3 groups | #4535 |
| male pulmonary | #4541 |
| 526 | #4542 |
| elastase | #4544 |
| hitherto | #4546 |
| fairly | #4552 |
| cardiovascular death | #4559 |
| 985 | #4564 |
| 1250 | #4567 |
| cerebrovascular disorders | #4571 |
| calculating | #4571 |
| multicenter trial | #4574 |
| 2c | #4585 |
| debate | #4586 |
| disadvantage | #4588 |
| plasma concentrations | #4591 |
| 283 | #4592 |
| preserves | #4594 |
| attenuating | #4594 |
| gradual | #4595 |
| eventually | #4595 |
| simplified | #4596 |
| 204 | #4596 |
| 4 | #4601 |
| 4000 | #4601 |
| encouraged | #4603 |
| icer | #4610 |
| frequently | #4611 |
| acetylsalicylic acid | #4613 |
| vii | #4613 |
| vaginal | #4614 |
| 917 | #4619 |
| assay | #4634 |
| subclinical atherosclerosis | #4636 |
| hospital costs | #4640 |
| risks benefits | #4640 |
| 242 | #4642 |
| genetic risk factors | #4644 |
| escalating | #4648 |
| priori | #4654 |
| 003 | #4658 |
| habitual | #4658 |
| survey | #4659 |
| transurethral | #4663 |
| myelofibrosis | #4670 |
| 171 | #4670 |
| thyroid hormone | #4673 |
| 40 | #4675 |
| 407 | #4679 |
| fh | #4680 |
| day | #4680 |
| recurrent stroke | #4681 |
| wheezing | #4693 |
| unchanged | #4698 |
| ranging | #4698 |
| 5 patients | #4701 |
| complicated | #4703 |
| truncated | #4709 |
| therapeutic intervention | #4715 |
| differential humans | #4719 |
| immobilization | #4725 |
| 129 | #4727 |
| orthopedic | #4735 |
| cardiovascular morbidity | #4738 |
| current guidelines | #4739 |
| therapeutic strategies | #4744 |
| ranged | #4769 |
| 027 | #4774 |
| chronic renal | #4775 |
| baseline patients | #4775 |
| acute coronary | #4784 |
| scheduled | #4785 |
| 44 | #4785 |
| molecular | #4792 |
| knee | #4800 |
| insulin glargine | #4801 |
| prophylactic | #4802 |
| arthroplasty | #4803 |
| alternatively | #4810 |
| extracranial | #4813 |
| courses | #4819 |
| diagnostic imaging | #4825 |
| therapy humans | #4836 |
| echocardiography | #4846 |
| 174 | #4848 |
| cholesterol levels | #4853 |
| acl | #4861 |
| definition | #4861 |
| efficiency | #4869 |
| nonvalvular atrial fibrillation | #4870 |
| gpiib | #4870 |
| increased plasma | #4875 |
| unexposed | #4876 |
| gynecological | #4880 |
| antiphospholipid syndrome | #4881 |
| screening tool | #4884 |
| 322 | #4886 |
| total | #4891 |
| antiplatelet therapy | #4891 |
| treating | #4896 |
| abstracted | #4897 |
| doses | #4902 |
| ischemic heart disease | #4905 |
| preparations | #4906 |
| tests prognosis | #4906 |
| served | #4910 |
| chlamydophila | #4913 |
| fmd | #4913 |
| 560 | #4914 |
| recommendation | #4918 |
| geriatrics | #4920 |
| acute ischemic | #4923 |
| renal dysfunction | #4929 |
| 556 | #4932 |
| 154 | #4933 |
| 870 | #4934 |
| cpb | #4939 |
| 325 | #4951 |
| 26 | #4952 |
| satisfied | #4957 |
| appeared | #4959 |
| fund | #4972 |
| manufacturers | #4976 |
| dose | #4976 |
| albeit | #4982 |
| orthopedics | #4982 |
| recommended | #4987 |
| cardiology | #5000 |
| references | #5006 |
| 389 | #5006 |
| epoprostenol | #5009 |
| reminder | #5009 |
| probnp | #5014 |
| point mutation | #5018 |
| risk women | #5023 |
| syndrome patients | #5033 |
| 156 | #5040 |
| screening test | #5040 |
| proposal | #5042 |
| global burden | #5044 |
| primary health | #5045 |
| analytic | #5047 |
| obstetrical | #5048 |
| lasted | #5049 |
| patients sepsis | #5051 |
| limitations | #5055 |
| diagnosis management | #5058 |
| patients myocardial infarction | #5062 |
| spinal surgery | #5065 |
| 255 | #5068 |
| conflicting | #5070 |
| saphenous | #5075 |
| inaccessible | #5078 |
| 1a | #5079 |
| switched | #5084 |
| regarded | #5089 |
| evaluable | #5089 |
| relation | #5090 |
| hip fractures | #5090 |
| transluminal | #5093 |
| menstrual | #5094 |
| fashion | #5098 |
| amputation | #5102 |
| external validation | #5103 |
| arteritis | #5107 |
| inflammatory responses | #5109 |
| oxadiazoles | #5110 |
| dalys | #5112 |
| tailor | #5115 |
| admission patients | #5118 |
| composite | #5120 |
| discriminative | #5123 |
| vivo studies | #5124 |
| bay | #5124 |
| 108 | #5125 |
| 282 | #5129 |
| ischaemic stroke | #5130 |
| 0018 | #5130 |
| 131 | #5131 |
| female | #5131 |
| transfused | #5134 |
| balancing | #5136 |
| contrast media | #5136 |
| fetal death | #5138 |
| activator | #5139 |
| scans | #5143 |
| 341 | #5146 |
| n6 | #5150 |
| kg1 | #5151 |
| disagreement | #5157 |
| shortly | #5157 |
| preclinical studies | #5160 |
| doppler | #5165 |
| predispose | #5170 |
| 11 patients | #5170 |
| hazard | #5171 |
| readers | #5173 |
| prescriptions | #5174 |
| graft failure | #5178 |
| weaknesses | #5185 |
| renal impairment | #5186 |
| 70 patients | #5190 |
| infarctions | #5191 |
| screening | #5193 |
| threefold | #5198 |
| highest | #5202 |
| extracellular vesicles | #5204 |
| acs | #5205 |
| 144 | #5206 |
| hospital patients | #5208 |
| remains | #5209 |
| excess mortality | #5210 |
| doppler color | #5221 |
| polysaccharides | #5223 |
| heparan | #5229 |
| articles | #5233 |
| emergencies | #5233 |
| indwelling | #5241 |
| flowmetry | #5242 |
| gram | #5244 |
| 3 | #5248 |
| platelet aggregation | #5252 |
| considerably | #5253 |
| comparison | #5262 |
| testing | #5264 |
| plasma levels | #5265 |
| estimate | #5288 |
| pooling | #5289 |
| 365 | #5289 |
| aware | #5300 |
| thrombus | #5301 |
| 36 patients | #5301 |
| urokinase | #5302 |
| atherogenesis | #5302 |
| triage | #5303 |
| case reports | #5305 |
| benefit | #5308 |
| reversal | #5310 |
| stroke treatment | #5314 |
| contrasted | #5316 |
| orthomyxoviridae | #5319 |
| openlabel | #5320 |
| 70 years | #5325 |
| aged postoperative | #5330 |
| animal drug evaluation | #5332 |
| dizziness | #5334 |
| absent | #5335 |
| factor humans | #5336 |
| stratify | #5340 |
| reagent | #5341 |
| acute ischemic stroke | #5341 |
| blood vessel | #5343 |
| ultrasound imaging | #5344 |
| fatality | #5347 |
| contrast agents | #5355 |
| arose | #5361 |
| male | #5363 |
| schedule drug | #5363 |
| based guidelines | #5370 |
| hyper | #5372 |
| obstetric | #5376 |
| accepted | #5383 |
| thyrotropin | #5401 |
| informed consent | #5402 |
| blood products | #5405 |
| selected patients | #5406 |
| adult | #5407 |
| heart valve | #5409 |
| intracranial | #5411 |
| questionnaire | #5414 |
| register | #5415 |
| summarized | #5416 |
| 19 | #5417 |
| noninvasive | #5421 |
| clinical risk | #5424 |
| nonsignificant | #5429 |
| protein levels | #5430 |
| concerns | #5439 |
| charts | #5440 |
| hyperprolactinemia | #5441 |
| familiarity | #5442 |
| 37 | #5445 |
| 630 | #5448 |
| retrieved | #5450 |
| cancer growth | #5455 |
| presently | #5456 |
| congenital heart | #5465 |
| registered | #5470 |
| recombinant human | #5474 |
| intermediate | #5475 |
| 340 | #5476 |
| 395 | #5484 |
| allocation | #5488 |
| 247 | #5490 |
| occurrences | #5490 |
| moyamoya disease | #5491 |
| ntprobnp | #5493 |
| kaplan meier | #5496 |
| 260 | #5497 |
| patient risk | #5497 |
| continuing | #5499 |
| discomfort | #5499 |
| 9 patients | #5500 |
| postal | #5503 |
| ssris | #5515 |
| correctly | #5517 |
| weight | #5524 |
| 309 | #5530 |
| period | #5533 |
| limitation | #5539 |
| erythema | #5539 |
| suggestions | #5541 |
| survival benefit | #5542 |
| imputed | #5545 |
| receptor1 | #5563 |
| established | #5563 |
| 175 | #5565 |
| 545 | #5566 |
| management | #5569 |
| 46 | #5573 |
| reduce risk | #5573 |
| 324 | #5595 |
| excludes | #5597 |
| circulating levels | #5598 |
| equivalent | #5598 |
| categorical | #5600 |
| stm | #5607 |
| grounds | #5617 |
| expert | #5620 |
| 02 | #5624 |
| microgram | #5626 |
| minus | #5627 |
| premenopausal women | #5629 |
| retrieve | #5633 |
| food preferences | #5637 |
| drug administration | #5641 |
| platelet count | #5643 |
| reclassification | #5644 |
| 80 years | #5644 |
| 65 | #5651 |
| trial | #5653 |
| 087 | #5667 |
| published data | #5671 |
| 48 | #5676 |
| seventy | #5684 |
| 214 | #5689 |
| latex | #5690 |
| platelet glycoprotein | #5692 |
| reproducible | #5696 |
| 1997 | #5698 |
| meier | #5714 |
| 370 | #5718 |
| return | #5721 |
| 40 years | #5729 |
| atherosclerotic | #5730 |
| 89 | #5732 |
| perform | #5734 |
| 995 | #5748 |
| 091 | #5755 |
| stand | #5756 |
| 0014 | #5761 |
| metabolic effects | #5764 |
| milder | #5771 |
| semiquantitative | #5771 |
| 241 | #5777 |
| recurrence patients | #5781 |
| varied | #5784 |
| creatinine clearance | #5788 |
| 3rd | #5791 |
| mpo | #5804 |
| incidence rates | #5804 |
| 95 women | #5809 |
| orthopedic procedures | #5810 |
| male middle aged | #5811 |
| url | #5812 |
| aircraft | #5819 |
| 1000 | #5819 |
| income countries | #5828 |
| diagnosed | #5840 |
| undergoing surgery | #5843 |
| true | #5852 |
| atrial | #5852 |
| 088 | #5854 |
| attending | #5856 |
| 290 | #5857 |
| women pregnancy | #5857 |
| hip | #5866 |
| advantageous | #5875 |
| complete resolution | #5878 |
| occurrence | #5894 |
| reliable | #5894 |
| excluded | #5899 |
| aged models | #5919 |
| adding | #5923 |
| safety patients | #5927 |
| 22 patients | #5928 |
| aged platelet | #5928 |
| graded | #5934 |
| premenopause | #5938 |
| revision | #5938 |
| 353 | #5945 |
| prodrugs | #5946 |
| rrs | #5949 |
| 141 | #5952 |
| gastrointestinal hemorrhage | #5954 |
| janus kinase | #5959 |
| rcts | #5962 |
| 43 | #5962 |
| families | #5967 |
| 328 | #5971 |
| deemed | #5977 |
| savings | #5980 |
| counseling | #5985 |
| blood platelets | #5987 |
| blood | #5990 |
| receiver operating | #5996 |
| guideline | #5998 |
| cancer incidence | #6006 |
| current standard | #6013 |
| therapeutic interventions | #6028 |
| nadir | #6034 |
| registries risk | #6039 |
| patients experience | #6042 |
| allocated | #6044 |
| ≥3 | #6052 |
| wash | #6059 |
| advance | #6062 |
| quarter | #6065 |
| spect | #6068 |
| glycosaminoglycans | #6069 |
| decompensated | #6074 |
| 24 | #6076 |
| bacteremia | #6090 |
| type iii | #6101 |
| topics | #6101 |
| suggestive | #6105 |
| emerging evidence | #6113 |
| prevent | #6117 |
| safety data | #6120 |
| directly | #6133 |
| 72 | #6135 |
| 267 | #6136 |
| lipid profile | #6140 |
| ≥2 | #6144 |
| normalization | #6151 |
| centuries | #6153 |
| 47 | #6157 |
| ffa | #6160 |
| generation | #6160 |
| lobar | #6161 |
| agents blood | #6164 |
| 292 | #6165 |
| informed | #6173 |
| pharmacodynamic | #6188 |
| lung male | #6190 |
| updating | #6192 |
| advantages disadvantages | #6194 |
| lower | #6195 |
| bilateral | #6198 |
| cyclosporine | #6208 |
| tumour growth | #6212 |
| pathogenetic | #6221 |
| femoral artery | #6224 |
| terminated | #6228 |
| mortality morbidity | #6228 |
| new drugs | #6229 |
| 312 | #6230 |
| evidence base | #6232 |
| vitro studies | #6234 |
| crp | #6235 |
| discontinued | #6236 |
| 111 | #6240 |
| abdomen | #6248 |
| denmark | #6254 |
| proportional | #6268 |
| colleagues | #6273 |
| practitioners | #6273 |
| administered | #6277 |
| 1978 | #6283 |
| screened | #6293 |
| infused | #6297 |
| 840 | #6318 |
| prostatectomy | #6330 |
| 017 | #6334 |
| saphenous vein | #6339 |
| 63 | #6340 |
| 135 | #6340 |
| percentile | #6344 |
| higher doses | #6345 |
| adequacy | #6347 |
| divided | #6348 |
| apache | #6351 |
| screen | #6357 |
| opinions | #6360 |
| opposed | #6362 |
| percentage | #6370 |
| longterm followup | #6372 |
| risk mortality | #6386 |
| dyslipidemias | #6390 |
| kaplan | #6391 |
| consensus | #6392 |
| 208 | #6397 |
| potential mechanisms | #6404 |
| roche | #6405 |
| factor gene | #6405 |
| initiated | #6408 |
| compensated | #6411 |
| investigating | #6427 |
| ultrasound | #6441 |
| restenosis | #6442 |
| bootstrap | #6452 |
| collection | #6457 |
| post operative | #6464 |
| enzyme linked | #6467 |
| bariatric surgery | #6468 |
| coronary syndrome | #6469 |
| decreased risk | #6471 |
| 218 | #6472 |
| perfusion | #6475 |
| imbalance | #6484 |
| angina pectoris | #6493 |
| calendar | #6498 |
| accuracy | #6501 |
| peripheral artery disease | #6501 |
| incidence risk | #6502 |
| cancer cell | #6502 |
| complement activation | #6505 |
| pregnancies | #6519 |
| surgical procedure | #6520 |
| supervised | #6521 |
| models male | #6522 |
| 138 | #6523 |
| triiodothyronine | #6524 |
| 318 | #6524 |
| washout | #6524 |
| peripheral | #6525 |
| vena | #6527 |
| cochrane | #6532 |
| increased incidence | #6532 |
| highrisk patients | #6532 |
| placebo patients | #6536 |
| replaced | #6537 |
| exogenous | #6538 |
| bowel | #6538 |
| thirteen | #6540 |
| aspirin patients | #6540 |
| year | #6546 |
| superior | #6549 |
| clinical assessment | #6550 |
| cohorts | #6555 |
| dilemma | #6560 |
| crt | #6561 |
| dosing | #6576 |
| tertile | #6581 |
| 231 | #6586 |
| limited | #6589 |
| md | #6592 |
| prediction | #6596 |
| treatment choice | #6600 |
| pooled | #6601 |
| occurs | #6610 |
| 510 | #6611 |
| belgium | #6620 |
| crude | #6621 |
| injections | #6638 |
| pancreatic neoplasms | #6641 |
| genetic testing | #6641 |
| individual | #6650 |
| complications | #6650 |
| complaints | #6652 |
| degranulation | #6663 |
| methylenetetrahydrofolate | #6665 |
| liver diseases | #6674 |
| patents | #6680 |
| smoking cessation | #6696 |
| 17 patients | #6704 |
| routinely | #6706 |
| tumour progression | #6708 |
| saline | #6709 |
| 194 | #6713 |
| approval | #6727 |
| hazard ratios | #6729 |
| recognised | #6729 |
| thromboxane | #6734 |
| allcause mortality | #6744 |
| multicenter | #6747 |
| appropriately | #6748 |
| increasing age | #6751 |
| 385 | #6766 |
| body temperature | #6766 |
| q1 | #6768 |
| clinical signs | #6771 |
| age patients | #6774 |
| 2 groups | #6780 |
| defined | #6780 |
| expense | #6781 |
| 42 patients | #6791 |
| train | #6796 |
| hyperglycemia | #6801 |
| reached | #6803 |
| premedication | #6803 |
| plasma proteins | #6807 |
| response relationship | #6807 |
| benefits | #6810 |
| cardiovascular risk | #6821 |
| 256 | #6831 |
| 280 | #6838 |
| iqr | #6839 |
| glucocorticoids | #6840 |
| summary | #6850 |
| 279 | #6854 |
| cancer diagnosis | #6856 |
| systematic | #6870 |
| points | #6877 |
| ambulatory | #6883 |
| weekly | #6884 |
| reviews | #6891 |
| physicians | #6893 |
| fibrillation patients | #6898 |
| adverse event | #6912 |
| disturbances | #6912 |
| sought | #6918 |
| 112 | #6923 |
| 251 | #6940 |
| complications patients | #6948 |
| vasopressin | #6957 |
| failure | #6965 |
| subsequent | #6971 |
| hematologic | #6974 |
| 246 | #6976 |
| intensity | #6976 |
| humans hydroxymethylglutaryl | #6982 |
| papers | #6983 |
| tpa | #6986 |
| intervals | #6987 |
| addressed | #6989 |
| 259 | #6992 |
| shock septic | #6995 |
| 222 | #6995 |
| adapted | #6998 |
| disclosed | #7001 |
| incidence risk factors | #7008 |
| hazards models | #7015 |
| cardiovascular disease | #7019 |
| myeloperoxidase | #7020 |
| lung cancer patients | #7023 |
| stenting | #7024 |
| responded | #7026 |
| cohort | #7037 |
| 1 patient | #7038 |
| unacceptable | #7039 |
| interleukin8 | #7042 |
| reductases | #7045 |
| preventing | #7056 |
| curve | #7058 |
| patients baseline | #7065 |
| animal doseresponse relationship | #7071 |
| reduced risk | #7075 |
| written | #7080 |
| applicability | #7084 |
| asymptomatic patients | #7086 |
| monoclonal antibody | #7098 |
| hospitalization humans | #7101 |
| betacoronavirus covid19 | #7104 |
| computed | #7104 |
| novartis | #7108 |
| complications pregnancy | #7111 |
| infarction stroke | #7114 |
| superiority | #7116 |
| interquartile range | #7120 |
| select | #7122 |
| carotid intima | #7141 |
| internationality | #7146 |
| surveys questionnaires | #7160 |
| 163 | #7166 |
| pharmacy | #7167 |
| patients renal | #7171 |
| physicians patients | #7177 |
| randomization | #7184 |
| liver cirrhosis | #7187 |
| 211 | #7188 |
| brain metastases | #7190 |
| oral animals | #7192 |
| walking | #7195 |
| drawn | #7196 |
| combination | #7197 |
| withdrawal | #7204 |
| 5year | #7204 |
| cardiovascular disease cvd | #7210 |
| acting | #7210 |
| disposition | #7212 |
| paucity | #7218 |
| humans lung | #7221 |
| 20 patients | #7225 |
| sulfate | #7240 |
| operating characteristic | #7244 |
| treatment children | #7250 |
| vldl | #7250 |
| hematocrit | #7255 |
| retrospective cohort study | #7257 |
| 199 | #7257 |
| alongside | #7258 |
| clinical benefit | #7265 |
| controls | #7267 |
| diagnostics | #7270 |
| option | #7273 |
| grouped | #7275 |
| young women | #7278 |
| products | #7282 |
| likelihood | #7284 |
| sensitivity analysis | #7290 |
| modest | #7290 |
| atrium | #7291 |
| 360 | #7303 |
| types | #7304 |
| factors stroke | #7305 |
| undergoing | #7327 |
| partial | #7330 |
| patients isolated | #7332 |
| ischemic stroke | #7338 |
| pectoris | #7338 |
| interleukin6 | #7352 |
| 1c | #7352 |
| myocardial infarction | #7356 |
| p0001 | #7356 |
| standardised | #7356 |
| betacoronavirus | #7357 |
| simple | #7360 |
| radiology | #7379 |
| pap | #7392 |
| patients aspirin | #7400 |
| angiopathies | #7401 |
| regimens | #7405 |
| 109 | #7409 |
| bias | #7411 |
| peptide fragments | #7413 |
| iiia | #7424 |
| intravenous injection | #7429 |
| 420 | #7431 |
| propranolol | #7438 |
| favourable | #7440 |
| hypercholesterolemia | #7441 |
| respective | #7444 |
| dose dependent | #7447 |
| infusion | #7448 |
| clinical setting | #7454 |
| ways | #7465 |
| risk adverse | #7497 |
| il6 | #7510 |
| mortality rates | #7515 |
| 209 | #7516 |
| considerations | #7517 |
| exclusions | #7518 |
| patient safety | #7520 |
| angina | #7522 |
| urgently | #7522 |
| cmv infection | #7541 |
| phase iii | #7555 |
| 257 | #7558 |
| € | #7559 |
| interim | #7561 |
| injection | #7564 |
| 191 | #7578 |
| cinahl | #7578 |
| comorbid | #7578 |
| pheochromocytoma | #7585 |
| ischaemic | #7598 |
| antibodies monoclonal | #7601 |
| reasons | #7602 |
| tended | #7608 |
| pooled analysis | #7609 |
| azathioprine | #7615 |
| 13 | #7616 |
| predictor | #7620 |
| femoral | #7640 |
| random allocation | #7646 |
| 29 patients | #7647 |
| epidemiological studies | #7647 |
| abrupt | #7655 |
| derivation | #7662 |
| interquartile | #7675 |
| manifestation | #7676 |
| temporary | #7679 |
| positive patients | #7687 |
| 18 | #7705 |
| medical conditions | #7705 |
| seventeen | #7710 |
| 304 | #7719 |
| ligament | #7732 |
| consent | #7733 |
| study association | #7735 |
| cytomegalovirus | #7736 |
| severe | #7742 |
| adverse outcomes | #7745 |
| costs | #7753 |
| cardiac surgical | #7760 |
| 189 | #7770 |
| cochrane library | #7771 |
| pregnancy outcome | #7787 |
| manufacturer | #7802 |
| 110 | #7802 |
| ≤ | #7803 |
| 9 | #7811 |
| oxygenases | #7813 |
| male gender | #7815 |
| interleukin | #7816 |
| pts | #7819 |
| label | #7828 |
| 31 patients | #7828 |
| hormone replacement | #7828 |
| cpr | #7829 |
| 5 | #7833 |
| abortion | #7838 |
| influenza | #7845 |
| radiation exposure | #7850 |
| regular | #7877 |
| tramadol | #7878 |
| academic | #7878 |
| septic patients | #7880 |
| 95 confidence | #7884 |
| replacing | #7886 |
| patients chemotherapy | #7888 |
| iib | #7908 |
| journals | #7922 |
| strict | #7927 |
| expertise | #7928 |
| bioavailability | #7930 |
| adoption | #7934 |
| highrisk | #7939 |
| urogenital | #7939 |
| diseased | #7944 |
| increasing evidence | #7947 |
| disadvantages | #7949 |
| 243 | #7965 |
| patients 1 | #7972 |
| human blood | #7973 |
| fragment | #7975 |
| new class | #7976 |
| 28 | #7989 |
| individualized | #7990 |
| aim | #7992 |
| premenopausal | #7995 |
| advice | #8016 |
| qol | #8022 |
| malignant disease | #8026 |
| pulmonary disease | #8031 |
| 99mtc | #8034 |
| oligonucleotides | #8040 |
| vascular disease | #8049 |
| preventable | #8051 |
| 600 | #8051 |
| medical | #8051 |
| list | #8059 |
| selective | #8062 |
| routine clinical | #8068 |
| fact | #8078 |
| lasting | #8080 |
| helpful | #8084 |
| 36 months | #8086 |
| outcome acute | #8092 |
| extracorporeal | #8095 |
| 248 | #8113 |
| 90 | #8114 |
| patients heart | #8120 |
| training | #8120 |
| 2004 | #8122 |
| initiating | #8123 |
| tsh | #8125 |
| cholesterol ldl | #8138 |
| sensorineural | #8140 |
| imaging studies | #8141 |
| investigational | #8141 |
| mild | #8156 |
| nosocomial | #8164 |
| multiple organ | #8175 |
| stroke | #8176 |
| 237 | #8183 |
| 158 | #8184 |
| arteries | #8190 |
| confidence | #8204 |
| parenteral nutrition | #8204 |
| renal dialysis | #8209 |
| 33 | #8223 |
| impairment | #8228 |
| renal function | #8228 |
| 81 | #8233 |
| therapy | #8235 |
| quantitative | #8240 |
| smoking | #8243 |
| lists | #8250 |
| lowest | #8250 |
| version | #8260 |
| activated | #8264 |
| 125i | #8264 |
| minimum | #8270 |
| mortality | #8280 |
| leukopenia | #8281 |
| 0008 | #8284 |
| agents | #8286 |
| 119 | #8290 |
| utilisation | #8298 |
| practice | #8310 |
| suffered | #8316 |
| schedule | #8320 |
| thrombectomy | #8322 |
| endothelium vascular | #8338 |
| postulated | #8338 |
| immunosorbent assay | #8339 |
| elimination | #8341 |
| linked immunosorbent | #8345 |
| hematology | #8351 |
| 2 years | #8382 |
| absence presence | #8382 |
| cell derived | #8384 |
| 229 | #8394 |
| draw | #8405 |
| occur | #8415 |
| 28 patients | #8415 |
| ≥50 | #8416 |
| reports | #8427 |
| 137 | #8433 |
| mentioned | #8436 |
| covid19 coronavirus | #8447 |
| 265 | #8452 |
| glucuronidase | #8458 |
| patient characteristics | #8459 |
| procedures operative | #8463 |
| transient ischemic | #8463 |
| 295 | #8466 |
| exceed | #8486 |
| knowledge | #8493 |
| 27 patients | #8496 |
| covariate | #8501 |
| evaluate | #8501 |
| criterion | #8504 |
| inborn | #8519 |
| validate | #8528 |
| rabbits | #8537 |
| atherosclerosis | #8557 |
| large cohort | #8558 |
| menstrual cycle | #8563 |
| 193 | #8565 |
| 250 | #8568 |
| adjusted life | #8574 |
| leukocytes | #8581 |
| 146 | #8582 |
| adolescent | #8582 |
| row | #8590 |
| carotid arteries | #8596 |
| thirty | #8596 |
| safety profile | #8602 |
| cox | #8604 |
| intensities | #8605 |
| risks | #8606 |
| fish oil | #8624 |
| 15 years | #8624 |
| attenuates | #8625 |
| entry | #8639 |
| thresholds | #8646 |
| presumed | #8652 |
| emissioncomputed | #8654 |
| 223 | #8655 |
| hydroxymethylglutaryl coa | #8656 |
| valves | #8658 |
| syndrome | #8664 |
| factors patients | #8666 |
| evaluations | #8679 |
| certainty | #8687 |
| markers | #8689 |
| renal failure | #8690 |
| biomarkers | #8693 |
| polytetrafluoroethylene | #8698 |
| publication aged aged | #8706 |
| portal vein | #8708 |
| 1 2 | #8723 |
| hold | #8723 |
| additional studies | #8726 |
| cardiotonic | #8729 |
| definitions | #8731 |
| address | #8733 |
| judgment | #8744 |
| platelet counts | #8754 |
| requiring | #8755 |
| endovascular | #8756 |
| practical | #8756 |
| cardiovascular | #8756 |
| vasoactive | #8762 |
| 236 | #8763 |
| interpret | #8766 |
| undetected | #8778 |
| subpopulation | #8789 |
| medical treatment | #8792 |
| illnesses | #8798 |
| cardiovascular mortality | #8802 |
| 249 | #8834 |
| internship | #8836 |
| convenient | #8837 |
| hydroxymethylglutaryl | #8837 |
| resolving | #8863 |
| representative | #8864 |
| 2 | #8872 |
| cesarean | #8876 |
| merits | #8887 |
| endarterectomy | #8896 |
| chronic liver disease | #8902 |
| mimics | #8903 |
| early treatment | #8910 |
| surgical intervention | #8911 |
| micrograms | #8914 |
| planned | #8914 |
| epoxide | #8916 |
| aged myocardial | #8919 |
| influenced | #8934 |
| normal subjects | #8936 |
| proportional hazards | #8945 |
| signs symptoms | #8945 |
| clinicians | #8956 |
| cessation | #8958 |
| experienced | #8960 |
| heparan sulfate | #8962 |
| leads | #8973 |
| 24 hours | #8977 |
| rct | #8980 |
| patients placebo | #9002 |
| options | #9002 |
| chemoprevention | #9005 |
| comprise | #9005 |
| clinical events | #9007 |
| societies medical | #9007 |
| reply | #9017 |
| receiver | #9026 |
| rank | #9043 |
| 7 | #9061 |
| databases factual | #9064 |
| early mortality | #9075 |
| diagnose | #9080 |
| mps | #9080 |
| frequency | #9083 |
| jan | #9088 |
| statins | #9090 |
| alpha1 | #9115 |
| blood proteins | #9116 |
| prone | #9142 |
| valve prosthesis | #9147 |
| time points | #9147 |
| patient patients | #9150 |
| pelvis | #9158 |
| square | #9165 |
| life threatening | #9170 |
| molecular mechanisms | #9179 |
| 75 patients | #9183 |
| advanced stage | #9184 |
| lysis | #9190 |
| editor | #9193 |
| consensus statement | #9209 |
| 361 | #9213 |
| considerable | #9225 |
| platelets | #9226 |
| 1 month | #9227 |
| pci | #9230 |
| dyspnea | #9230 |
| performs | #9233 |
| contrast | #9238 |
| 4 hours | #9259 |
| extrinsic | #9263 |
| hazards | #9264 |
| illness surveys | #9264 |
| experts | #9266 |
| uncomplicated | #9267 |
| mumol | #9278 |
| attenuation | #9283 |
| positive | #9286 |
| rabbit | #9286 |
| trial registration | #9297 |
| corresponded | #9298 |
| dialysis | #9319 |
| feasibility | #9320 |
| earlier | #9339 |
| suboptimal | #9342 |
| patients negative | #9355 |
| p0004 | #9355 |
| preceded | #9376 |
| loss | #9378 |
| 014 | #9380 |
| higher incidence | #9380 |
| purposes | #9383 |
| invited | #9384 |
| single center | #9385 |
| death patients | #9391 |
| radioactivity | #9394 |
| bacterial infections | #9401 |
| fourth | #9402 |
| 2b | #9412 |
| ascending | #9415 |
| haemorrhage | #9425 |
| 167 | #9436 |
| properly | #9442 |
| rheumatic | #9446 |
| hospitalised | #9448 |
| dysfunction | #9460 |
| belonged | #9480 |
| secondary analysis | #9483 |
| respiratory tract | #9486 |
| 169 | #9490 |
| 240 | #9493 |
| ipd | #9502 |
| factual | #9503 |
| valvular | #9505 |
| thyroid function | #9507 |
| selectin | #9509 |
| hrs | #9524 |
| inflammatory agents | #9529 |
| confirms | #9530 |
| designed | #9535 |
| cardiopulmonary bypass | #9540 |
| swelling | #9542 |
| 3 4 | #9544 |
| insight | #9557 |
| cooperation | #9561 |
| requirements | #9566 |
| hemoglobins | #9573 |
| rose | #9592 |
| il10 | #9597 |
| observational cohort | #9598 |
| lpa | #9600 |
| rates | #9617 |
| comparative effectiveness | #9630 |
| kidney failure | #9638 |
| primary point | #9638 |
| successful treatment | #9639 |
| laboratories | #9644 |
| cardiogenic | #9645 |
| optimal treatment | #9650 |
| 2008 | #9656 |
| hf | #9670 |
| published | #9674 |
| congestive | #9695 |
| pathophysiological | #9704 |
| patients hospital | #9713 |
| spontaneously | #9720 |
| modalities | #9721 |
| inappropriate | #9724 |
| reuptake | #9727 |
| acts | #9729 |
| identifier | #9730 |
| 2007 | #9732 |
| lactoferrin | #9734 |
| 42 | #9744 |
| substitutes | #9747 |
| hypothetical | #9754 |
| nested | #9764 |
| nonesterified | #9768 |
| 90 patients | #9777 |
| reproducibility | #9778 |
| sepsis | #9802 |
| 210 | #9803 |
| absence | #9813 |
| straightforward | #9814 |
| easily | #9817 |
| precise | #9817 |
| coa reductase | #9828 |
| nmol | #9828 |
| classification | #9836 |
| 212 | #9839 |
| craniotomy | #9839 |
| 0006 | #9849 |
| utility | #9855 |
| danish | #9857 |
| labile | #9865 |
| nonhuman primates | #9871 |
| heterozygotes | #9871 |
| discordant | #9908 |
| moderately | #9919 |
| cmv | #9930 |
| 60 years | #9933 |
| lower limb | #9936 |
| promise | #9937 |
| degradation | #9941 |
| 2003 | #9941 |
| tomography | #9944 |
| treatment strategy | #9951 |
| 216 | #9958 |
| low dose | #9971 |
| investigator | #9983 |
| detecting | #9992 |
| regimen | #9995 |
| 12 hours | #9997 |
| casecontrol studies | #9997 |
| pancreatic | #9997 |
| 213 | #10000 |
| neoplasm metastasis | #10001 |
| chance | #10008 |
| physician | #10015 |
| extending | #10027 |
| informative | #10028 |
| hereditary | #10041 |
| protective | #10045 |
| obstacles | #10045 |
| addressing | #10051 |
| medication adherence | #10052 |
| mthfr | #10079 |
| presentations | #10082 |
| familial | #10087 |
| higher prevalence | #10089 |
| chart | #10108 |
| recipients | #10113 |
| qualitative | #10117 |
| 1980 | #10134 |
| completely | #10145 |
| tested | #10150 |
| aged obesity | #10170 |
| 182 | #10176 |
| invasive | #10181 |
| abnormalities | #10186 |
| regularly | #10189 |
| cast | #10193 |
| multicentre | #10198 |
| cell activation | #10199 |
| investigations | #10199 |
| cardiovascular risk factors | #10209 |
| medical therapy | #10213 |
| clinical data | #10213 |
| tumor necrosis factoralpha | #10215 |
| replacement therapy | #10225 |
| routine | #10234 |
| syndrome humans | #10253 |
| heart failure | #10265 |
| 183 | #10280 |
| gaps | #10291 |
| hospitalization | #10293 |
| blood transfusion | #10293 |
| postpartum | #10305 |
| measuring | #10314 |
| aetiology | #10315 |
| 8 | #10318 |
| photon emission | #10329 |
| 032 | #10336 |
| dilution | #10336 |
| worldwide | #10337 |
| 667 | #10337 |
| aorta | #10352 |
| greatly | #10352 |
| indirectly | #10377 |
| restoration | #10378 |
| creatinine | #10381 |
| cardiopulmonary | #10385 |
| pneumonia viral | #10397 |
| medical management | #10404 |
| p0003 | #10408 |
| outcome measures | #10408 |
| tissue injury | #10411 |
| bidirectional | #10419 |
| reductase inhibitors | #10432 |
| circulation | #10432 |
| transfusion | #10435 |
| enrolment | #10446 |
| reflux | #10457 |
| patients age | #10461 |
| priority | #10461 |
| quality life | #10471 |
| phase 3 | #10481 |
| activity levels | #10489 |
| increased prevalence | #10489 |
| 1991 | #10491 |
| style | #10491 |
| 147 | #10501 |
| predictive factors | #10514 |
| sex age | #10526 |
| assessing | #10529 |
| necrosis | #10534 |
| matched | #10556 |
| lower rate | #10558 |
| portable | #10563 |
| ray | #10570 |
| patients moderate | #10570 |
| 125 | #10574 |
| p002 | #10576 |
| pulmonary artery | #10578 |
| inform | #10580 |
| antisense | #10583 |
| recurrences | #10583 |
| 293 | #10584 |
| 180 | #10598 |
| manifestations | #10601 |
| closer | #10602 |
| 159 | #10605 |
| microvascular | #10605 |
| vasoconstrictor | #10607 |
| hospitals | #10612 |
| medical oncology | #10615 |
| november | #10628 |
| percutaneous coronary | #10633 |
| persist | #10635 |
| fragments | #10637 |
| ascertained | #10641 |
| 1b | #10647 |
| publication administration | #10653 |
| postoperative | #10659 |
| held | #10674 |
| concerned | #10674 |
| pulmonary vascular | #10690 |
| term | #10697 |
| discriminate | #10697 |
| risk developing | #10704 |
| synergism | #10709 |
| multivariable analysis | #10713 |
| neutrophil | #10729 |
| consultation | #10735 |
| centres | #10751 |
| median duration | #10755 |
| decisions | #10759 |
| entire | #10774 |
| haemoglobin | #10797 |
| perioperative | #10798 |
| patients cirrhosis | #10804 |
| term mortality | #10829 |
| 300 | #10832 |
| 38 | #10849 |
| prospective observational | #10855 |
| sustained | #10865 |
| randomised controlled | #10867 |
| anatomical | #10873 |
| diagnoses | #10903 |
| airways | #10903 |
| neurosurgical | #10905 |
| monoclonal antibodies monoclonal | #10909 |
| coronavirus infections | #10921 |
| maximal | #10924 |
| threatening | #10963 |
| amniotic | #10987 |
| coronary intervention | #10989 |
| relative | #10990 |
| blocker | #10996 |
| needed | #11009 |
| obese | #11037 |
| ischemic | #11057 |
| neutropenia | #11057 |
| attained | #11062 |
| summarizes | #11062 |
| ethical | #11062 |
| treatment option | #11070 |
| balloon | #11071 |
| 12 weeks | #11074 |
| originally | #11083 |
| inability | #11108 |
| location | #11108 |
| catheters | #11143 |
| beta2 | #11159 |
| ischemic attack | #11165 |
| hematoma | #11189 |
| confirmation | #11199 |
| neoplasms risk | #11201 |
| metabolic syndrome | #11202 |
| iia | #11204 |
| strokes | #11217 |
| choice | #11228 |
| eligible patients | #11247 |
| risk groups | #11263 |
| 1992 | #11272 |
| humans kidney | #11281 |
| cerebrovascular | #11281 |
| waiting | #11282 |
| ≥1 | #11291 |
| endothelial function | #11297 |
| troponin | #11304 |
| determine | #11306 |
| 202 | #11308 |
| aged prevalence | #11331 |
| post | #11332 |
| adherent | #11338 |
| acute respiratory | #11345 |
| acute myocardial infarction | #11361 |
| event | #11363 |
| combination therapy | #11380 |
| glycoprotein | #11391 |
| factors smoking | #11395 |
| reconstructive | #11397 |
| apply | #11399 |
| developed | #11405 |
| 2005 | #11415 |
| competent | #11416 |
| medically | #11426 |
| treatment decisions | #11427 |
| prostaglandins | #11434 |
| diuretics | #11439 |
| hematological malignancies | #11443 |
| morbidity | #11445 |
| media | #11464 |
| protocol | #11487 |
| satisfying | #11502 |
| performances | #11525 |
| hospital admission | #11526 |
| placebo treatment | #11533 |
| occlusion | #11533 |
| outflow | #11542 |
| multicenter study | #11542 |
| enrolled | #11545 |
| humans intensive | #11570 |
| 55 | #11577 |
| chronic inflammation | #11600 |
| definitive | #11621 |
| younger patients | #11624 |
| baseline | #11624 |
| sct | #11638 |
| investigate | #11670 |
| normal controls | #11684 |
| contribution | #11687 |
| reference | #11694 |
| life qol | #11697 |
| lipopolysaccharides | #11699 |
| hypotension | #11715 |
| ascites | #11717 |
| myoglobin | #11741 |
| independent risk | #11745 |
| acute myocardial | #11753 |
| radiopharmaceuticals | #11783 |
| extent | #11786 |
| orally | #11790 |
| involving | #11792 |
| 2010 | #11802 |
| nonspecific | #11809 |
| vena cava | #11829 |
| distinction | #11841 |
| episodes | #11865 |
| eclampsia | #11872 |
| release | #11874 |
| woman | #11885 |
| 151 | #11891 |
| 006 | #11906 |
| elicited | #11912 |
| icu patients | #11915 |
| vasculitis | #11937 |
| activating | #11948 |
| age | #11953 |
| sulphate | #11955 |
| began | #11957 |
| lethality | #11967 |
| collectively | #11970 |
| inferior | #11978 |
| serum creatinine | #11979 |
| myocardial injury | #11980 |
| adp | #11981 |
| immunosorbent | #12006 |
| cardiovascular diseases | #12015 |
| mortality rate | #12041 |
| reduced | #12043 |
| dietary intake | #12057 |
| thirds | #12057 |
| minority | #12058 |
| monitored | #12061 |
| differently | #12066 |
| early pregnancy | #12076 |
| humanized | #12077 |
| wounds injuries | #12079 |
| fair | #12096 |
| thoracotomy | #12111 |
| evidenced | #12130 |
| 1995 | #12135 |
| elevated risk | #12140 |
| 085 | #12141 |
| profile | #12143 |
| prostate | #12153 |
| 149 | #12157 |
| 120 | #12170 |
| digoxin | #12177 |
| offset | #12179 |
| uncommon | #12187 |
| healthcare | #12202 |
| lung | #12208 |
| causality | #12208 |
| spent | #12219 |
| takes | #12233 |
| tendency | #12271 |
| pregnancy risk | #12276 |
| expectancy | #12281 |
| resolve | #12300 |
| flaps | #12302 |
| micromol | #12326 |
| mismatch | #12335 |
| favored | #12342 |
| births | #12351 |
| obstructive pulmonary | #12358 |
| epinephrine | #12365 |
| dependently | #12372 |
| prescription | #12394 |
| registration | #12398 |
| incremental | #12399 |
| switzerland | #12409 |
| inflammatory response | #12409 |
| consistent | #12418 |
| potential confounders | #12425 |
| echocardiographic | #12450 |
| fifty patients | #12451 |
| arginine | #12475 |
| patient discharge | #12480 |
| apparent | #12483 |
| prospective randomized | #12486 |
| sensitivity analyses | #12490 |
| 117 | #12494 |
| switch | #12513 |
| 10 years | #12521 |
| standards | #12524 |
| guide | #12540 |
| requires | #12540 |
| statistically | #12548 |
| prognostic | #12579 |
| chronic obstructive | #12584 |
| monoclonal | #12589 |
| rapidly | #12597 |
| tomography ray | #12611 |
| lipoprotein | #12619 |
| literature | #12637 |
| repeat | #12653 |
| single dose | #12673 |
| drug interactions | #12680 |
| hypertension pulmonary | #12684 |
| physiological | #12687 |
| pharmacogenetics | #12706 |
| 45 | #12708 |
| prostatic | #12708 |
| endocrine | #12709 |
| ifngamma | #12722 |
| minute | #12733 |
| dosage | #12736 |
| congestive heart failure | #12747 |
| cardiac surgery | #12756 |
| personal | #12770 |
| estrogens | #12778 |
| animal model | #12796 |
| thyroid | #12808 |
| settings | #12820 |
| malignancies | #12823 |
| infections | #12836 |
| burden | #12849 |
| intraoperative complications | #12862 |
| cancer patient | #12864 |
| reporting | #12866 |
| 196 | #12881 |
| 1999 | #12904 |
| cvd | #12906 |
| raised | #12910 |
| endpoints | #12912 |
| extracted | #12940 |
| confirming | #12947 |
| 18 years | #12976 |
| ray computed | #12983 |
| postoperative complications | #12990 |
| filters | #13009 |
| monotherapy | #13017 |
| transiently | #13024 |
| oral administration | #13041 |
| instance | #13041 |
| located | #13049 |
| tumor angiogenesis | #13067 |
| based cohort | #13094 |
| fold | #13100 |
| severity | #13106 |
| cancer risk | #13107 |
| escalation | #13107 |
| physical | #13112 |
| vomiting | #13112 |
| latin | #13125 |
| sexes | #13143 |
| drug therapy | #13144 |
| 0 | #13145 |
| ratio | #13159 |
| focused | #13189 |
| appearance | #13195 |
| compliance | #13199 |
| pregnant women | #13202 |
| optimal | #13213 |
| expensive | #13226 |
| support | #13231 |
| exist | #13235 |
| 142 | #13236 |
| lack | #13240 |
| narcotic | #13261 |
| formal | #13262 |
| commercially | #13265 |
| participant | #13273 |
| median follow | #13286 |
| indirect | #13288 |
| emission computed | #13352 |
| mediator | #13366 |
| maintain | #13391 |
| electronic databases | #13394 |
| hypothesized | #13395 |
| advantage | #13432 |
| admitted | #13437 |
| p00001 | #13442 |
| anti | #13455 |
| reliably | #13459 |
| surveys | #13463 |
| endothelial dysfunction | #13466 |
| transient | #13478 |
| patients experienced | #13481 |
| provided | #13489 |
| crosssectional study | #13491 |
| patients patient | #13494 |
| surrogate | #13537 |
| vivo | #13545 |
| retrospectively | #13548 |
| maintained | #13555 |
| 195 | #13556 |
| pulmonary hypertension | #13563 |
| accurate | #13563 |
| longterm outcomes | #13585 |
| monitoring | #13620 |
| laboratory | #13629 |
| elucidated | #13643 |
| abdominal | #13652 |
| whilst | #13665 |
| mitral | #13682 |
| north america | #13705 |
| marker | #13707 |
| vascular | #13708 |
| competence | #13708 |
| 45 years | #13716 |
| 2009 | #13734 |
| icu | #13748 |
| drug effects | #13753 |
| medicine | #13755 |
| healthy individuals | #13758 |
| inhibitory effects | #13763 |
| establishing | #13766 |
| pelvic | #13773 |
| explanation | #13773 |
| participating | #13774 |
| phospholipid | #13776 |
| heart diseases | #13789 |
| women risk | #13816 |
| conservative | #13820 |
| circulating | #13824 |
| condition | #13859 |
| kidney diseases | #13860 |
| systematically | #13868 |
| tissue | #13876 |
| coronary angiography | #13889 |
| internal | #13916 |
| techniques | #13923 |
| microparticles | #13927 |
| dissemination | #13928 |
| 1993 | #13939 |
| 176 | #13979 |
| require | #13986 |
| castration | #13998 |
| radioisotopes | #14011 |
| 48 patients | #14013 |
| insufficiency | #14022 |
| algorithms | #14029 |
| members | #14033 |
| risk death | #14033 |
| requirement | #14046 |
| independent predictors | #14058 |
| continuous | #14060 |
| organ failure | #14072 |
| focus | #14084 |
| situations | #14084 |
| vasoconstriction | #14119 |
| offer | #14137 |
| supporting | #14164 |
| activates | #14188 |
| cardiac output | #14194 |
| leukocyte | #14204 |
| mitral valve | #14205 |
| sensitivities | #14216 |
| document | #14242 |
| primary prevention | #14248 |
| newborns | #14256 |
| nausea | #14276 |
| making | #14285 |
| effectiveness | #14304 |
| independent | #14342 |
| inhibition | #14357 |
| 4 years | #14367 |
| meaningful | #14371 |
| pathologic | #14372 |
| female fetal | #14377 |
| acquired | #14378 |
| min1 | #14391 |
| 6 patients | #14391 |
| amniotic fluid | #14403 |
| substances | #14409 |
| pregnant | #14423 |
| disease chronic | #14460 |
| interleukin1 | #14489 |
| infarction | #14491 |
| influence | #14509 |
| interventions | #14510 |
| costeffectiveness | #14535 |
| locations | #14586 |
| participated | #14592 |
| similarities | #14608 |
| 205 | #14632 |
| statistics | #14637 |
| renal insufficiency | #14637 |
| reasonable | #14646 |
| comparative | #14648 |
| natural | #14667 |
| blood samples | #14672 |
| surgery patients | #14696 |
| entered | #14698 |
| pandemics | #14707 |
| classify | #14715 |
| institutes | #14736 |
| surveyed | #14741 |
| 39 patients | #14742 |
| sampled | #14749 |
| 2017 | #14783 |
| arms | #14785 |
| independent predictor | #14787 |
| validity | #14787 |
| databases | #14808 |
| heart association | #14814 |
| white matter | #14816 |
| complete | #14819 |
| stable | #14828 |
| cox proportional | #14835 |
| pge2 | #14844 |
| duplex | #14845 |
| population | #14872 |
| contribute | #14928 |
| retest | #14931 |
| criteria | #14938 |
| premature | #14952 |
| critical illness | #15004 |
| phospholipids | #15030 |
| european society | #15041 |
| cardiac catheterization | #15042 |
| prostheses | #15059 |
| questionnaires | #15082 |
| treatment failure | #15087 |
| sf36 | #15089 |
| elective surgical | #15107 |
| controlled clinical | #15109 |
| flight | #15110 |
| ldl | #15120 |
| relate | #15127 |
| health costs | #15128 |
| initiation | #15140 |
| obstruction | #15142 |
| obstructive | #15146 |
| stratification | #15164 |
| proper | #15177 |
| selection | #15187 |
| registries | #15197 |
| copd | #15201 |
| decrease | #15201 |
| randomized controlled trial | #15210 |
| unilateral | #15223 |
| ongoing | #15230 |
| induces | #15231 |
| individuals | #15239 |
| young patients | #15247 |
| previous | #15250 |
| methods retrospective | #15255 |
| drug | #15278 |
| disorders | #15278 |
| myocardial | #15279 |
| 4 weeks | #15296 |
| quantitation | #15298 |
| fewer | #15300 |
| hospital discharge | #15328 |
| quantify | #15340 |
| activators | #15356 |
| neonates | #15370 |
| consequence | #15405 |
| locally | #15441 |
| impaired | #15446 |
| pedigree | #15471 |
| women age | #15474 |
| randomised controlled trial | #15474 |
| grafts | #15484 |
| zealand | #15509 |
| asthma | #15511 |
| undetectable | #15512 |
| current literature | #15513 |
| records | #15520 |
| 1994 | #15522 |
| aggregation | #15535 |
| thrombocytopenia | #15537 |
| implementation | #15538 |
| pa | #15540 |
| intended | #15567 |
| reviewed | #15577 |
| surgery | #15590 |
| updated | #15592 |
| discharged | #15616 |
| immunoenzyme | #15617 |
| purpose | #15634 |
| heterozygosity | #15660 |
| centre | #15666 |
| standard | #15679 |
| patients admitted | #15702 |
| perinatal | #15711 |
| explain | #15726 |
| view | #15729 |
| unexpected | #15737 |
| detection | #15766 |
| start | #15808 |
| effectively | #15813 |
| examination | #15813 |
| prescribing | #15823 |
| vary | #15829 |
| febrile | #15847 |
| confer | #15849 |
| serologic | #15853 |
| reach | #15876 |
| interpretation | #15881 |
| janus | #15892 |
| numerous | #15899 |
| inter | #15907 |
| quality adjusted | #15919 |
| dyslipidemia | #15942 |
| prominent | #15961 |
| blocked | #15985 |
| severely | #15997 |
| discuss | #15997 |
| alanine | #15998 |
| external | #16007 |
| causal | #16021 |
| hepatectomy | #16025 |
| complication | #16054 |
| compared controls | #16057 |
| rarely | #16076 |
| systemic inflammation | #16077 |
| fever | #16082 |
| metabolic | #16112 |
| demonstrates | #16117 |
| insensitive | #16125 |
| affect | #16135 |
| conditional | #16136 |
| basis | #16144 |
| carotid | #16168 |
| bypass | #16221 |
| early | #16262 |
| antiretroviral | #16271 |
| neoplasms | #16294 |
| hospital | #16314 |
| special | #16336 |
| signs | #16384 |
| cost | #16418 |
| recommendations | #16420 |
| aimed | #16432 |
| area | #16442 |
| syndromes | #16485 |
| unable | #16508 |
| develop | #16513 |
| prevented | #16513 |
| cancer treatment | #16516 |
| 106 | #16543 |
| radiography | #16545 |
| calibrated | #16568 |
| multivariable | #16576 |
| 2021 | #16583 |
| descriptive | #16618 |
| alternatives | #16629 |
| integrins | #16641 |
| creactive protein | #16645 |
| gained | #16652 |
| consists | #16666 |
| weeks | #16674 |
| downregulation | #16681 |
| residual | #16708 |
| prior | #16725 |
| explained | #16763 |
| fat | #16775 |
| electrocardiography | #16807 |
| epidemiology | #16821 |
| potent | #16848 |
| thought | #16868 |
| genetic risk | #16876 |
| survival | #16892 |
| 093 | #16911 |
| humans liver | #16932 |
| constitute | #16939 |
| gestational age | #16946 |
| vasodilator | #16950 |
| driven | #16958 |
| critically patients | #16965 |
| enable | #16976 |
| verify | #16984 |
| smokers | #16998 |
| inherent | #17023 |
| carotid artery | #17040 |
| apolipoproteins | #17063 |
| individual patients | #17078 |
| markedly | #17097 |
| units | #17139 |
| estimates | #17144 |
| assayed | #17145 |
| elderly patients | #17150 |
| regard | #17197 |
| critically | #17220 |
| adjustment | #17237 |
| lung neoplasms | #17262 |
| cooperative | #17262 |
| estimated | #17274 |
| largest | #17288 |
| acute phase | #17288 |
| 400 | #17295 |
| clinician | #17339 |
| desirable | #17347 |
| 2019 | #17393 |
| limb | #17439 |
| dilated | #17443 |
| disease cvd | #17451 |
| synthetic | #17459 |
| increasingly | #17488 |
| kinds | #17510 |
| antibodies | #17538 |
| prompt | #17565 |
| demographics | #17584 |
| cirrhosis | #17586 |
| 0002 | #17604 |
| finding | #17620 |
| applicable | #17636 |
| obtaining | #17637 |
| coronary | #17653 |
| sex factors | #17688 |
| prosthesis | #17710 |
| independent risk factor | #17712 |
| distal | #17714 |
| multivariate analysis | #17792 |
| gastrointestinal | #17804 |
| selecting | #17815 |
| 3 years | #17833 |
| 2006 | #17840 |
| illustrated | #17852 |
| 1 | #17853 |
| hemorrhagic | #17855 |
| drugs | #17878 |
| current evidence | #17881 |
| undergone | #17883 |
| marked | #17903 |
| epidemiologic | #17920 |
| hospitalizations | #17922 |
| nationwide | #17924 |
| global | #17933 |
| percutaneous | #17942 |
| essential | #17964 |
| corticosteroids | #17975 |
| distant | #18007 |
| intensive | #18031 |
| reductase | #18047 |
| verified | #18052 |
| peptide | #18060 |
| defects | #18070 |
| 000 | #18092 |
| operated | #18111 |
| trend | #18115 |
| centers | #18134 |
| protein crp | #18152 |
| clinical significance | #18164 |
| consistently | #18169 |
| quality | #18175 |
| chemotherapy | #18203 |
| prenatal | #18250 |
| participate | #18252 |
| deaths | #18263 |
| year follow | #18286 |
| ventricular function | #18296 |
| metastases | #18296 |
| inflammatory bowel | #18314 |
| gestation | #18344 |
| tolerated | #18425 |
| attributable | #18434 |
| and or | #18480 |
| coa | #18497 |
| larger | #18513 |
| mutations | #18533 |
| humans hypertension | #18543 |
| stratified | #18569 |
| heart disease | #18579 |
| commercial | #18589 |
| bayes | #18675 |
| ≥ | #18700 |
| extra | #18726 |
| mechanisms | #18742 |
| questions | #18760 |
| plasma | #18797 |
| conventional | #18799 |
| monoclonal antibodies | #18844 |
| increases | #18850 |
| life | #18851 |
| vessel | #18855 |
| oligopeptides | #18887 |
| clearance | #18903 |
| validation | #18907 |
| classical | #18919 |
| hormone | #18938 |
| molecular basis | #19034 |
| single | #19069 |
| worse | #19094 |
| statistical | #19103 |
| soluble | #19124 |
| simultaneously | #19131 |
| tailored | #19134 |
| real | #19158 |
| 5 years | #19189 |
| variable | #19205 |
| moderate | #19239 |
| contributes | #19241 |
| decade | #19291 |
| infarct | #19308 |
| ages | #19312 |
| pubmed | #19345 |
| 0005 | #19412 |
| essentially | #19469 |
| ventricular | #19481 |
| investigates | #19493 |
| 2 3 | #19507 |
| therapies | #19511 |
| called | #19515 |
| partially | #19535 |
| explore | #19544 |
| endothelium | #19553 |
| systemic | #19561 |
| january | #19567 |
| uterine | #19582 |
| reversed | #19601 |
| procedures | #19611 |
| tka | #19675 |
| etiology | #19677 |
| operating | #19692 |
| guided | #19709 |
| histology | #19727 |
| characterised | #19753 |
| inflammation | #19779 |
| median followup | #19863 |
| exclusively | #19881 |
| autologous | #19886 |
| graft | #19904 |
| endothelial cell | #19986 |
| controlled trial | #20019 |
| comorbidities | #20045 |
| 2002 | #20050 |
| gestational | #20050 |
| additionally | #20057 |
| cytokines | #20058 |
| salvage | #20102 |
| inversely | #20149 |
| concentration | #20153 |
| predisposition disease | #20162 |
| diastolic | #20170 |
| small | #20201 |
| alterations | #20228 |
| body | #20230 |
| alpha | #20261 |
| polymorphism genetic | #20264 |
| variables | #20277 |
| subjects | #20283 |
| combine | #20369 |
| adjusting | #20377 |
| catheterization | #20391 |
| introduced | #20458 |
| 1 3 | #20492 |
| younger | #20499 |
| hormones | #20508 |
| length | #20512 |
| theoretically | #20515 |
| ability | #20536 |
| analyses | #20553 |
| clarify | #20561 |
| elisa | #20562 |
| persistent | #20562 |
| improves | #20570 |
| september | #20598 |
| persons | #20696 |
| humans models | #20753 |
| active | #20756 |
| observational | #20823 |
| incorporated | #20843 |
| prognosis | #20934 |
| fetal | #20955 |
| reduce | #21005 |
| measure | #21033 |
| auc | #21046 |
| report | #21048 |
| intrinsic | #21055 |
| responsible | #21081 |
| constructed | #21098 |
| innate | #21135 |
| operative | #21137 |
| attenuated | #21137 |
| 1 year | #21144 |
| designated | #21167 |
| october | #21177 |
| performing | #21185 |
| × | #21191 |
| upper | #21226 |
| reflecting | #21230 |
| selected | #21264 |
| depending | #21267 |
| preschool female | #21270 |
| 005 | #21324 |
| hemodynamics humans | #21403 |
| symptoms | #21425 |
| center | #21469 |
| differed | #21501 |
| 1990 | #21507 |
| 0004 | #21546 |
| logistic | #21639 |
| explored | #21757 |
| animals antibodies | #21767 |
| young | #21860 |
| 139 | #21894 |
| majority | #21894 |
| observe | #21969 |
| facilitate | #21994 |
| decreased | #22047 |
| progression | #22078 |
| genotype | #22116 |
| imaging | #22125 |
| coronary disease | #22178 |
| tract | #22180 |
| neoadjuvant | #22207 |
| generally | #22291 |
| regression | #22321 |
| surgical procedures | #22327 |
| authors | #22330 |
| demonstrated | #22352 |
| inhibiting | #22426 |
| newborn male | #22473 |
| varying | #22556 |
| significance | #22586 |
| represented | #22593 |
| slower | #22607 |
| allogeneic | #22614 |
| grade | #22615 |
| phase | #22698 |
| older | #22831 |
| differential | #22835 |
| july | #22843 |
| modified | #22851 |
| march | #22907 |
| application | #22920 |
| combining | #22961 |
| ratios | #22986 |
| 2012 | #23037 |
| anti inflammatory | #23123 |
| offered | #23214 |
| protocols | #23283 |
| 2016 | #23284 |
| challenging | #23285 |
| yielding | #23334 |
| prevents | #23432 |
| resting | #23488 |
| includes | #23496 |
| renal | #23566 |
| median | #23599 |
| inhibits | #23686 |
| inbred c57bl mice | #23705 |
| increasing | #23723 |
| endopeptidases | #23727 |
| advanced | #23745 |
| adverse | #23767 |
| naive | #23767 |
| reactive protein | #23807 |
| minimal | #23827 |
| interestingly | #23831 |
| showing | #23885 |
| longer | #23967 |
| surgical | #24020 |
| vascular endothelial | #24085 |
| prolonged | #24478 |
| generate | #24487 |
| count | #24514 |
| december | #24569 |
| unrelated | #24572 |
| determining | #24577 |
| activity | #24581 |
| changed | #24651 |
| implies | #24682 |
| underlying | #24749 |
| suggests | #24813 |
| august | #24821 |
| linearly | #24940 |
| february | #24945 |
| frequent | #25109 |
| june | #25175 |
| representing | #25214 |
| acceptable | #25300 |
| carried | #25310 |
| illness | #25373 |
| suitable | #25501 |
| enhance | #25503 |
| 0003 | #25598 |
| linked | #25616 |
| local | #25663 |
| mm | #25732 |
| fully | #25888 |
| reducing | #25912 |
| describes | #25923 |
| difficult | #26054 |
| supported | #26091 |
| scanning | #26181 |
| differentiate | #26212 |
| respect | #26378 |
| promising | #26384 |
| asked | #26410 |
| define | #26421 |
| defective | #26510 |
| female heart | #26685 |
| dependent | #26722 |
| leading | #26774 |
| improving | #27057 |
| contained | #27059 |
| national | #27215 |
| strongest | #27229 |
| quantitatively | #27333 |
| recognized | #27386 |
| mass bmi | #27411 |
| commonly | #27411 |
| implicated | #27484 |
| caused | #27495 |
| remain | #27689 |
| correlate | #27710 |
| artery | #27999 |
| cross | #28142 |
| recorded | #28182 |
| detected | #28405 |
| inflammatory | #28439 |
| multivariate | #28454 |
| examine | #28475 |
| beta | #28655 |
| allowed | #28793 |
| hypothesis | #28801 |
| improved | #28920 |
| required | #29047 |
| large | #29116 |
| chemically | #29137 |
| short | #29272 |
| patients chronic | #29316 |
| genetic predisposition | #29434 |
| bmi | #29470 |
| female health | #29531 |
| achieved | #29589 |
| 001 | #29634 |
| underwent | #29797 |
| 2011 | #30149 |
| indicating | #30233 |
| approved | #30511 |
| declined | #30756 |
| participants | #30828 |
| predisposition | #30981 |
| genotype humans | #31051 |
| aims | #31216 |
| measured | #31265 |
| antineoplastic agents | #31706 |
| expected | #31791 |
| specific | #31901 |
| endothelial | #32294 |
| modality | #32386 |
| inhibit | #32629 |
| conducted | #32675 |
| predicted | #32889 |
| inhibited | #33631 |
| agreement | #33673 |
| sensitive | #34362 |
| antineoplastic | #34560 |
| correlated | #34744 |
| greater | #34856 |
| poor | #35078 |
| neoplasms male | #35230 |
| humans magnetic | #35433 |
| 0001 | #35646 |
| free | #35793 |
| sectional | #35852 |
| include | #39773 |
| collected | #40746 |
| examined | #41010 |
| mediated | #41310 |
| neoplasm | #47468 |
Kjør rapport | |
Prominent publications by Harry Roger Büller
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
[ PUBLICATION ]
BACKGROUND: Guidelines addressing the management of venous thromboembolism (VTE) in cancer patients are heterogeneous and their implementation has been suboptimal worldwide.
OBJECTIVES: To establish a common international consensus addressing practical, clinically relevant questions in this setting.
METHODS: An international consensus working group of experts was set up to develop guidelines according to an evidence-based medicine approach, using the GRADE system.
RESULTS: For the ...
| Kjent for Vte Patients | Venous Thromboembolism | Prophylaxis Lmwh | 3 Months | Practice Guidelines |
KOL-Index: 20177
OBJECTIVES: The objective of this study was to compare the predictive performance of bleeding risk-estimation tools in a cohort of patients with atrial fibrillation (AF) undergoing anticoagulation.
BACKGROUND: Three bleeding risk-prediction schemes have been derived for and validated in patients with AF: HEMORR(2)HAGES (Hepatic or Renal Disease, Ethanol Abuse, Malignancy, Older Age, Reduced Platelet Count or Function, Re-Bleeding, Hypertension, Anemia, Genetic Factors, Excessive Fall ...
| Kjent for Atrial Fibrillation | Bled Bleeding | Hemorr2hages Atria | Intracranial Hemorrhage | Topic Risk |
Antithrombotic Therapy for Venous Thromboembolic Disease The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
[ PUBLICATION ]
This chapter about antithrombotic therapy for venous thromboembolic disease is part of the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patients' values may lead to different choices (for a full understanding of the grading see Guyatt et al, CHEST 2004; 126:179S-187S). Among the key ...
| Kjent for Antithrombotic Therapy | Grade 1a | Venous Thromboembolic Disease | Vka Lmwh | Inr Range |
KOL-Index: 16684
PURPOSE: Initial heparinization followed by vitamin K antagonists is the treatment of choice for patients with venous thromboembolism. There is controversy whether known malignancy is a risk factor for recurrences and bleeding complications during this treatment. Furthermore, the incidence of such events in these patients is dependent on the achieved International Normalized Ratio (INR). The aim of this study was to assess the incidence of venous thromboembolic recurrence and major ...
| Kjent for Venous Thromboembolism | Bleeding Complications | Patients Malignancy | Retrospective Analysis | International Normalized |
KOL-Index: 16378
BACKGROUND: Venous thromboembolism occurs commonly in patients with cancer. Direct oral anticoagulants are non-inferior to conventional anticoagulants for the treatment of venous thromboembolism. We hypothesised that edoxaban, a direct oral inhibitor of activated clotting factor Xa, might be more suitable than conventional anticoagulants in the management of cancer-associated venous thromboembolism. The aim of this study was to assess the efficacy and safety of edoxaban compared with ...
| Kjent for Venous Thromboembolism | Patients Cancer | Hazard Ratio | Clinically Relevant Bleeding | Factor Inhibitors |
KOL-Index: 15975
BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear.
METHODS: In a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), ...
| Kjent for Warfarin Patients | Hazard Ratio | Venous Thromboembolism | Pulmonary Embolism | Primary Efficacy Outcome |
ADAMTS‐13 and von Willebrand factor predict venous thromboembolism in patients with cancer
[ PUBLICATION ]
ESSENTIALS: Cancer patients are at high risk of venous thromboembolism (VTE). In this study, cases and controls were cancer patients who did or did not develop VTE. von Willebrand factor (VWF) levels were higher if compared with controls and correlated with cancer stage. VWF and ADAMTS-13 are associated with the occurrence of VTE in cancer.
BACKGROUND: Patients with cancer are at high risk of venous thromboembolism (VTE). ADAMTS-13 regulates von Willebrand factor (VWF) activity, which ...
| Kjent for Willebrand Factor | Venous Thromboembolism | Vte Cancer | Vwf Adamts13 | Khorana Score |
KOL-Index: 15571
BACKGROUND: Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring.
METHODS: We conducted an open-label, randomized, event-driven, noninferiority study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with subcutaneous enoxaparin followed by a vitamin K antagonist (either warfarin or ...
| Kjent for Oral Rivaroxaban | Venous Thromboembolism | Vitamin Antagonist | Continued Treatment | Hazard Ratio |
KOL-Index: 15512
BACKGROUND: After hip replacement surgery, prophylaxis following discharge from hospital is recommended to reduce the risk of venous thromboembolism. Our aim was to assess the oral, direct thrombin inhibitor dabigatran etexilate for such prophylaxis.
METHODS: In this double-blind study, we randomised 3494 patients undergoing total hip replacement to treatment for 28-35 days with dabigatran etexilate 220 mg (n=1157) or 150 mg (1174) once daily, starting with a half-dose 1-4 h after ...
| Kjent for Hip Replacement | Dabigatran Enoxaparin | Venous Thromboembolism | Etexilate Versus | Primary Efficacy Outcome |
KOL-Index: 15505
CONTEXT: Previous studies have evaluated the safety of relatively complex combinations of clinical decision rules and diagnostic tests in patients with suspected pulmonary embolism.
OBJECTIVE: To assess the clinical effectiveness of a simplified algorithm using a dichotomized clinical decision rule, D-dimer testing, and computed tomography (CT) in patients with suspected pulmonary embolism.
DESIGN, SETTING, AND PATIENTS: Prospective cohort study of consecutive patients with clinically ...
| Kjent for Pulmonary Embolism | Computed Tomography | Dimer Testing | Patients Suspected | 3 Months |
KOL-Index: 15415
BACKGROUND: Dabigatran etexilate is an oral direct thrombin inhibitor undergoing evaluation for the prevention of venous thromboembolism (VTE) following orthopedic surgery.
METHODS: In a multicenter, parallel-group, double-blind study, 1973 patients undergoing total hip or knee replacement were randomized to 6-10 days of oral dabigatran etexilate (50, 150 mg twice daily, 300 mg once daily, 225 mg twice daily), starting 1-4 h after surgery, or subcutaneous enoxaparin (40 mg once daily) ...
| Kjent for Total Hip | Dabigatran Etexilate | Thromboembolic Events | Knee Replacement | Vte Patients |
KOL-Index: 14849
BACKGROUND: Oral anticoagulants, such as dabigatran etexilate, an oral, direct thrombin inhibitor, that do not require monitoring or dose adjustment offer potential for prophylaxis against venous thromboembolism (VTE) after total knee replacement surgery.
METHODS: In this randomized, double-blind study, 2076 patients undergoing total knee replacement received dabigatran etexilate, 150 mg or 220 mg once-daily, starting with a half-dose 1-4 hours after surgery, or subcutaneous enoxaparin ...
| Kjent for Subcutaneous Enoxaparin | Oral Dabigatran | Total Knee Replacement | Venous Thromboembolism | Prevention Vte |
Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism
[ PUBLICATION ]
BACKGROUND: The standard initial treatment of hemodynamically stable patients with pulmonary embolism is intravenous unfractionated heparin, requiring laboratory monitoring and hospitalization.
METHODS: We conducted a randomized, open-label trial involving 2213 patients with acute symptomatic pulmonary embolism to compare the efficacy and safety of the synthetic antithrombotic agent fondaparinux with those of unfractionated heparin and to document noninferiority in terms of efficacy. ...
| Kjent for Unfractionated Heparin | Pulmonary Embolism | Initial Treatment | Subcutaneous Fondaparinux | Intravenous Injections |
KOL-Index: 14727
OBJECTIVES: To determine the rate of a first recurrent venous thromboembolism (VTE) event after discontinuation of anticoagulant treatment in patients with a first episode of unprovoked VTE, and the cumulative incidence for recurrent VTE up to 10 years.
DESIGN: Systematic review and meta-analysis.
DATA SOURCES: Medline, Embase, and the Cochrane Central Register of Controlled Trials (from inception to 15 March 2019).
STUDY SELECTION: Randomised controlled trials and prospective cohort ...
| Kjent for Anticoagulant Treatment | Recurrent Vte | Unprovoked Venous | 10 Years | 95 Confidence Interval |
Nøkkelpersoner for Pulmonary Embolism
Toppkols i verden
Harry Roger Büller:Ekspertvirkning
Konsepter somHarry Roger Büllerhar direkte innflytelse:Pulmonary embolism, Venous thromboembolism, Venous thrombosis, Major bleeding, Deep vein thrombosis, Atrial fibrillation, Vein thrombosis.
Harry Roger Büller:Kol Impact
Konsepter relatert til arbeidet til andre forfattere somfor which Harry Roger Büller har innflytelse:Venous thromboembolism, Pulmonary embolism, Atrial fibrillation, Deep vein thrombosis, Oral anticoagulants, Major bleeding, Vte patients.
Tools
Er dette profilen din? Krev profilen din Kopier url Legg inn lenke til profilen din |